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Zusammenfassung  
 
Enterohämorrhagische Escherichia coli (EHEC) sind durch kontaminierte Speisen oder 
Wasser übertragene, hochinfektiöse Pathogene, die weltweit vorkommen und immer wieder 
lokale Krankheitsausbrüche verursachen. Ihre Pathogenitätsfaktoren beinhalten Shigatoxine 
und ein Typ III Sekretionssystem mit Effektorproteinen, die in die menschliche Wirtszelle 
injiziert werden, um diese zu manipulieren. Die Pathogenitätsfaktoren liegen auf dem 
bakteriellen Chromosom in so genannten Pathogenitätsinseln, die von Sequenzen 
lambdoider Phagen flankiert werden. Manche dieser Phagen sind noch in der Lage nach 
UV-Induktion infektiöse Partikel zu bilden. 
Im Rahmen dieser Arbeit habe ich zwei Protein-Protein Interaktome generiert, nämlich das 
EHEC-Mensch und das Phage Lambda-E. coli Interaktom.  
Für das EHEC-Mensch Interaktom wurden 34 Effektorproteine kloniert und im Hefe-Zwei-
Hybrid-System gegen menschliche ORF Kollektionen und cDNA-basierte Gensammlungen 
gescreent. Insgesamt konnten 35 reproduzierbare Interaktionen von 15 EHEC Effektoren mit 
34 menschlichen Proteinen identifiziert werden, von denen bisher lediglich vier in der 
Literatur bekannt sind. Das EHEC-Mensch Interaktom wurde durch die in BioGRID 
befindlichen Interaktionen der 34 menschlichen Proteine erweitert. Dadurch konnte 
festgestellt werden, dass die EHEC Effektorproteine in der Wirtszelle untereinander über 
primäre und sekundäre Interaktionen mit menschlichen Proteinen vernetzt sind.  
Für den ’translocated intimin recepror’ (TIR) wurden acht Interaktionen (darunter zwei bereits 
bekannte) identifiziert. Die menschlichen Interaktoren wurden dann zu Vergleichszwecken in 
binären Hefe-Zwei-Hybrid Tests auf Interaktionen mit dem homologen TIR von 
enteropathogenen E. coli (EPEC) untersucht. Fünf der acht EHEC-TIR Interaktoren 
interagierten auch mit EPEC-TIR. 
Eine weitere Interaktion zwischen dem Effektorprotein NleF und der menschlichen 
Caspase-9 wurde im Rahmen dieser Arbeit entdeckt. Durch LUMIER Tests gegen weitere 
menschliche Caspasen wurden auch die Caspasen 4 und 8 als Interaktionspartner 
identifiziert. In vitro Versuche mit aufgereinigtem Protein ergaben, dass NleF ein potenter 
Inhibitor der Proteaseaktivität aller drei Caspasen ist. Weiterhin ist es in der Lage die 
Caspaseaktivität in Zelllysaten zu mindern und die Apoptoseinduktion in HeLa und Caco-2 
Zellen signifikant zu hemmen. Einem Kollaborationspartner gelang es die Kristallstruktur des 
Caspase-9/NleF Komplexes aufzulösen, welche eine dominante Rolle der carboxyterminalen 
vier Aminosäuren von NleF bei der Caspase-9 Bindung und Hemmung vermuten ließ. Durch 
die Generierung von NleF Mutanten mit verändertem Carboxyterminus gelang es mir, dies 
zu bestätigen. Die Verhinderung oder Verzögerung der Apoptoseinduktion in Wirtszellen ist 
eine gängige Strategie vieler Pathogene. Obwohl NleF längst nicht das einzige 
Effektorprotein ist, das in die Apoptoseinduktion eingreift, so ist es doch der einzige bekannte 
Effektor, der direkt an Caspasen bindet, um diese zu inhibieren. 
Das Phage Lambda-E. coli Interaktom wurde von mir während eines Forschungsaufenthaltes 
am J. Craig Venter Institut in Rockville USA realisiert. Dazu habe ich 68 Phage Lambda 
Proteine im Hefe-Zwei-Hybrid-System gegen eine E. coli W3110 ORF Sammlung gescreent, 
wodurch 144 reproduzierbare Proteininteraktionen zwischen Lambda und E. coli identifiziert 
wurden. Die in Interaktionen involvierten Phage Lambda und E. coli Proteine wurden in 
funktionelle Gruppen unterteilt und auf Interaktionen zwischen den Virus- und Wirtsgruppen 
untersucht. 
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Summary 
 
 
 
Enterohemorrhagic E. coli (EHEC) are highly infectious food-borne pathogens that cause 
severe diarrhoea in both, industrialised and developing countries all over the world. Their 
pathogenicity factors involve shiga-like toxins and a type III secretion system along with 
so-called effector proteins, which are translocated directly into the cytoplasm of their host 
cells, usually enterocytes. Most of these proteins are encoded in pathogenicity islands within 
the bacterial genome that are framed by sequences of lambdoid phages. Some of these 
phages are still able to produce infectious particles after UV induction. 
In this study I generated two protein-protein interactomes, namely EHEC-host and phage 
lambda-E. coli. For the EHEC-host interactome, 34 effector proteins that had been previously 
shown to be secreted into human host cells were cloned and screened against pooled 
human cDNA and ORF libraries via yeast two-hybrid screening. This resulted in 35 
reproducible interactions of 15 EHEC effectors with 34 human proteins, of which only four 
had been published previously. Inclusion of secondary human protein interactors retrieved 
from the BioGRID database revealed that EHEC effectors are interconnected in the human 
cell.  
The translocated intimin receptor (TIR) that was found to interact with eight human proteins 
was compared to its homologue in enteropathogenic E. coli (EPEC). This revealed that five 
of the eight EHEC TIR interactors also interact with EPEC TIR. 
Another interaction discovered in this study involves the EHEC effector NleF, previously a 
protein of unknown function, and human caspase-9. LUMIER assays against other human 
caspases identified caspase-4 and -8 as additional binding partners of NleF. Tests with 
purified enzymes revealed that NleF can potentially inhibit all three caspases. The effector 
decreased caspase activity significantly in HeLa cell lysate and impaired apoptosis induction 
in HeLa and Caco-2 cells. A collaboration partner solved the crystal structure of the 
NleF/caspase-9 complex, which suggested a dominant role of the carboxy-terminal four 
amino acids in caspase-9 binding and inhibition. I was able to confirm these findings by 
constructing NleF versions with mutagenized carboxy-termini. NleF versions that lacked the 
last four amino acids or comprised an additional carboxy-terminal alanine were unable to 
bind any of the three caspases or impair apoptosis. Apoptosis inhibition is a strategy often 
applied by viral and bacterial pathogens. Even though NleF is not the only effector protein 
capable of inhibiting apoptosis in human cells, direct inhibition of caspases by bacterial 
effectors has not been reported to date. 
The phage lambda-E. coli.interactome was generated during my research stay at the J. Craig 
Venter Institute in Rockville (USA). I screened 68 phage lambda proteins against the 
E. coli W3110 ORF library via yeast two-hybrid screening using two different vector systems. 
This resulted in 144 reproducible interacting pairs. The phage lambda and E. coli proteins 
involved in interactions were categorized in functional groups and analysed for interactions 
between phage and host groups. 
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1 Introduction 
1.1 Pathogenic Escherichia coli 
Pathogenic bacteria that cause infectious diarrhoea are a major health problem worldwide. 
Among them are enterohemorrhagic Escherichia coli (EHEC), which cause severe foodborne 
diarrhoea and hemolytic-uremic syndrome (HUS). As highly infectious pathogens requiring 
less than 100 CFU to cause disease in humans, susceptible food, such as ground beef can 
be easily contaminated during industrial food processing in developed countries, especially 
since EHEC is a natural inhabitant of the intestine of ruminants (BfR, 2012). Due to these 
facts and EHECs ability to also contaminate vegetables (Berger et al., 2010; Wendel et al., 
2009) more than 900 EHEC/STEC (shiga-like toxin-producing E. coli) cases occur annually 
in Germany (data obtained from the website of the Robert Koch Institute; 
http://www3.rki.de/SurvStat/), which is comparable to its occurrence in the United States. 
Although the number of EHEC/STEC cases is usually low, it can rise to up to several 
thousand affected people during outbreaks, as happened 2011 in Germany. 
1.1.1 Type III secretion 
E. coli are common inhabitants of the intestinal tract of several mammals and humans. Even 
though mainly beneficial for their carrier, some strains, such as EHEC O157:H7, acquired 
pathogenicity islands via horizontal gene transfer (Berger et al., 2010). These genomic 
islands are framed by sequences originating from lambdoid phages out of which some are 
still capable of producing functional virions after induction by e.g. UV light or some antibiotics 
(Datz et al., 1996; Gamage et al., 2003; Herold et al., 2005; Miyamoto et al., 1999; 
Yokoyama et al., 2000). The best known pathogenicity island is probably the so-called locus 
of enterocyte effacement (LEE). It encodes the type III secretion system, the adhesin intimin, 
chaperones, several effector proteins and the LEE encoded regulator (Ler) that is involved in 
the regulation of the LEE2-4 promoters (Elliott et al., 2000). The type III secretion system 
(T3SS) is a syringe like apparatus composed of more than 20 proteins and highly similar to 
the flagellum of gram negative bacteria (Erhardt et al., 2010). It is shared by and conserved 
among many gram negative pathogens such as Salmonella  sp., Yersinia sp., 
enteropathogenic and enterohemorrhagic Escherichia coli (EPEC and EHEC), Shigella sp., 
Chlamydia sp. and even plant pathogens like Erwinia carotovora (Blocker et al., 2003; Galan 
and Wolf-Watz, 2006). Its main function lies in the injection of bacterial effector proteins into 
host cells. Even though the number of these virulence-effectors is variable between bacterial 
strains, they act in concert aiming at the subversion of cellular antagonistic responses and 
the establishment of an environment suitable for pathogen proliferation. Effector protein 
secretion is a complex process, on effector site commonly involving an amino-terminal export 
signal and a downstream chaperone binding domain that recognizes a class I chaperone. 
Class I chaperones are dedicated chaperones that bind their cognate effectors (some 
chaperones can bind to more than one effector), targeting them to the T3S machinery 
(Cornelis, 2006; Ghosh, 2004; Parsot et al., 2003). The chaperons prevent premature 
interactions between effectors and facilitate rapid unfolding of to be translocated proteins 
(Galan and Wolf-Watz, 2006; Stebbins and Galan, 2003), which is required due to the small 
channel of the T3SS (~25 Å inner diameter) (Cornelis, 2006). The process of T3S is 
schematized in figure 1. 
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After translocon formation by EspA, EspB and EspD, involving membrane insertion of the 
latter two, the T3SS is ready for injection of subsequent effectors (Hartland et al., 2000; Ide 
et al., 2001; Knutton et al., 1998; Wachter et al., 1999), including those responsible for the 
characteristic attaching and effacing (A/E) lesions. These lesions occur as a consequence of 
intimate attachment of the pathogens to the plasma membrane of enterocytes and involve 
the destruction of microvilli and rearrangements of the cytoskeleton underneath adherent 
bacteria (reviewed in Frankel et al., 1998). EHEC and EPEC mutants deficient in lesion 
formation can neither colonize their host nor cause disease, marking the process as critical 
for pathogenicity (Kaper et al., 2004; Spears et al., 2006). 
1.1.2 TIR signalling and pedestal formation 
(Shaw et al., 2005) demonstrated that the A/E phenotype is mainly caused by the interaction 
of the effector protein TIR, the translocated intimin receptor, with the intimate adhesin intimin. 
After the translocon forming proteins EspB and EspD, TIR is the first effector protein 
translocated into the host cell. It integrates into the plasma membrane with both, the amino- 
and the carboxy-terminus exposed to the host cell cytoplasm. A 55 amino acid extracellular 
loop on the host cell surface mediates intimin binding (Hamaguchi et al., 2008; Hartland et 
al., 1999), which further leads to TIR clustering and the formation of actin-rich pedestals 
(Campellone et al., 2004). These structures are highly flexible and even able to promote 
 
Figure 1. Type III secretion. Effector proteins bind to their cognate chaperons and the complex is 
targeted to the T3SS, where it is recognized by the ATPase complex. The latter strips the effector from 
the chaperone and mediates translocation of the unfolded protein through the central channel of the 
secretion system and the translocon pore formed by EspB and EspD. The figure is taken from (Galan 
and Wolf-Watz, 2006). 
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bacterial motility on top of cultured cells (Campellone, 2010). Despite the homology of EPEC 
and EHEC TIR, these bacteria employ different ways to achieve actin polymerization. After 
clustering, EPEC TIR is phosphorylated at the tyrosine residue Y474 and sometimes also at 
Y454. Phosphorylation can be performed by different host kinases like c-Fyn, Abl, Ark and 
Etk (Bommarius et al., 2007; Phillips et al., 2004; Swimm et al., 2004) and is essential for 
pedestal formation by EPEC (Kenny, 1999). A 12 amino acid (AA) sequence around 
phosphorylated Y474 binds the host cell adaptor proteins Nck1 and Nck2 through their 
phosphotyrosine-binding SH2 regions (Campellone et al., 2002; Gruenheid et al., 2001). The 
adaptors then recruit and activate the cellular N-WASP protein either by direct binding of the 
Nck SH3 domain to the proline-rich domain (PRD) of N-WASP or indirectly through a 
WIP-like protein (Campellone, 2010). So activated N-WASP is in turn able to stimulate 
Arp2/3-triggered actin polymerization that finally results in pedestal formation (figure 2 A). 
Aside from previously described mechanism, EPEC has additional Nck independent 
pathways that influence pedestal formation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EHEC TIR has no equivalent to EPEC TIR Y474 and does not bind Nck1 or Nck2. As a 
consequence EHEC TIR is unable to form pedestals when expressed in EPEC (Kenny, 
2001). Instead, pedestal formation by EHEC TIR requires the conserved Asn-Pro-Tyr 
(NPY458) motif, which is homologous to NPY454 in EPEC TIR. This motif is able to recruit 
Figure 2. EPEC (A) and 
EHEC (B) Tir signalling.  
P – phosphate; PRD – proline-
rich domain; N – amino-
terminal secretion signal; R1-7 
– proline-rich repeats of 
EspFU; GBD - GTPase-binding 
domain. Figure modified after 
(Campellone, 2010; Wong et 
al., 2011). 
(A) EPEC mediates pedestal 
formation employing the 
phosphorylated Y474 Tir 
residue, which is crucial for 
Nck recruitment, in turn 
resulting in N-WASP activation 
and Arp2/3 mediated actin 
polymerization. (B) EHEC uses 
the non-phosphorylated 
NPY458 motif for 
IRSp53/IRTKS recruitment. 
These host cellular proteins 
bind to the EHEC effector 
EspFU which is able to activate 
N-WASP and trigger Arp2/3 – 
mediated actin assembly. 
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IRSp53 and IRTKS (Vingadassalom et al., 2009; Weiss et al., 2009) which in turn bind to 
another EHEC effector not present in EPEC, namely TccP/EspFU. This second effector 
consists almost entirely of proline-rich repeats capable of binding to the GTPase-binding 
domain (GBD) of N-WASP and as a consequence activating the protein to stimulate Arp2/3-
mediated actin assembly. The two ways of pedestal formation used by EPEC and EHEC are 
schematized in figure 2 (previous page). 
1.1.3 EHEC effector proteins 
The EHEC strain O157:H7 Sakai, known from severe outbreaks in Sakai (Japan) in 1982 
and 1996, encodes for 62 effector genes including duplicates (Tobe et al., 2006). The known 
cellular functions of these virulence proteins include cytoskeleton remodelling, guanine 
exchange factor (GEF) mimicry, inhibition of apoptosis, manipulation of inflammatory 
signalling pathways and interference with phagocytosis (reviewed in (Wong et al., 2011). A 
list of EHEC effectors along with their (putative and known) host interaction partners and 
cellular function(s) is shown in table 1. 
 
Table 1. EHEC O157:H7 effector proteins along with their host cellular localization and 
function. The table is obtained from (Wong et al., 2011). TJ – tight junction; PM – plasma membrane; 
ER – endoplasmic reticulum; AJ – adherens junction. Aside from EspK, EspM, EspN, EspR, EspV, 
EspW, EspX, EspY and EspFU these effectors are shared by EPEC O127:H6 E2348/69. 
EHEC 
effector 
Localization Host binding partners Cellular function 
EspB Cytosol, PM Alpha 1-antitrypsin, 
alpha-catenin, myosin-1c 
Translocation pore component, AJ 
disruption, binds myosins to inhibit 
phagocytosis 
TIR PM 14-3-3tau, alpha-actinin, 
cortactin, CK18, IQGAP1, 
IRTKS, IRSp53, Nck, PI3K, 
talin, vinculin 
Receptor for the adhesion intimin, 
actin pedestal formation, 
downregulates Map-dependent 
filopodia formation, SGLT-1 
inactivation 
EspF Mitochondria, 
cytosol, nucleus, 
TJ, apical 
membrane, 
lateral 
membrane 
14-3-3zeta, ABCF2, actin, 
Arp2, CK18, N-WASP, 
profilin, SNX9, ZO-1/ZO-2 
Mitochondrial disruption, NHE3 
inactivation, SGLT-1 inactivation, TJ 
disruption, disrupts nucleolus, disrupts 
intermediate filaments, activates 
SNX9 to induce membrane 
remodelling, binds and activates N-
WASP, inhibits PI3K-dependent 
phagocytosis 
Map Mitochondria EBP50 (NHERF1), 
NHERF2, Cdc42 
Cdc42 GEF that induces transient 
filopodia formation, mitochondrial 
disruption, SGLT-1 inactivation, TJ 
disruption 
EspG Cytosol, golgi Tubulin, Arf1/6, PAK1/2/3 Disrupts microtubules, blocks ARF 
GTPase signalling and stimulates 
PAKs to inhibit endomembrane 
trafficking 
EspH PM, pedestal DH-PH RhoGEFs Blocks Rho GTPase signalling and 
FCgR-mediated phagocytosis, 
promotes actin pedestal length 
EspZ PM CD98 Enhances b1-integrin and FAK 
signalling to inhibit apoptosis and 
cellular cytotoxicity 
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EspI/NleA Golgi, PM Syntrophin, Sec23/24, 
MALS3, PDZK11, SNX27, 
TCOF1, EBP50 (NHERF1), 
NHERF2, MAGI-3, SAP97, 
SAP102, PSD-95 
Inhibits COPII-dependent protein 
export from ER, TJ disruption 
EspJ Cytosol, 
mitochondria  
Unknown Inhibits FCgR-mediated and CR3-
mediated trans-phagocytosis 
EspK Unknown Unknown Unknown 
EspL Pedestal Annexin 2 Enhances F-actin bundling activity of 
Annexin 2 
EspM Cytosol RhoA RhoA GEF that induces stress fibre 
formation 
EspN Unknown Unknown Unknown 
EspO Unknown Integrin-linked kinase (ILK) Unknown 
EspR Unknown Unknown Unknown 
EspV Cytosol Unknown Modulates cytoskeleton 
EspW Unknown Unknown Unknown 
EspX Unknown Unknown Unknown 
EspY Unknown Unknown Unknown 
NleB Cytosol Unknown Inhibits TNF-induced NF-kB activation 
NleC Cytosol, nucleus   p65 (RelA), p50, c-Rel, IkB Metalloprotease that cleaves p65 
(RelA), c-Rel, p50 and IkB to inhibit 
NF-kB activation 
NleD Cytosol JNK Metalloprotease that cleaves JNK to 
inhibit AP-1 activation 
NleE Cytosol Unknown Blocks IkB degradation to inhibit NF-
kB activation 
NleF Unknown Unknown Unknown 
NleG/NleI Cytosol UBE2D2 U-box E3 ubiquitin ligase 
NleH ER, PM, cytosol Bax-inhibitor 1, NHERF2, 
RPS3 
Binds Bax-inhibitor 1 to block 
apoptosis, sequesters RPS3 to inhibit 
NF-kB signalling 
EspFU Cytosol N-WASP, IRTKS, IRSp53, 
cortactin 
Relieves N-WASP autoinhibition to 
trigger actin pedestal formation 
 
An interesting group of effector proteins present not only in EHEC and EPEC, but also in 
Shigella sp. and Salmonella sp. as well as other pathogens harbouring a T3SS are the 
so-called WxxxE effectors. This group comprises a number of non-homologous proteins that 
share a characteristic Trp-X-X-X-Glu signature motif (Alto et al., 2006) and the ability to bind 
and activate cellular GTPases by mimicking guanine exchange factors (GEFs). The EHEC 
WxxxE effectors Map and EspM target the GTPases Cdc42 and RhoA (Arbeloa et al., 2010; 
Huang et al., 2009), respectively, which further leads to their activation and the formation of 
filopodia and stress fibres within the host cell (Orchard and Alto, 2012) (figure 3). 
Aside from GEF mimicry, Map is also involved in the disruption of tight junctions and 
mitochondria as well as in the inactivation of the sodium-dependent glucose co-transporter 
SGLT-1, which leads to decreased fluid uptake by the host cells (Dean and Kenny, 2004; 
Dean et al., 2006; Kenny and Jepson, 2000; Ma et al., 2006). 
Actions like those of Map and EspF (degenerates anti-apoptotic proteins; see table 1 for 
other functions), along with the bundle-forming pili and the surface properties of EHEC and 
EPEC provide sufficient stimuli to trigger intrinsic and extrinsic apoptosis pathways in host 
cells (Abul-Milh et al., 2001; Barnett Foster et al., 2000; Nougayrede and Donnenberg, 2004; 
Nougayrede et al., 2007; Papatheodorou et al., 2006).  
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But despite the presence of these pro-apoptotic factors, a decrease in apoptotic rates was 
observed upon infection of rabbits with a related REPEC O103 strain (Heczko et al., 2001). 
This successful subversion of pro-apoptotic effects is mediated by effectors interfering 
directly or indirectly with apoptosis pathways, such as NleD and NleH. NleD is a zinc 
metalloprotease that cleaves MAPK14 and JNK, the c-Jun N-terminal kinase also known as 
MAPK8, which is required for TNF-alpha and UV radiation induced apoptosis (Tournier et al., 
 
Figure 3. Actions of selected EHEC effectors in enterocytes. The two WxxxE effectors Map and 
EspM mimic Cdc42 and RhoA GEFs, respectively, and thus trigger formation of filopodia and stress 
fibers. The actions of Map and EspF as well as of attached bacteria stimulate apoptosis induction, 
which is counteracted by NleD and NleH. NleH binds Bax inhibitor-1 (BI-1) and blocks different 
intrinsic apoptotic pathways. NleD cleaves MAPK14 and JNK, which prevents c-Jun dependent 
transcription and thus associated pathways (cell proliferation, differentiation and inflammation) which 
can normally lead to apoptosis induction. Figure modified after (Orchard and Alto, 2012; Wong et al., 
2011) 
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2000) and thus prevents previously mentioned apoptotic pathways (Baruch et al., 2011). The 
two NleH effectors NleH1 and NleH2 bind the anti-apoptotic protein, Bax inhibitor-1 (BI-1) 
and as a consequence are able to block several intrinsic apoptotic pathways (Hemrajani et 
al., 2010). Aside from NleD and NleH, another effector, namely EspZ, is able to reduce 
cytotoxicity of EPEC infections probably by stabilization of the host epithelium (Shames et 
al., 2010). However regarding the importance that subversion of apoptosis has for many viral 
and bacterial pathogens, it is likely that more than just the three previously described 
effectors are involved in this process. The roles of WxxxE and anti-apoptotic effectors are 
schematized in figure 3. 
1.1.4 EPEC versus EHEC 
Although EHEC and EPEC share many pathogenicity factors such as the T3SS and most 
effector proteins, they differ in the expression of shiga-like toxins, which are harboured by 
EHEC only. Shiga-like toxins belong to the group of AB5 toxins and as such harbour one 
toxic A and five receptor-binding B subunits. The five B subunits bind to the ganglioside 
globotriaosylceramide, which results in the uptake of the A subunit through a macropinosome 
(Lukyanenko et al., 2011) and thus to A-dependent arrest of protein synthesis through 
cleavage of the 28S RNA of the 60S ribosomal subunit (Kaper et al., 2004; Sandvig et al., 
2010). This usually results in cell death. Shiga-like toxins (Stx) are the causing agents of 
hemolytic-uremic syndrome, which can only be caused by EHEC and STEC. However, their 
function and contribution to EHEC pathogenesis is not subject of this work. 
1.2 Infection, cell death and pathogen interference 
Bacterial and viral pathogens can cause cell death through different ways, namely necrosis, 
pyroptosis and apoptosis (Ashida et al., 2011). 
1.2.1 Necrosis 
Necrosis is a rather broad term describing a caspase-independent cell death, which can be 
induced among others by reactive oxigen species production, lysosomal destabilization, 
calpain activation, cathepsin release and depletion of ATP (Ashida et al., 2011; Lamkanfi and 
Dixit, 2010; Vanlangenakker et al., 2008). Aforementioned conditions can occur as a result of 
trauma, intoxication or infection.  
1.2.2 Pyroptosis 
Pyroptosis is defined as caspase-1 dependent cell death and shares features with necrosis 
as well as with apoptosis. It is usually a result of pathogen invasion of dendritic cells or 
macrophages, which leads to the assembly of inflammasomes and subsequent caspase-1 
activation (Lamkanfi and Dixit, 2009). Studies in mice revealed that at least four different 
inflammasomes can be assembled, depending on which pathogen is involved. They 
comprise receptors (usually members of the NOD-like receptor (NLR) family (Kanneganti et 
al., 2007)) that are able to recognize pathogen-associated molecular patterns (PAMPs) in 
intracellular compartments using variable leucine rich repeat (LRR) motifs (Kawai and Akira, 
2006; Lamkanfi and Dixit, 2010). The four inflammasomes are named after aforementioned 
receptors as the Ipaf inflammasome (Franchi et al., 2006; Mariathasan et al., 2004; Miao et 
al., 2006), the Nlrp1b inflammasome (Boyden and Dietrich, 2006), the Nlrp3 inflammasome 
(Barnett Foster et al., 2000; Kanneganti et al., 2006; Mariathasan et al., 2006; Sutterwala et 
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al., 2006) and the AIM2 inflammasome (Fernandes-Alnemri et al., 2010; Jones et al., 2010; 
Rathinam et al., 2010; Sauer et al., 2010).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The adaptor protein ‘apoptosis-associated speck-like protein containing a caspase 
recruitment domain’ (ASC; also known as ‘PYD and CARD domain containing’ = PYCARD) is 
believed to bridge the interaction between the receptors and caspase-1 (direct proof exists 
only for AIM2 and Nlrp3 inflammasomes) (Burckstummer et al., 2009; Fernandes-Alnemri et 
 
Figure 4. Pathogen stimuli and resulting formation of inflammasomes in mammalien cells. The 
figure is modified after (Lamkanfi and Dixit, 2010). As a result of different pathogen stimuli, four 
different inflammasomes can assemble in mammalian cells, namely the Ipaf, the Nlrp1b, the Nlrp3 and 
the AIM2 inflammasomes, which are named after their corresponding NOD-like receptors (NLR). Aside 
from AIM2 that harbours a HIN-200 and a PYD domain, the NLRs have LRR and NACHT domains for 
the sensing of PAMPs and self-oligomerization, respectively, as well as PYD or CARD domains for the 
interaction with the adaptor protein ASC. Procaspase-1 interacts with ASC and is activated upon 
pathogen attack. In its active form it cleaves proIL-1β and proIL-18, activates caspase-7 and yet 
unknown other substrates and as a consequence induces pyroptosis and inflammation processes. 
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al., 2009; Hornung et al., 2009), which as a consequence undergoes autoactivation 
(Lamesch et al., 2007). Active caspase-1 then processes proIL-1β and proIL-18 into the 
active proinflammatory forms interleukin (IL)-1β and IL-18 and activates caspase-7 as well as 
other to be identified substrates resulting in membrane permeabilization and DNA 
fragmentation (Lamkanfi and Dixit, 2010). Pyroptosis finally results in cell death and 
inflammation (see figure 4). 
1.2.3 Apoptosis 
Apoptosis is the most common form of programmed cell death. It critically contributes to the 
maintenance of cellular homeostasis in multicellular organisms by deletion of damaged, aged 
and excess cells and also by removal of infected cells along with associated pathogens 
(Elliott and Ravichandran, 2010; Johnstone et al., 2008; Strasser et al., 2000). In contrast to 
pyroptosis, it is a non-inflammatory process after whose completion dead cells are cleared 
through engulfment by professional phagocytes or neighbouring cells (Elliott and 
Ravichandran, 2010). Apoptotic cells are characterized by typical morphological and 
biochemical features such as membrane blebbing, cell shrinkage, chromosomal DNA 
fragmentation, nuclear condensation, the formation of so-called apoptotic bodies and 
presentation of ‘eat-me’ signals on the cell surface (e.g. phosphatidylserine). 
Apoptosis can be induced through different pathways in response to extrinsic or intrinsic 
stimuli and is executed by a family of cysteinyl aspartate-specific proteases called caspases. 
Caspases can be categorized in initiator and executioner caspases. Initiator caspases like 
caspase-2, -8, -9 and -10 are the first to be recruited and activated (by autoprocessing) upon 
apoptotic stimulation. Executioner caspases such as caspase-3, -6, and -7 are activated 
through proteolytic processing by active initiator caspases and, once active, cleave 
numerous cellular substrates, which finally leads to the typical morphological hallmarks of 
apoptosis (Fischer et al., 2003; Taylor et al., 2008; Timmer and Salvesen, 2007).  
Depending on the stimulus cells execute either of two major apoptosis pathways, namely the 
extrinsic receptor-mediated one or the intrinsic mitochondria-mediated way. The extrinsic 
pathway is activated by extracellular factors such as the ‘tumor necrosis factor related 
apoptosis inducing ligand’ (TRAIL), the tumor necrosis factor (TNF) and the Fas ligand 
(FasL) that bind death receptors like DR4, DR5 (TRAIL receptors) (Song and Lee, 2008), 
Fas and the TNF receptor. As a consequence of ligand binding the receptors trimerize and 
form together with the adaptor protein ‘Fas-associated death domain’ (FADD) the 
characteristic death-inducing signalling complex (DISC) (Johnstone et al., 2008). Through 
FADD-binding, the caspases 8 and 10 are recruited to the DISC and activated by proximity-
induced autoprocessing. Active caspase-8 activates caspase-3 and cleaves the Bcl-2 
homology domain 3 (BH3)-only protein Bid. Cleaved Bid (tBid = truncated Bid) activates the 
proapoptotic Bcl-2 family proteins Bax and Bak and inhibits antiapoptotic Bcl-2, which leads 
to the permeabilization of the mitochondrial membrane and thus to the release of 
cytochrome-c, Smac/DIABLO and HtrA2/Omi (Johnstone et al., 2008; Lamkanfi and Dixit, 
2010). The release of cytochrome c from the mitochondria instigates the intrinsic apoptotic 
pathway, which is also activated in response to intracellular apoptotic stimuli such as DNA 
damaging agents, chemotherapeutic drugs, UV irradiation, growth factor depletion and 
infection (Saelens et al., 2004). After cytochrome c release, a 700-1400 kDa protein complex 
called apoptosome is assembled. It consists of the released cytochrome c bound to the 
carboxy-terminal WD-40 repeats of the ‘apoptotic protease-activating factor-1’ (Apaf-1) and 
procaspase-9, associated with the amino-terminal CARD domain of the same protein. 
Caspase-9 is activated by autoprocessing within the apoptosome and activates recruited 
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caspase-3 by proteolytic cleavage, which in turn executes apoptosis together with other 
effector caspases (Cain et al., 2002; Lamkanfi and Dixit, 2010). Intrinsic and extrinsic 
apoptosis pathways are schematized in figure 5. 
Extrinsic and intrinsic apoptosis pathways are connected by Bid, which can be cleaved by 
caspase-8 as well as by other cellular proteases like granzyme B and cathepsin B (Saelens 
et al., 2004). This interconnection is of special interest for the distinction between so-called 
type I and type II cells that differ in their way to execute Fas-induced apoptosis. In type I 
cells, typically lymphocytes, activated initiator caspase-8 directly cleaves a sufficient amount 
of effector caspases to execute apoptosis, whereas in type II cells (most somatic cells are 
type II) caspase-8 dependent Bid cleavage and thus apoptosome formation and caspase-9 
activation are required for apoptosis induction (Jost et al., 2009; Strasser et al., 2009; Wang 
et al., 1996; Yin et al., 1999). However, the definition was challenged for jurkat cells (type II), 
which seem to be independent from apoptosome-mediated caspase-9 activation (Shawgo et 
al., 2009). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To keep their suicide a tightly regulated process and prevent accidental induction, the cells 
employ different pro- and antiapoptotic proteins that are able to promote or stop apoptosis 
 
Figure 5. Intrinsic and extrinsic apoptosis pathway. Apoptosis can be induced by different stimuli, 
such as extracellular ligands that bind death receptors and intrinsic insults. Extrinsic stimuli activate 
caspase-8, which cleaves Bid and activates effector caspases to execute apoptosis. Intrinsic stimuli 
like DNA damage or infection stimulate the release of cytochrome c from the mitochondria which leads 
to apoptosome formation and caspase-9 activation. Active caspase-9 then cleaves the effector 
caspases. 
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signalling. Proapoptotic proteins include Smac/DIABLO and HtrA2/Omi, which upon their 
release from the mitochondria are able to block the X-linked inhibitor of apoptosis (XIAP) 
(Lamkanfi and Dixit, 2010). XIAP is one of eight presently known human inhibitors of 
apoptosis proteins (IAPs), which can be recognized by the presence of one or more 
baculovirus IAP repeats (BIR) and zink finger folds (Altieri, 2010). Aside from XIAP, which is 
able to directly inhibit caspases 3, 7 and 9, the seven other human IAPs are c-IAP-1, c-IAP-
2, ILP2, ML-IAP (LIVIN), survivin, NAIP and BRUCE (Altieri, 2010; Deveraux and Reed, 
1999; Shin et al., 2001).  
1.2.4 Caspases 
Caspases play a crucial role in different cellular processes, such as apoptosis, inflammation 
and development. These conserved cysteine proteases are synthesized as inactive 
zymogens and require proteolytic cleavage to become active. They share an amino-terminal 
prodomain, an intermediate large domain (17 – 21 kDa) and a carboxy-terminal small subunit 
domain (10 – 13 kDa). All caspases possess an active cysteine residue in the central domain 
and cleave specifically after an aspartate residue in substrate proteins (Yazdi et al., 2010). 
Aside from the human apoptosis initiator caspases 2, 8, 9 and 10 and the apoptosis 
executioner caspases 3, 6 and 7, there is a group of inflammatory caspases consisting of 
caspase-1, -4, and -5. The best characterized inflammatory caspase is caspase-1, which is 
involved in pryoptosis (see the chapter on pyroptosis above).  
Caspase-5 is a component of the Nlrp (Nalp) inflammasome (Martinon et al., 2002; Martinon 
and Tschopp, 2007).  
Caspase-4 was suggested to play a role in ER stress induced apoptosis (Hitomi et al., 2004; 
Pelletier et al., 2006), a conclusion that was challenged by other studies (Obeng and Boise, 
2005) and remained controversial thus far (Martinon and Tschopp, 2007). A recent study 
found that caspase-4 is a positive regulator of TNF-α-induced NF-kB signalling (Nickles et 
al., 2012). However, further work will be necessary to clarify to what extent caspase-4 is 
involved in apoptosis and inflammation. 
1.2.5 Pathogens and apoptosis 
Pathogens do both, they induce and inhibit apoptosis (Bannerman and Goldblum, 2003; 
Grassme et al., 2001; Hay and Kannourakis, 2002). They induce apoptosis accidentally, as a 
result of exposure by the immune system or on purpose as a defence mechanism as 
employed by many bacteria that target macrophages or neutophiles to prevent their deletion 
(Faherty and Maurelli, 2008; Grassme et al., 2001; Kobayashi et al., 2003). Several viral 
pathogens inhibit apoptosis to keep their host cells alive until the process of replication is 
completed. Well-timed apoptosis induction can then promote spreading to neighbouring cells 
that engulf the virus-loaded apoptotic bodies, which leads to the infection of surrounding cells 
with minimal risk of detection by the immune system due to avoidance of any contact with 
extracellular fluids (Hay and Kannourakis, 2002; Teodoro and Branton, 1997). 
Examples for viral inhibitors of apoptosis are baculovirus p35 and IAP, Epstein-Barr virus 
(EBV) BHRF1, LMP-1 and BALF1, human papillomavirus E6, SV40 Large T antigen, human 
immunodeficiency virus (HIV) GPx, Tat, Vpr and p17/p24 and cowpox virus (CPV) CrmA. 
that interfere with different parts of the intrinsically and extrinsically mediated apoptosis 
pathway (Hay and Kannourakis, 2002). 
The need for bacteria to prevent apoptosis is not as obvious as for viruses, since bacteria are 
autonomous self-replicating systems that do not depend on the viability of their host cells in 
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an absolute manner as viruses naturally do. However, not only obligate intracellular 
pathogens such as Ehrlichia chaffeensis, Rickettsia rickettsii and Chlamydia trachomatis, but 
also facultative intracellular (Shigella sp., Salmonella sp.) and extracellular pathogens 
(EHEC, EPEC) seem to profit from apoptosis prevention in vivo. According to (Faherty and 
Maurelli, 2008) apoptosis inhibition by pathogenic bacteria can be grouped into three 
different classes: 1. Protection of mitochondria, 2. Activation of cell survival pathways and 
3. Regulation of caspase activity. 
Examples for the first group, protection of mitochondria and prohibition of cytochrome c 
release, are Neisseria sp. and Chlamydia sp. Chlamydia sp. secrete a protein named 
‘clamydial proteasome-like activity factor’ (CPAF), which targets cellular BH3 domain 
containing proteins like Bik, Puma and Bim for degradation and thus prevents mitochondrial 
membrane permeabilization and subsequent cytochrome c release (Dong et al., 2005; 
Fischer et al., 2004; Pirbhai et al., 2006; Xiao et al., 2004; Zhong et al., 2006). Neisseria sp. 
targets its outer membrane protein PorB to the hosts’ mitochondria where it is thought to bind 
and block the mitochondrial permeability transition pore leading to the prevention of 
cytochrome c release (Massari et al., 2000; Massari et al., 2003) (see figure 6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The second strategy, activation of cell survival pathways, is employed by intracellular 
pathogens like Bartonella, Ehrlichia and Rickettsia that prevent cytochrome c release 
indirectly through upregulation of NF-kB and pro-survival gens (also cellular IAPs). 
Anaplasma phagocytophilum, the cause of granulocytic anaplasmosis, prevents apoptosis in 
its host cells, neutrophiles, not only by NF-kB activation, but also by upregulation of the p38 
MAPK, the extracellular signalregulated kinase (ERK) and the PI3K/Akt pathways (Choi et 
al., 2005; Lee and Goodman, 2006; Sarkar et al., 2012). Salmonella manipulate PI3K/Akt 
 
Figure 6. Interference of different pathogens with host cell pathways to prevent apoptosis. The 
inhibition modes of depicted pathogens are described in the text. 
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signalling through phosphorylation and thus activation of the cellular pro-survival 
serine/threonine kinase Akt via the bacterial T3SS effector SopB. Akt activation is sufficient 
to prevent cytochrome c release and thus apoptosis. 
The third strategy involves the manipulation of caspase activity and is used by Legionella 
pneumophila and Shigella flexneri. Shigella flexneri is able to prevent caspase-3 activation 
with one of its 17 MxiE regulated T3SS effectors; which one is unknown. Legionella 
pneumophila activates caspase-3 to evade the endosomal-lysosomal pathway (Abu-Zant et 
al., 2005) but keeps the host cell alive until at a late stage of infection, apoptosis is permitted 
and facilitates the pathogen’s escape from the dying cell (figure 6). 
Numerous pathogenic bacteria encode for several proteins involved in apoptosis regulation 
and employ more than one strategy to modify apoptosis pathways. This, and the fact that the 
majority of pathogens has evolved such mechanisms, suggests the assumption that 
apoptosis regulation provides an evolutionary advantage in successful host colonization in 
vivo. However, novel bacterial apoptosis regulators are identified constantly, thus further 
research is required to estimate the range of human cellular pathways manipulated by the 
large toolbox of bacterial pathogens. 
1.3 Phage Lambda 
1.3.1 Phages and bacterial pathogenesis 
Phages are viruses that target bacteria. With 107 particles/ml in coastal seawater and a 
global population of 1031 phages, they are the most abundant species on earth (Hendrix et 
al., 1999; Wommack and Colwell, 2000) and can be found pretty much everywhere from 
water and soil through to the intestine of animals. Phage infections do not always follow the 
common predator-prey mode that ends in bacterial lysis and release of phage progeny. 
Some pages are able to integrate into the hosts’ genome and stay there as prophages in a 
dormant stage to form so-called lysogenic bacteria or lysogens. During dormancy, prophage 
protein expression is, though reduced, not completely silent; they still express a small 
number of proteins that perform actions in the host cell, such as repression of the phages’ 
lytic genes. As horizontally mobile elements phages play a major role in the transfer of new 
genes into bacterial cells and thus promote bacterial evolution (Tinsley et al., 2006). To 
support spreading, delivered genes alter the phenotype of infected bacteria and provide 
evolutionary advantages, such as pathogenicity factors and/or toxins, to the lysogen, a 
process called lysogenic conversion. Well known examples for toxin encoding prophages are 
the CTXф phage of Vibrio cholerae (Waldor and Mekalanos, 1996), the β-phage of 
Corynebacterium diphtheriae and the H-19B phage of Escherichia coli that encode the 
cholera toxin ctxAB, the diphtheria toxin tox and the shiga-like toxins stx1 and stx2, 
respectively (Brussow et al., 2004). Additionally most EHEC and EPEC effector proteins and 
the T3SS are linked to a metagenome mainly consisting of lambdoid prophages (Tobe et al., 
2006). Thus phage biology is closely linked to bacterial pathogenicity and a closer look at 
different phages will certainly be worthwile cosidering the impact of phage infection on their 
host bacteria. 
1.3.2 Coliphage lambda 
Since its discovery in 1951 by Esther Lederberg, enterobacteria phage lambda is one of the 
most intensely studied biological organisms (Lederberg, 1951). There are many thousand 
papers about this phage and various molecular tools were derived from its genetic make-up. 
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Examples of such tools are phage display, the gateway technology and the recombineering 
technique, only to mention a few. Taxonomically enterobacteria phage lambda belongs, 
together with lambda-like viruses such as HK97, HK022 and the Stx-converting phages, to 
the family of Siphoviridae. Characteristics of this bacteriophage family are double stranded 
genomic DNA and a non-contractile tail. 
The lambda virion consists of an icosahedral capsid (the head), a tail and tail fibers. Due to a 
frame shift, the tail fibers are absent in laboratory strains, but occur in Ur-lambda (Hendrix 
and Duda, 1992). The head comprises a linear 48.5 kb double stranded DNA genome with 
12 bp single-stranded ends, the so-called cohesive ends or cos sites (Gottesman and 
Weisberg, 2004). In total, the phage lambda DNA comprises 92 open reading frames 
(ORFs), out of which 73 encode proteins.  
To perform infection, phage adsorption on the bacterial surface is required. It is mediated 
through an interaction between the tip protein of the central tail fiber, gpJ and the E. coli 
receptor lamB, which is a trimeric maltoporine located in the outer membrane (Charbit, 2003; 
Werts et al., 1994). The binding of gpJ to lamB leads to conformational changes in the tail 
and as a consequence triggers the injection of the DNA (Roessner et al., 1983) into the 
cytoplasm of the host, where it circularizes with the help of the terminal cos sites and finally 
gets fused by the host’s DNA ligase. The transition through the plasma membrane is not as 
well understood as through the outer membrane, but the proteins ManY and ManZ, which 
serve as a mannose transporter, are involved in lambda DNA transport though the inner 
membrane (Erni et al., 1987; Huber and Erni, 1996; Wegrzyn et al., 2012; Williams et al., 
1986). 
Once inside the bacterial cell, phage lambda can ‘choose’ between the lysogenic and the 
lytic way of infection. Establishment of either of the two life cycles is mediated through a 
complex set of regulations involving the presence of bacterial proteases and thus the 
condition of the host cell. Among the first lambda proteins to be expressed are early lytic 
genes like N, O and P as well as cII and cIII (Echols, 1986). CIII is a small 54 residue protein 
comprising a central α-helical domain (AS 14 to 37) sufficient for its function. It directly 
interacts with the bacterial FtsH (HflB) protease, which in turn is complexed with HflK and 
HflC at the cytoplasma membrane. Once bound cIII acts as a competitive inhibitor and at the 
same time as a substrate of HflB, keeping the protease busy, so that cII is unable to bind. 
The half-life of the so protected cII protein increases and with it its promoting effect on cI 
expression (Datta et al., 2005a; Herman et al., 1997; Kobiler et al., 2007). In addition cII was 
shown to interact with HflD, another protein that contributes to cII short half-life in the 
bacterial cell (Gottesman et al., 1981; Kihara et al., 2001; Parua et al., 2010). 
Altogether high levels of cIII correspond negatively with high levels of HflB and/or with an 
increased protease activity of the latter. Since stability of cII and expression of cI depend on 
sufficient levels of cIII for stabilization, phage lysogeny is only established when protease 
(HflB and probably others) activity is low. 
Once established lysogeny is a stable state until the lysogens are exposed to UV light or 
other DNA damaging agents leading to the activation of RecA, which in turn cleaves the 
lambda repressor cI, subsequently leading to induction of the lytic cycle. Further information 
on the establishment of lysogeny and the genetic switch can be obtained from (Court et al., 
2007; Friedman and Court, 2001; Gottesman and Weisberg, 2004; Ptashne, 2006). 
1.3.2.1 Lambda-host protein-protein interactions 
Just as for the lysis/lysogeny decisison, phage-host protein-protein interactions are relevant 
for different parts of the lambda life cycle, such as gpN and gpQ antitermination, replication, 
virion assembly and even lambda DNA integration into the bacterial genome, an essential 
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step for lysogeny establishment. In the following, I will discuss interactions of host and phage 
proteins involved in gpN antitermination and phage DNA replication as examples. A list of 
known phage lambda-host interactions is shown in table 2. 
 
Table 2. Published phage lambda-E. coli protein-protein interactions. Table obtained from 
(Hauser et al., 2012). 
λ Host Description References 
Transcription 
cI RecA RecA degrades cI* (Kobiler et al., 2004) 
cI RpoA  (Kedzierska et al., 2007) 
cI RpoD  (Li et al., 1994; Nickels et al., 2002) 
cI σ70 Interaction required for cI dependant 
gene expression at PRM promoter 
(Nickels et al., 2002) 
cII ClpYQ ClpYQ degrades cII in vitro (Kobiler et al., 2004) 
cII ClpAP ClpAP degrades cII in vitro (Kobiler et al., 2004) 
cII HflD HflD makes cII more vulnerable to 
FtsH (hfl = high frequency 
lysogenization) 
(Kihara et al., 2001) 
cII HflB HflB (= FtsH) protease degrades cII (Kobiler et al., 2004; Shotland et al., 2000) 
cII RpoA  (Kedzierska et al., 2004; Marr et al., 2004) 
cII RpoD  (Kedzierska et al., 2004) 
cIII HflB cIII inhibits HflB; HflB degrades cIII (Herman et al., 1997; Kornitzer et al., 1991) 
gpN NusA Transcriptional regulation (Friedman and Court, 2001) 
gpN Lon Lon degrades gpN (Gottesman et al., 1981; Kobiler et al., 
2004) 
gpQ σ70 gpQ antitermination  (Marr et al., 2001; Nickels et al., 2002; 
Roberts and Roberts, 1996; Roberts et al., 
1998) 
gpQ rpoB gpQ interacts with the β subunit of 
the RNA polymerase during gpQ 
antiterminaton 
(Deighan et al., 2008) 
Head 
gpB GroE genetic interaction; E. coli GroE (Ang et al., 2000; Georgopoulos et al., 
1973; Murialdo, 1979) 
gpE GroE genetic interaction (Georgopoulos et al., 1973) 
Tail 
gpJ LamB LamB is the E. coli receptor (Buchwald and Siminovitch, 1969; Clement 
et al., 1983; Mount et al., 1968; Wang et al., 
2000; Werts et al., 1994) 
Stf OmpC OmpC is a secondary E. coli 
receptor 
(Hendrix and Duda, 1992) 
Recombination 
Xis Lon Xis is degraded by E. coli Lon 
protease 
(Leffers and Gottesman, 1998) 
Xis  FtsH Xis is degraded by E. coli FtsH 
protease 
(Leffers and Gottesman, 1998) 
Xis Fis both required for excIsion  (Ball and Johnson, 1991; Cho et al., 2002; 
Esposito and Gerard, 2003) 
Int IHF Both catalyze recombination at 
attP/attB 
(Campbell et al., 2002; Crisona et al., 1999)
Gam RecB Gam inhibits RecBCD (Marsic et al., 1993) 
Gam sbcC  (Kulkarni and Stahl, 1989) 
Bet S1 Ribosomal S1 protein interacts with 
lambda bet 
(Muniyappa and Mythili, 1993) 
NinB SSB NinB also binds ssDNA (Maxwell et al., 2005) 
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λ Host Description References 
Replication 
gpO ClpXP ClpXP degrades gpO (Kobiler et al., 2004) 
gpO DnaK  (Liberek et al., 1988) 
gpO rpoB  (Szambowska et al., 2011) 
gpP DnaK  (Liberek et al., 1988) 
gpP DnaA  (Datta et al., 2005b; Datta et al., 2005c) 
gpP DnaB  (Mallory et al., 1990) 
 
1.3.2.2 Antitermination 
For the successful completion of the phage lambda lytic cycle, gpN and gpQ antitermination 
are required. The gpN antitermination complex is among the largest procaryotic transcription 
complexes; it comprises the phage lambda antitermination protein gpN along with several 
host proteins like NusA, NusB, NusE (s10) and NusG (Wegrzyn et al., 2012). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. A model of the gpN antitermination complex. RNA polymerase transcribes the phage 
lambda DNA starting from the immediate early promoter, which leads to the expression of gpN. As 
soon as gpN is present and the nut sites are transcribed, it modifies the transcription complex by 
recognizing the nut sites and directly interacting with NusA. Note: lambda gpN interacts with RNA (not 
DNA) comprising the nut sequence. The modified complex is capable of overreading the normally valid 
termination signal. Lambda gpN is degraded by the host lon protease, thus ongoing antitermination 
requires constant transcription of gpN.  
* = weekly bound to the RNA polymerase. Modified after (Das, 1992; Mason and Greenblatt, 1991). 
See also (Hauser et al., 2012). 
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GpN antitermination can start as soon as the lambda nut sites (N utilization sequence) are 
transcribed. The N protein captures the bacterial RNA polymerase (RNAP) by directly 
interacting with the RNAP-bound adaptor protein NusA. In addition gpN recognizes the boxB 
stem loop within the nut site and modifies the transcription complex such that it is capable of 
overreading the termination signal normally preventing delayed early transcription. N 
antitermination depends on the presence of the nut sites and thus affects only terminators 
located in the early phage lambda operons that reveal these sites (Conant et al., 2005). 
Since lambda gpN is constantly threatened by degradation through the host lon protease, 
ongoing antitermination requires constant transcription of gpN. Lambda gpN antitermination 
is schematized in figure 7. 
The other phage lambda antiterminator, gpQ, that controls the expression of the late genes, 
contacts the RNAP via the σ70 factor and competes with it for access to the flap domain of 
the β-subunit of the RNAP (rpoB). Another difference between gpN and gpQ antitermination 
is that gpN binds to nut sites on previously transcribed RNA, whereas the gbQ binding 
element (QBE, olso called qut site) is on DNA level (Deighan et al., 2008; Nickels et al., 
2002). 
1.3.2.3 Replication initiation 
Since lambda does not bring its own DNA polymerase, phage DNA replication critically 
depends on the hijacking of the host’s machinery via the replication proteins gpO and gpP. 
Lambda gpO, once expressed, forms dimers capable of binding to the four 18 bp direct 
repeats of the lambda origin, which in turn is located within the sequence of the lambda O 
gene. Each of the repeats is able to bind a gpO dimer, leading to a total of eight monomers 
directly bound to the DNA. In addition, non-DNA-bound gpO protein associates with the 
complex solely by protein-protein interaction (Dodson et al., 1986). The so formed 
nucleoprotein complex is called the O-some. After O-some assembly, the gpP protein 
withdraws the host’s DnaB helicase from the DnaB-DnaC complex (Zylicz et al., 1989). The 
DnaB helicase is inactive as long as it is tightly associated with gpP. The protein pair is 
added to the O-some through the protein-protein interaction between gpP and gpO. The 
three heat shock proteins DnaK, DnaJ and GrpE recruited in the following (DnaK through 
direct interaction with gpP and gpO) activate the DnaB helicase by liberating it from its 
inhibitory interaction with gpP. Then gpP as well as the chaperones are released and 
replication starts with the help of primase, DNA polymerase III, gyrase and the SSB (single-
strand binding) proteins (Dodson et al., 1986; LeBowitz and McMacken, 1986). 
In addition to the process described above, there are other factors that support replication in 
vivo, such as transcriptional activity in the lambda O region proceeding downstream of the 
lambda origin. Systems utilizing solely purified enzymes do not rely on transcriptional 
activation, whereas it is restored as soon as HU (histone-like) protein is added (Mensa-
Wilmot et al., 1989). Recently Szambowska et al. showed that the RNA polymerase β 
subunit (rpoB) directly interacts with gpO. Even though not yet fully understood, the role of 
the host RNA polymerase seems to be more complex than simply changing DNA topology as 
previously believed (Szambowska et al., 2011). Phage lambda DNA replication initiation is 
depicted in figure 8. 
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1.3.2.4 Lambda protein-protein interactions 
Only recently a study was published in which phage lambda proteins were systematically 
tested for protein-protein interactions (PPIs) among themselves using yeast two hybrid array 
screening (Rajagopala et al., 2011). In total 97 lambda-lambda interactions were detected, 
out of which 16 were previously published ones. This tells that even in a well-investigated 
organism such as phage lambda not all occurring PPIs are known and suggests the 
assumption that also many phage-host interactions are yet uncovered. However, a 
comparable approach for phage lambda-host interactions has not been published to date. 
 
 
 
Figure 8. Initiation of phage lambda DNA replication. Four dimers of the replication initiator protein 
gpO bind to sequences in the phage lambda origin. Subsequent delivery of the DnaB helicase by 
lambda gpP and its liberation from gpP by the host proteins DnaK, DnaJ and GrpE lead to the 
assembly of the lambda primosome and the initiation of replication. Figure obtained from (Hauser et 
al., 2012) 
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1.4 Yeast two-hybrid 
A variety of methods can be used to investigate protein-protein interactions. These involve 
bimolecular fluorescence complementation (BiFC) (Hu et al., 2002), phage display, yeast 
two-hybrid (Y2H) and co-immunoprecipitation as well as biophysical methods like surface 
plasmon resonance and microscale thermophoresis (MST) (Baaske et al., 2010; Wienken et 
al., 2010). Despite the availability of many different methods, co-immunoprecipitation of 
endogenous proteins is still seen as gold standard for the isolation of protein complexes and 
the detection of protein-protein interactions. However, as a labor-intensive method it suffers 
from several limitations making it unsuitable for high-throughput applications. 
A method that can be easily automated is yeast two-hybrid. It is an in vivo technique for the 
detection of binary protein interactions using yeast as a vessel to provide a cellular 
environment for protein folding. Aside from automatization, its main advantages in 
comparison to alternate methods include the avoidance of protein purification and the 
production of specific antibodies, making it a rather fast and cost-effective method and thus 
the technology of choice for the generation of high-throughput interactome datasets. 
1.4.1 The method in general 
Yeast two-hybrid (Y2H) was developed by Stanley Fields in 1989 (Fields and Song, 1989) 
and has thenceforth been a widely used method. In peak times nearly one thousand 
research articles were published annually using yeast two-hybrid for the detection of protein-
protein interactions. In addition, the principle was adapted by many other methods to detect 
not only protein-protein, but also protein-DNA and protein-RNA interactions. Some protocols 
use E. coli instead of yeast as a vessel (bacterial two-hybrid) (Hurt et al., 2003; Joung et al., 
2000). 
The basic principle of yeast two-hybrid relies on the binding of a transcription factor, usually 
GAL4, to DNA sequences resulting in the activation of downstream reporter genes. 
Transcription factors consist of two domains, namely a DNA-binding domain (DBD) and a 
transcription activation domain (AD), which do not work independently. The two domains are 
separately expressed from two different vectors, whereas the one harbouring the DBD is 
called bait vector and the other one that contains the AD is the prey vector. Two proteins of 
interest to be tested for binary interactions are then cloned into bait and prey vectors, which 
leads to gene-fusions with the GAL4-DBD and GAL4-AD, respectively. These clones are 
transformed either separately or combined into haploid yeast cells. In case of a separate 
transformation, two yeast strains with complementary mating types are used and bait and 
prey clones are combined in diploid yeast after mating. For high-throughput applications 
separate transformations are far more practical, since this allows one bait protein to be easily 
combined with many preys without the effort of retransformation. 
Yeast harbouring both plasmids is grown on selective medium usually lacking three essential 
amino acids, namely tryptophan, leucine and histidine. Whereas the leucine and tryptophan 
auxotrophy selection markers are constitutively expressed from the bait and prey vectors, 
respectively, the HIS3 gene is only expressed when a functional GAL4 transcription factor is 
available. Since GAL4-DBD and GAL4-AD are split, a functional GAL4 is only achieved if bait 
and prey protein interact with each other, leading to a reunification of both domains and thus 
to a recovery of GAL4 function. If bait and prey do not interact, the yeast remains histidine 
auxotroph and as such unable to grow on selective media lacking histidine. See figure 9 for 
an overview. 
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The stringency of Y2H can be varied by adding a competitive inhibitor of the 
imidazoleglycerol-phosphate dehydratase (the HIS3 gene product), such as 3-amino-1,2,4-
triazole (3-AT), to the medium. This reduces the concentration of functional enzyme and thus 
 
Figure 9. Flow chart visualizing the principle of yeast two-hybrid screening. Two genes of 
interest are fused to the GAL4 DBD and AD domains in the bait and prey vectors, respectively. Both 
vectors are transformed in haploid yeast, either as single or as co-transformations. For single 
transformants, bait and prey plasmids are combined by mating. If bait and prey are expressed as 
GAL4-DBD and -AD fusions in one yeast cell, the two domains of GAL4 are reunified if both proteins 
of interest (POI and POI2) interact with each other. This leads to GAL4-dependent transcription of 
reporter genes such as HIS3 (imidazoleglycerol-phosphate dehydratase) and Mel1 (α-galactosidase). 
If POI and POI2 do not interact, no transcription occurs. 
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the growth speed and survival rate of yeast on HIS selective medium. Many proteins 
generate unspecific interaction signals when co-expressed in yeast. These signals are often 
weaker than those from biologically relevant interactions and can thus be removed by adding 
variable amounts of 3-AT. 
1.4.2 High-throughput application 
As previously mentioned, Y2H provides many advantages for automatization and thus for 
high throughput application. These involve its practicability in any lab with no need for 
sophisticated equipment, its cost efficiency and scalability as well as its data quality, which is 
comparable to that of coaffinity purification followed by mass spectrometry (Yu et al., 2008). 
The method has already been used for the generation of many interactomes, e.g. (Albers et 
al., 2005; Hauser et al., 2011; Rajagopala et al., 2011; Sabri et al., 2011; Titz et al., 2008; 
Uetz et al., 2006; Uetz et al., 2000), which as such verified its applicability. 
1.4.2.1 Array screens versus pooled library screens 
Automatization can be done in different ways: as a series of binary tests arrayed as 
quadruplicates on agarose plates in a 384 format (array screens) or as pooled library 
screens. Array screens qualify especially for the generation of rather small interactomes such 
as those of bacteria, viruses and phages. Their advantage lies in the fact that each protein 
can be tested for binding separately against all potential interaction partners. However, even 
for bacteria with an average genome size like E. coli (~ 4200 protein coding genes in 
Escherichia coli str. K-12 substr. MG1655) this equals 4200*4200 (~ 18 million) binary tests. 
As a consequence this can only be afforded with the help of pipetting robots and is 
impracticable for organisms with larger genomes. 
When testing a relatively small number of baits against large proteomes as is the case for 
pathogen-host interactomes, pooled library screens (Mohr and Koegl, 2012) can be an 
alternative. The principle relies on the screening of a single bait protein against libraries 
containing a pool of prey proteins to be tested for interaction with the corresponding bait. 
Pooled libraries can contain a mixture of sequence-verified full-length ORF clones as well as 
batch-cloned cDNA or sheared genomic DNA of procaryotes. Both library types have 
advantages and disadvantages such as the increased quality of ORF clones and the 
coverage of a complete transcriptome or genome in case of batch-cloned libraries. 
Depending on the experimental requirements, both methods, array and pooled library 
screening, can be combined, leading to an array of small-scale pooled library screens. 
Therefore the bait protein is tested for binding against a prey pool consisting of up to 50 
preys. After the mating of bait and prey pool, the diploids are arrayed instead of spread on 
agarose plates. The interacting preys are identified by sequencing as done in standard 
pooled library screens. The combination of both methods reduces the number of binary tests 
usually required for array screens. However, if the bait interacts with more than one protein in 
the small prey pool, each prey has to be retested in pairwise tests. See figure 10 for a 
visualization of the procedures of array and pooled library screening. 
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1.4.2.2 False positives versus false negatives 
The usually high number of novel protein-protein interactions identified in high-throughput 
studies constrains the possibilities for verification by alternative methods and thus makes it 
especially prone to false positive and false negative identifications. To reduce the rather high 
false-discovery rate of yeast two-hybrid screens (Deane et al., 2002) several efforts have 
been made in the past (Chen et al., 2010; Koegl and Uetz, 2007; Stellberger et al., 2010). 
Screening with different vector systems that allow different expression levels of bait and prey 
proteins as well as the use of amino- and carboxy-terminal fusions of GAL4 domains result in 
the detection of different proteins of a ‘gold standard’ reference set of well characterised 
interactions. Even though the overlap between the vector systems is usually low, they can 
complement each other such that up to 80 percent of all interactions can be detected when 
more than one vector system is used for screening (Chen et al., 2010). This reduces the 
false negative rate to 20 percent, which is even lower than that determined by a comparable 
study using several different methods for the detection of the same gold standard reference 
set (Braun et al., 2009). 
The problem concerning false positive discoveries is more difficult to address, since there are 
many different reasons for their occurrence. Examples are proteins that are able to activate 
reporter gene transcription on their own (transcriptional activation), false-folded proteins 
aggregating randomly with any other protein or proteins that truly interact but would never get 
in touch with each other in their native biological systems. Even though useful strategies to 
address this problem have been introduced previously, such as binary tests of all bait 
proteins against pure prey vectors or the utilization of multiple reporter genes (Serebriiskii 
 
Figure 10. Yeast two-hybrid automatization as array and pooled library screening. Figure ‘pooled 
library screens’ modified after (Mohr and Koegl, 2012). 
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and Golemis, 2001), more comprehensive approaches are required to identify artefacts and 
thus clean up high throughput datasets from false positive interactions. 
1.5 Aims of this work 
E. coli is both, a suitable host for bacteriophages like phage lambda and a severe pathogen 
for several mammals and humans. With this work I hope to contribute to the clarification of 
the roles protein-protein interactions (PPIs) play in these cross-species reciprocations. My 
goal was to identify novel PPIs and thus to generate two representative host-pathogen 
interactomes, namely that of phage lambda and E. coli as well as that of EHEC effector 
proteins and their human target cells. 
Another aim arising in the course of this work was the functional characterization of a 
particular interesting interacting pair, namely EHEC NleF and human caspase-9, which was 
discovered in the frame of this study.  
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2 Material and methods 
2.1 Chemicals 
Unless otherwise specified, chemicals were ordered from Sigma-Aldrich Chemie GmbH 
(Steinheim), Carl-Roth GmbH (Karlsruhe), AppliChem GmbH (Darmstadt), MP Biomedicals 
(Illkirch Cedex, France), Bio-Rad (Munich), NeoLab (Heidelberg) and Biozyme GmbH 
(Hessisch Oldendorf). All solutions and buffers were prepared with deionised water and 
autoclaved for 20 min at 121 °C (2 bar) or sterile filtered with filters from Millipore 
(Schwalbach), 0.22 µM pore size. 
All enzymes and buffers for molecular biology were further ordered from Invitrogen GmbH 
(Karlsruhe), Fermentas (St. Leon-Rot), Promega (Mannheim), Roche (Mannheim) and New 
England Biolabs (Frankfurt am Main). 
2.2 Buffers and solutions 
1 M 3-AT        1 M   3-amino-triazole 
Dissolved in SD-∆LWH and stored at 4 °C.  
 
1 M CaCl2    111.1 g CaCl2 (anhydrous) 
     add 1 L ddH2O 
For 100 mM CaCl2 with 15 % glycerol mix 100 ml 1 M CaCl2 with 300 ml 50 % (v/v) glycerol 
and 600 ml ddH2O. 
 
Carrier DNA       10 mg/ml  herring- or salmon sperm DNA in ddH2O 
The carrier DNA solution was denaturized for 5 min at 95 °C and then stored at -20 °C. 
 
Caspase-9 storage buffer    20 mM Tris-HCl pH 8.0 
     130 mM NaCl 
 
10 mM Coelenterazine      1.0 mg coelenterazine (PJK GmbH, 
Kleinblittersdorf) (MW 423.5g) 
     236.0 µl methanol 
The stock solution is stable at -20 °C.  
Note: Coelenterazine is stable only in methanol, ethanol and basic solutions. Preferentially it 
is stored in methanol or in an inert gas. 
 
6x DNA loading dye:   10 mM  Tris-HCl (pH 7.6) 
60 mM  EDTA 
  0.03 %  bromophenol blue 
  0.03 %  xylene cyanol FF 
60 %   glycerol 
 
0.5 M EDTA    186.1 g EDTA 
       17.0 g NaOH pellets 
     add 1 L H2O  
Note: EDTA is soluble only at pH 8.0. The solution was autoclaved for 20 min at 121 °C 
(2 bar). 
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20 % Glucose     20 % (w/v) glucose in H2O (autoclaved) 
 
HMFM part I        3.6 g MgSO4 x 7 H2O 
       18.0 g trisodium cItrate (Na3C6H5O7 x 2 H2O) 
       36.0 g (NH4)2SO4 
              1760.0 g glycerol 
     add 3.2 L H2O 
The solution was autoclaved for 20 min at 121 °C (2 bar). 
 
HMFM part II      72.0 g KH2PO4 
     188.0 g K2HPO4 
     add 0.8 L  H2O 
The solution was autoclaved for 20 min at 121 °C (2 bar). 
 
1 L 10x HMFM   800.0 ml HMFM part I 
     200.0 ml HMFM part II 
 
1 M KxPO4        1.0 M KH2PO4 
     add 1 L H2O 
The solution is adjusted to pH 5.1 using KOH.  
 
Lithium acetate solution (100 ml)   10 ml  1 M lithium acetate  
         1 ml  1 M Tris-HCl, pH 7.8 
         0.2 ml 500 mM EDTA pH 8.0 
       89 ml  ddH2O 
 
LUMIER lysis buffer part I (1.1x)   22.0 mM  Tris-HCl, pH 7.5 
    1.1 %  Triton X 100 
275.0 mM  NaCl 
  11.0 mM  EDTA (pH 8.0) 
After mixing the buffer can be stored at 4 °C for up to one year. Note: The buffer is prepared 
as a 1.1x concentration.  
 
LUMIER lysis buffer   900.0 µL  LUMIER lysis buffer part I 
100.0 µL  Phosphatase Inhibitor Cocktail (Roche, 
Mannheim; stock: 1 tablet per 1 ml water) 
  40.0 µL  Protease Inhibitor Cocktail (Roche, 
Mannheim, stock: 1 tablet per 2 ml water) 
  10.0 µL  1M DTT 
    0.5 µL  Benzonase (Novagen, 25 U/µl) 
200 µl Dynabeads M-280 sheep anti-rabbit IgG 6-7x108 beads/ml, approximately 10 mg/ml 
(Roche) are used for 1 ml lysis buffer. Prior to use their storage liquid is removed and the 
beads are washed 3 times with 1 x PBS using a magnetic stand and finally resuspended in 
lysis buffer. The LUMIER lysis buffer is prepared freshly prior to use. The Phosphatase 
Inhibitor Cocktail, Protease Inhibitor Cocktail, DTT and Benzonase stock solutions are stored 
at -20 °C and the Dynabeads at 4 °C, respectively. 
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LUMIER renilla buffer      1.10 M NaCl 
       2.20 mM  EDTA pH 8.0 
    0.22 M  KxPO4 pH 5.1 
    0.44 g/L  BSA powder (Serva 11930) 
   *2.50 µM  coelenterazine (PJK 260350; MW 423.5) 
add 1 L H2O 
In general 1 L of LUMIER renilla buffer was prepared and stored in 50 ml aliquots at -20 °C 
for future usage.  
*The coelenterazine is added from a 10 mM stock (also stored at -20 °C) freshly prior to use.  
 
60 mM 4-MU    100 mM 4-methylumbelliferyl-alpha-D-galactoside 
       (4Mu-X, Biosynth, Sigma, M-7633) 
         5 ml  dimethylformamide 
No sterilisation is required; the solution is stored at -20 °C. 
 
NleF storage buffer     25 mM Hepes-NaOH pH 7.5 
     250 mM NaCl 
 
10x PBS      80.0 g  NaCl 
    2.0 g  KCl 
       14.6 g  Na2HPO4 (anhydrous) 
          2.0 g KH2PO4 
add 1 L H2O 
The solution was adjusted to pH 7.4 (HCl) and autoclaved for 20 min at 121 °C (2 bar). 
 
40 % PEG      40 % (w/v) PEG6000 in H2O 
The solution was autoclaved. For 50 % PEG use 50 % (w/v) PEG6000 in H2O. 
 
40 % PEG solution (100 ml)   80 ml  50 % PEG6000    
       10 ml  1 M lithium acetate 
         1 ml  1 M Tris-HCl pH 8.0 
         0.2 ml  0.5 M EDTA pH 8.0 
         9 ml  ddH2O 
 
0.25 % SDS        2.5 g sodium dodecyl sulfate (SDS) 
     add 1 L H2O 
The solution was autoclaved. 
 
Solution I (500 ml)   125 ml  2 M sorbitol (autoclaved) 
         5 ml  1 M Bicine-NaOH pH 8.35 
       15 ml  ethylene glycol 
       25 ml  DMSO 
     330 ml  ddH2O 
 
Solution II (50 ml)     40 ml  50 % PEG6000 
       10 ml  1 M Bicine-NaOH pH 8.35 
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Solution III (50 ml)       1.5 ml 5 M NaCl (autoclaved) 
     500 µl  1 M Bicine-NaOH pH 8.35 
       48 ml  ddH2O 
 
staurosporine 1 mg/ml 500 µg  staurosporine (Roche Diagnostics, 
Mannheim, Germany) 
     500 µl  DMSO 
The solution is stored at 4 °C for 3 months at maximum or at -80 °C for up to 6 months. 
 
50x TAE    242.0 g Tris base 
       57.1 ml glacial acetic acid 
     100 ml  0.5M EDTA pH 8.0 
     add 1 L  H2O 
The solution was adjusted to pH 8.0 and autoclaved. 
 
20 % Triton X-100     20 % (v/v) Triton X-100 in H2O 
The solution is stored at 4 °C. 
2.3 Culture media 
LB medium      10 g  Bacto Tryptone 
         5 g  yeast extract (Becton Dickinson) 
       10 g  NaCl 
     add 1 L H2O 
The medium was adjusted to pH 7.0. 
For preparation of LB solid medium 12 g/L of agar (GERBU Biotechnik GmbH, Wieblingen) 
was added prior to autoclaving. 
 
Antibiotic selection  Stock    Final concentration 
LB Kan     30 mg/ml (H2O)    30 µg/ml  
LB Amp   100 mg/ml (50%EtOH) 100 µg/ml 
LB Chloramphenicol   35 mg/ml (EtOH)    35 µg/ml  
LB Zeocin   250 mg/ml (ready to use)   25 µg/ml (low salt medium)  
LB Spectionomycin    50 mg/ml (H2O)    50 µg/ml  
LB Gentamycin    10 mg/ml (ready to use)   10 µg/ml 
 
Kanamycin, ampicIllin, chloramphenicol, zeocin, spectinomycin and gentamycin were 
obtained from AGS GmbH (Heidelberg), Sigma-Aldrich Chemie GmbH (Steinheim), 
Invitrogen GmbH (Karlsruhe), Genaxxon BioScience GmbH (Biberach) and PAA 
Laboratories GmbH (Pasching, Austria), respectively. 
 
200x Adenine       4.0 g adenine 
         Dissolve in 0.1 M  NaOH (in H2O) 
The solution was sterile filtered. 
 
10x CSM-∆L      70.0 g CSM -Leu (MP Biomedicals, Illkirch 
Cedex, France) 
     add 1.0 L H2O 
The solution was sterile filtered. 
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10x CSM-∆LW     67.0 g CSM -Leu -Trp (MP Biomedicals, Illkirch 
Cedex, France) 
     add 1.0 L H2O 
The solution was sterile filtered. 
 
10x CSM-∆LWH     62.0 g CSM -Leu -Trp -His (MP Biomedicals, 
Illkirch, Cedex, France) 
     add 1.0 L H2O 
The solution was sterile filtered. 
 
10x CSM-∆W      74.0 g CSM -Trp (MP Biomedicals, Illkirch, 
Cedex, France) 
     add 1.0 L H2O 
The solution was sterile filtered. 
 
SD-Medium    100 ml  10x YNB 
     100 ml  20% glucose  
     100 ml  10x CSM solution 
     700 ml  H2O (autoclaved) 
For SD-∆L, SD-∆W, SD-∆LW and SD-∆LWH, 10x CSM-∆L, 10x CSM-∆W, 10x CSM-∆LW 
and 10x CSM-∆LWH were used, respectively. For agar plates autoclave 700 ml H2O with 
16 g agar in a 1 L bottle and add the YNB, 20 % glucose and CSM solutions to the still liquid 
H2O/agar (~60 °C). 
 
10x YNB      67.0 g YNB (MP Biomedicals, Illkirch Cedex, 
France) 
     add 1.0 L H2O 
The solution is sterile filtered. 
  
YPDA full medium     22.2 g Bacto Peptone 
       11.1 g yeast extract  
     add 895 ml H2O 
The medium was autoclaved and the following solutions were added. 
     100 ml  20 % glucose 
         5 ml  200x Adenine 
Alternatively YPD ready to use powder was ordered at MP Biomedicals (Illkirch Cedex, 
France).  
2x YPD    100 g/L YPD powder 
The solution is sterile filtered. For 1x YPDA it is diluted 1:1 with sterile ddH2O and 5 ml 200x 
adenine were added per 1 L medium. 
 
YPDA/PEG mating medium   12 ml  2x YPD 
       60 µl  200x adenine 
       12 ml  40 % PEG6000 
The solution requires being prepared freshly prior to usage.  
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Human cell culture MEM  500 ml  Minimum Essential Medium (MEM) 
       50 ml  fetal calf serum (FCS) 
         5 ml  nonessential amino acids (NeAA) 
         5 ml  sodium pyruvate (100mM) 
         5 ml  Pen/Strep 
MEM, FCS, NeAA and sodium pyruvate were obtained from Gibco (Invitrogen). Pen/Strep 
(penicIllin and streptomycin) was ordered from the PAN Biotech GmbH (Aidenbach) 
2.4 Human cell culture 
2.4.1 HEK-293T, HeLa and Caco-2 cell culture 
All three human cell lines were grown in 100 mm tissue-culture dishes (Grainer) with 10 ml of 
minimum essential medium and 10 % of fetal calf serum at 37 °C and 5 % CO2 atmosphere. 
For cell passaging, which was done every third day, the cells were washed with DPBS 
(Gibco, Invitrogen), trypsinized as needed with 1.5 ml of 0.05 % trypsin-EDTA (PAN Biotech) 
and resuspended in 5.5 ml culture medium. Generally 0.5 – 1.0 ml of the cell suspension was 
added to 10 ml culture medium and replated in a fresh culture dish. 
2.4.2 Freezing and thawing cells 
Two culture dishes with human cells were grown for two days and harvested as described 
above for cell passaging. After trypsinization the cells were resuspended in 10 ml culture 
medium, sedimented at 400 rpm for 5 min and resuspended in 8 ml medium supplemented 
with 12.5 % DMSO. The cell suspension was distributed to four CryoTubes (nuncTM), placed 
in a freezing container (Nalgene) filled with 2-propanol and stored for 2 days in a -80 °C 
freezer. Finally the tubes were transferred to a liquid nitrogen container. 
If needed, the cells were thawed in a water bath at 37 °C until the medium was defrosted (not 
longer than 10 min, otherwise the viability of the cells decreases rapidly) and washed with 
10 ml of room temperature culture medium. Then the cells were resuspended in 10 ml 
prewarmed (37 °C) medium and plated in a tissue-culture dish. To remove dead cells the 
culture medium was changed daily until a cell density was reached that allowed passaging. 
2.4.3 Transient transfection of human cell lines 
300,000 HeLa or Caco-2 cells per well were plated on 6-well culture plates (Greiner) in 3 ml 
antibiotic-free culture medium at least 3 h before transfection. The transfection mixture was 
prepared in two separate tubes with 160 µl OptiMEM (invitrogen) in each. 1.5 µl of 
Lipofectamine™ 2000 (Invitrogen) were added to the first tube and 1.8 µg plasmid DNA to 
the other. After 5 min incubation time, the two tubes were combined and incubated for 20 to 
30 min at room temperature. Then the mixture was added to the cells (don’t remove the 
culture medium). After 6 hours the transfection media was replaced by 3 ml of antibiotic-free 
medium. After another 10 h the medium was changed into MEM containing 1 % Pen/Strep 
(PAN Biotech). Transfected cells were used 48 h after transfection. 
Transfection of HEK-293T cells was mostly done in 96-well plates with 10,000 cells and 
100 µl culture media per well. The transfection mixtures contained 0.075 µl 
Lipofectamine™ 2000 and 24 ng plasmid in 12 µl OptiMEM each. For HEK-293T cells no 
medium changes are required. 
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2.5 Molecular biology 
2.5.1 Primers 
If not otherwise specified, all primers used in the context of this work were ordered from 
Invitrogen GmbH (Karlsruhe), Sigma-Aldrich GmbH and Eurofins MWG GmbH (Ebersberg). 
Underlined, bold and red letters indicate restriction sites, start/stop codons and the Kozak 
sequence (CCACC), respectively.  
Y = C or T; Y is illustrated in red and bold.  
If Y equals T, there is no BamHI restriction site in the sequence indicating that the primer has 
a terminal stop codon. In case of Y = C, a BamHI site is available, which reveals that there is 
no stop codon in the end. This strategy allows the one shot cloning of constructs with and 
without terminal stop codon. Finally colonies were selected due to the presence or absence 
of a BamHI restriction site. 
 
List of primers used in this work 
ID Name   Primer  sequence (5´-3´) 
o0155 ECs0061  forw  AGGCTCCACCATGAAAGTATCAGTTCCAGG 
o0156 ECs0061  rev  CTGGGTGGATYCATTCAATAATTGCGTTGTCAGTAATT 
o0157 ECs0847  forw  AGGCTCCACCATGAAAATTCCCTCATTACAG 
o0158 ECs0847  rev  CTGGGTGGATYCATTGCTGATTGTGTTTGTCCAC 
o0159 ECs0848  forw  AGGCTCCACCATGTTATCGCCATATTCTGT 
o0160 ECs0848  rev  CTGGGTGGATYCAAATTTTACTTAATACCACACTAATAAGATC 
o0161 ECs0850  forw  AGGCTCCACCATGCGCCCTACGTCCCTC 
o0162 ECs0850  rev  CTGGGTGGATYCAAAGCAATGGATGCAGTCTTAC 
o0163 ECs0876  forw  AGGCTCCACCATGGATTGTTCAAAATGCAATG 
o0164 ECs0876  rev  CTGGGTGGATYCACAGCCATGCGTCTGGCG 
o0165 ECs1560  forw  AGGCTCCACCATGCTGCCCACTACAAATATC 
o0166 ECs1560  rev  CTGGGTGGATYCAACGCCACGCAACAGG 
o0167 ECs1561  forw  AGGCTCCACCATGAAAATAACAAACTATATACTGCC 
o0168 ECs1561  rev  CTGGGTGGATYCATTTCGATGCATTTACCATTGAG 
o0169 ECs1567  forw  AGGCTCCACCATGCCATTTTCAATCAAAAACAG 
o0170 ECs1567  rev  CTGGGTGGATYCATTCTTTTGTGTTGTGTATCTCTG 
o0171 ECs1568  forw  AGGCTCCACCATGCTTCCTACATCGC 
o0172 ECs1568  rev  CTGGGTGGATYCAAGAATATTTATATGTGGAACCAGAGTAT 
o0173 ECs1812  forw  AGGCTCCACCATGAACATTCAACCGACC 
o0174 ECs1812  rev  CTGGGTGGATYCAGACTCTTGTTTCTTGGATTATATCAAAG 
o0175 ECs1814  forw  AGGCTCCACCATGTTATCGCCCTCTTC 
o0176 ECs1814  rev  CTGGGTGGATYCATATCTTACTTAATACTACACTAATAAGATCCAG 
o0177 ECs1815  forw  AGGCTCCACCATGTTACCAACAAGTGGTTC 
o0178 ECs1815  rev  CTGGGTGGATYCATCCACATTGTAAAGATCCTTTGTTG 
o0179 ECs1824  forw  AGGCTCCACCATGCCTGTCATATTAAACTTTTC 
o0180 ECs1824  rev  CTGGGTGGATYCAAATTCTAGTGCATATATTTTGTGTGG 
o0181 ECs1825  forw  AGGCTCCACCATGCCAGTAAATGCGACA 
o0182 ECs1825  rev  CTGGGTGGATYCACCCCTGTATAACACGACTCAT 
o0183 ECs1994  forw  AGGCTCCACCATGCCATTAACCTCAGATA 
o0184 ECs1994  rev  CTGGGTGGATYCAATTACCCTTTATAACGAAGTTTCCTC 
o0185 ECs1995  forw  AGGCTCCACCATGCCTGTTACCACC 
o0186 ECs1995  rev  CTGGGTGGATYCACTTACAACAAAAAGCTTCTCTTTTTG 
o0187 ECs1996  rev  CTGGGTGGATYCAATTTTTTAAAACGAAGTTACCTCTGTCAG 
o0188 ECs2154  forw  AGGCTCCACCATGCCTGTAGATTTAACGCC  
o0189 ECs2156  rev  CTGGGTGGATYCAATTACCCTTTATAATGAAGTTTCCTCTG 
o0190 ECs2714  forw  AGGCTCCACCATGTCAATTATAAAAAACTGCTTATC 
o0191 ECs2714  rev  CTGGGTGGATYCATTTTTTGAGAGGATATATGTCAACATCG 
o0192 ECs2715  forw  AGGCTCCACCATGATTAACAATGTTTCTTCACTTTT 
o0193 ECs2715  rev  CTGGGTGGATYCACGAGCGCTTAGATGTATTAAT 
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o0194 ECs3485  forw  AGGCTCCACCATGCCGATGAATACTACAG 
o0195 ECs3485  rev  CTGGGTGGATYCATCCCTGTATAGCACGCATC 
o0196 ECs3486  forw  AGGCTCCACCATGCCAGTCATATTAAATTTTTCTAA 
o0197 ECs3486  rev  CTGGGTGGATYCAAATACTGTTTTGTTGAAGTGGGTATATG 
o0198 ECs3487  forw  AGGCTCCACCATGCCCAAAATATCATCAGT 
o0199 ECs3487  rev  CTGGGTGGATYCAATTTCTAACCAAGGGGTCCCATG 
o0200 ECs3855  forw  AGGCTCCACCATGCCAATAATAAACAAATCGG 
o0201 ECs3855  rev  CTGGGTGGATYCAATTGGAATAATAATTATATACATCGAGGAA 
o0202 ECs3857  forw  AGGCTCCACCATGTTATCTTCATTAAATGTCCTTC 
o0203 ECs3857  rev  CTGGGTGGATYCACCATGAACTGCAGGTATACAT 
o0204 ECs3858  forw  AGGCTCCACCATGATTAATCCTGTTACTAATACTC 
o0205 ECs3858  rev  CTGGGTGGATYCACTCAATTTTAGAAAGTTTATTATTTATGTATTTC 
o0206 ECs4550  forw  AGGCTCCACCATGCTTAATGGAATTAGTAACG 
o0207 ECs4550  rev  CTGGGTGGATYCACCCTTTCTTCGATTGCTCATAGG 
o0208 ECs4554  forw  AGGCTCCACCATGAATACTATTGATAATACTCAAG 
o0209 ECs4554  rev  CTGGGTGGATYCACCCAGCTAAGCGACCCG 
o0210 ECs4561  forw  AGGCTCCACCATGCCTATTGGTAATCTTGG 
o0211 ECs4561  rev  CTGGGTGGATYCAGACGAAACGATGGGATCCC  
o0212 ECs4562  rev  CTGGGTGGATYCACAATCGGGTATCCTGTACA 
o0213 ECs4564  rev  CTGGGTGGATYCATAATACGCTATAAGAGGAAGCTC 
o0214 ECs4571  rev  CTGGGTGGATYCAGGCATATTTCATCGCTAATGC 
o0215 ECs4590  rev  CTGGGTGGATYCAAGTGTTTTGTAAGTACGTTTCAGATG 
o0216 ECs4653  rev  CTGGGTGGATYCAAGCCTGGGTTATATTTTGTACAATATCG 
o0217 Second Primer attB2 GGGGACCACTTTGTACAAGAAAGCTGGGTGGATYCA  
o0218 Second Primer attB1 GGGGACAAGTTTGTACAAAAAAGCAGGCTCCACCATG   
o0219 ECs4562  forw  AGGCTCCACCATGTTTAGTCCAATGACAATG 
o0220 ECs4564  forw  AGGCTCCACCATGTCGTTATCAGGAGC 
o0221 ECs4571  forw  AGGCTCCACCATGGAAGCAGCAAATTTAAG 
o0222 ECs4590  forw  AGGCTCCACCATGATACTTGTTGCCAAATTG 
o0223 ECs4653  forw  AGGCTCCACCATGGTCGCTAAATTAAAACCA  
o0243 seq* pDONR221 forw CGGCCAGTCTTAAGCTCGGGC 
o0244 seq* pDONR221 rev GGGGATATCAGCTGGATGGC 
o0245 seq* ECs0061 forw CAATGAACTCAAAACATGCGC 
o0246 seq* ECs0847 forw GCCGATCACAGACATTTCG 
o0247 seq* ECs0848 forw CGAGTGTGGACTATAACAGGTTG 
o0248 seq* ECs0876a forw GTGATGAGAAAGGGATCACCG 
o0249 seq* ECs0876b forw CGCAATTAACTGATGGCATG 
o0250 seq* ECs0876c forw TGTCAGAGATGATCCAGAAACG 
o0251 seq* ECs1560a forw GCATATGATGTCAGTCAAGGC 
o0252 seq* ECs1560b forw GTAATACCATTAATCTAGGAGGGTG 
o0253 seq* ECs1560c forw TTATCCTGTCACACAGCAGAGTG 
o0254 seq* ECs1568a forw GCATCGAGTGCCTGACGG 
o0255 seq* ECs1568b forw AACGCAGTATGGGACCCC 
o0256 seq* ECs1812a forw CCTAGTTCCGTTTCAGGCATC 
o0257 seq* ECs1812b forw CTCTAGGGCTGGAGTTTGGC 
o0258 seq* ECs1814 forw CTCTGTTCATTCGAACAGACCTG 
o0259 seq* ECs2715 forw CCTCTGCCTGATGTGGCTC 
o0260 seq* ECs3487 forw AACGGTTATAAAACTACAAGGGC 
o0261 seq* ECs3855a forw CGCGACGCATAAACGAG 
o0262 seq* ECs3855b forw CCATACCTGGTTTATATCAGGC 
o0263 seq* ECs3857 forw GAATCATACCCTGCCAGTGAGAG 
o0264 seq* ECs4550 forw CACCGCCGCCACCG 
o0265 seq* ECs4554 forw GCGGCTAAAGGGGCTGG 
o0266 seq* ECs4561 forw CAGAGGAATGGTGTTGAGACC 
o0267 seq* ECs4561 forw GCGATTCCGTCAGGGG 
o0268 seq* ECs4590 forw GTGCTCCTGGAGTCAAACG 
o0269 seq* ECs4653a forw CTACACGGGGGCTACTTCG 
o0270 seq* ECs4653b forw GGAGGATGTTGTCCTGGCTC 
o0271 seq* ECs4653c forw GTGGAGATAGGTGCAAAGACTG 
o0272 seq* ECs4653d forw CCGCCGCCAGATGG 
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o0273 seq* pGBKCg rev CATGTCAAGGTCTTCTCGAGG 
o0274 ECs4561 rev  CTGGGTGGATYCAGTCGGTCGTGGTTGGGC 
o0275 ECs4561 forw  AGGCTCCACCATGGAAAATAATGCTCAGGCGC 
o0276 ECs1561  rev  CTGGGTGGATYCAACTTTCCCTCCCGTAAAG 
o0277 ECs1561  forw  AGGCTCCACCATGGGGGGGCTGAGTGGTG 
o0278 ECs1561  rev  CTGGGTGGATYCACCAAATAAACTGCTGCCCGC 
o0279 ECs1561  forw  AGGCTCCACCATGGGCGGGCAGCAGTTTATTTGG 
o0280 ECs4653  rev  CTGGGTGGATYCAACAGTCTTTGCACCTATCTCCA 
o0281 ECs4653  forw  AGGCTCCACCATGAGTGGAGATAGGTGCAAAGACTG 
o0282 ECs0876  rev  CTGGGTGGATYCAGCGCATTACT CGCCCAGA 
o0283 ECs0876  forw  AGGCTCCACCATGACGCAATTAACTGATGGCATG 
o0284 ECs1560  rev  CTGGGTGGATYCACCCTCCTAGA TTAATGGTAT TAC 
o0285 ECs1560  forw  AGGCTCCACCATGTAATACCATTAATCTAGGAGGGTG 
o0304 Casp8 forw  AGGCTCCACCATGGACTTCAGCAGAAATCTT 
o0305 Casp8 rev  CTGGGTGGATTCAATCAGAAGGGAATACAAGCTT 
o0306 Casp8 rev open  CTGGGTGGATCCAATCAGAAGGGAATACAAGCTT 
o136 Y2H PCRI forw  CTACAGGGATGTTTAATACCACTACAATGG 
o137 Y2H PCRI rev  GGTTACATGGCCAAGATTGAAACTTAGAGG 
o0080 Y2H PCRII forw  TGTTTAATACCACTACAATGGATGATG 
o0081 Y2H PCRII rev  CATAAAAGAAGGCAAAACGATG 
o0229 pGADCg PCRI forw CAAGCATACAATCAACTCCAAG 
o0230 pGADCg PCRI rev GAGGAGGCAATTGGTTGTG 
o0231 pGADCg PCRII forw GCAAAGATGGATAAAGCGG 
o0232 pGADCg PCRII rev GAGGTTCGGACCGTTGC 
o0303 ECs1815 C188Srev CTGGGTGGATTCATCCAGATTGTAAAGATCCTTTGTTG 
o0313 ECs1815 -1 rev  CTGGGTGGATTCAACATTGTAAAGATCCTTTGTTG 
o0314 ECs1815 +1 rev  CTGGGTGGATTCACGCTCCACATTGTAAAGATCCTTTGTTG 
o0315 ECs1815 -4 rev  CTGGGTGGATTCAAGATCCTTTGTTGTAAGTAAGATC 
o0316 ECs1815 L186A rev CTGGGTGGATTCATCCACATTGGGCAGATCCTTTGTTG 
o0317 ECs1815 Q187A rev CTGGGTGGATTCATCCACATGCTAAAGATCCTTTGTTG 
o0318 ECs1815 C188A rev CTGGGTGGATTCATCCAGCTTGTAAAGATCCTTTGTTG 
o0319 ECs1815 G189A rev CTGGGTGGATTCATGCACATTGTAAAGATCCTTTGTTG 
o0320 EPEC TIR forw  AGGCTCCACCATGCCTATTGGTAACCTTGG 
o0321 Nterm rev (stop)  CTGGGTGGATTCAATCGGTGGTTGTAGGATC 
o0322 EPEC TIR rev (stop) CTGGGTGGATTCAAACGAAACGTACTGGTCCC 
o0323 Cterm forw  AGGCTCCACCATGGAAAGCAATGCACAGGCGC 
o0324 Nterm rev (w/o stop) CTGGGTGGATCCAATCGGTGGTTGTAGGATC 
o0325 EPEC TIR rev (w/o stop) CTGGGTGGATCCAAACGAAACGTACTGGTCCC 
Seq* = sequencing; Primers marked as such were only used for sequence verification 
purposes.  
2.5.2 DNA Vectors 
The following vectors were used for cloning, transformation and transfection into E. coli, 
yeast and human cell lines. 
 
Entry vectors 
pDONR/zeo   ZeoR, gateway cassette 
pDONR221   KanR, gateway cassette 
 
LUMIER 
pTREX-dest30-ntPrA  AmpR, gateway cassette, SV40 origin of replication, N-terminal 
Staphylococcus aureus protein A tag. 
pcDNA3-Rluc-GW   AmpR, gateway cassette, SV40 origin of replication, N-terminal 
Renilla reniformis luciferase tag. 
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Protein expression in HeLa, Caco-2 and HEK-293T cells 
pdEYFP-C1amp AmpR, gateway cassette, N-terminal eYFP tag, SV40 origin of 
replication, CMV promotor 
 
Yeast two-hybrid prey vectors 
pDEST22 AmpR, Trp, gateway cassette, N-terminal GAL4-AD tag, 
ARS4/CEN6 origin (low copy vector in yeast) 
pGAD424_GW AmpR, Leu, gateway cassette, N-terminal GAL4-AD tag, 2 µ 
origin (high copy vector in yeast) 
pGADT7g  AmpR, Leu, gateway cassette, N-terminal GAL4-AD tag, 2 µ 
origin (high copy vector in yeast) 
pGADCg AmpR, Leu, gateway cassette, carboxy-terminal GAL4-AD tag 
(Stellberger et al., 2010), 2 µ origin (high copy vector in yeast) 
 
Yeast two-hybrid bait vectors 
pDEST32  AmpR, Leu, gateway cassette, N-terminal GAL4-DBD tag, 
ARS4/CEN6 origin (low copy vector in yeast) 
pGBT9_GW AmpR, Trp, gateway cassette, N-terminal GAL4-DBD tag, 2 µ 
origin (high copy vector in yeast) 
pGBKT7g KanR, Trp, gateway cassette, N-terminal GAL4-DBD tag, 2 µ 
origin (high copy vector in yeast) 
pGBKCg KanR, Trp, gateway cassette, carboxy-terminal GAL4-DBD tag 
(Stellberger et al., 2010), 2 µ origin (high copy vector in yeast) 
2.5.3 PCR 
DNA amplification for purposes other than cloning was generally performed with Taq 
polymerase from Thermus aquaticus. A polymerase with proofreading abilities, such as Pfu 
polymerase from Pyrococcus furiosus or Phusion® High Fidelity DNA Polymerase, a 
synthetic polymerase (New England Biolabs, Frankfurt am Main, Germany), were used if a 
precise nucleotide sequence was required.  
2.5.3.1 Standard PCR 
The standard PCR was done in a 50 µl reaction volume using the BIOTAQTM Red DNA 
Polymerase and corresponding reaction buffer from Bioline (Luckenwalde, Germany). An 
exemplary PCR reaction reads as follows: 
 
10x NH4 Buffer   5.0 µl 
50 mM MgCl2    2.0 µl 
100 mM dNTP Mix (Bioline)  0.5 µl 
Template    1.0 µl 
Primer forward   1.0 µl 
Primer reverse   1.0 µl 
BIOTAQTM Red   1.0 µl 
ddH2O              38.5 µl 
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The standard PCR program reads as follows: 
 
Initial denaturation   95 °C   3 min 
Denaturation    94 °C   1 min 
25x  Annealing    55 °C   1 min  
Elongation    72 °C   1 min per 1 kb DNA 
Final elongation step   72 °C            10 min 
Hold       4 °C 
 
An annealing temperature (Ta) of 55 °C was used as standard. If the optimal temperature 
differed significantly or if unspecific bands were observed, it was adjusted using the following 
formula:  Ta = [4 x (G+C) + 2 x (A+T)] - 5°C 
For E. coli colony PCR a variety of the standard PCR was used with a prolonged initial 
denaturation time of 5 min. 
2.5.3.2 Yeast colony PCR 
The yeast colonies obtained after each yeast two-hybrid library screen were identified using 
a two-step colony PCR protocol. For efficient lysis, a yeast colony was first resuspended in 
50 µl of a 0.25 % SDS (in ddH2O) and boiled at 95 °C for 5 min. 5 µl of the lysate were used 
in the first PCR step (see below). 
 
PCR no. 1 10x NH4 Buffer   5.0 µl 
50 mM MgCl2    2.0 µl 
100 mM dNTP Mix (Bioline)  0.5 µl 
Yeast lysate    5.0 µl 
Primer o136 Y2H PCRI*  0.3 µl 
Primer o137 Y2H PCRI*  0.3 µl 
ddH2O              35.9 µl 
After mixing, 2.5 µl of the reaction mix are removed and replaced by 2.5 µl of 20 % 
Triton X-100.  
Add BIOTAQTM Red   1.0 µl 
 
Run the following PCR program: 
 
Initial denaturation   95 °C   5.0 min 
Denaturation    95 °C   0.5 min 
27x  Annealing    55 °C   1.5 min  
Elongation    72 °C   3.5 min 
Final elongation step   72 °C   7.0 min 
Hold       4 °C 
 
1 µl of PCR no. 1 was used as template for PCR no. 2. 
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PCR no. 2 10x NH4 Buffer   5.0 µl 
50 mM MgCl2    2.0 µl 
100 mM dNTP Mix (Bioline)  0.5 µl 
PCR no. 1    1.0 µl 
Primer o0080 Y2H PCRII*  0.3 µl 
Primer o0081 Y2H PCRII*  0.3 µl 
ddH2O              39.9 µl 
BIOTAQTM Red   1.0 µl 
 
The program for PCR no. 2 is similar to that of the first PCR step, but with only 20 cycles and 
an increased annealing temperature of 58 °C. 
* The primers mentioned here are for the amplification of prey library inserts in pGADT7 or 
pGAD424 prey vectors. If a prey library with a carboxy-terminal GAL4 activation domain tag 
is used (vector: pGADCg), the primer pairs o0229/o0230 and o0231/o0232 have to be used 
for PCR no.1 and no.2, respectively. 
2.5.3.3 PCR mutagenesis 
Site-directed mutagenesis of the NleF C-terminus was done using the modified reverse 
primers o0313 – o0319 along with the ECs1815 forward primer (o0177). Due to the short 
length of nleF, amplification was done using the reaction mixture described for standard PCR 
(and the enzyme BIOTAQTM Red, Bioline). The PCR program was slightly modified, since it 
included the stepwise attachment of the Gateway ® attB sites. The program reads as follows: 
 
 Initial denaturation   95 °C     5 min 
Denaturation    95 °C     1 min 
9 x  Annealing    50 °C     1 min  
Elongation    72 °C     1 min 
Denaturation    95 °C     1 min 
25 x  Annealing    55 °C     1 min  
Elongation    72 °C     1 min 
Final elongation step   72 °C   10 min 
Hold       4 °C 
This program was run twice, once with EHEC genomic DNA as template and the gene-
specific primers (o0313 – o0319 and o0177) and again with 1 µl of the first PCR as template 
and the Gateway ® attB primers (o0217 and o0218). 
2.5.4 Gel electrophoresis and DNA extraction from agarose gels 
First all samples were mixed with 6x loading dye, then the electrophoresis of DNA was done 
using agarose gels containing 1 % agarose in 1x TAE buffer for 1 h at 90 -120 V, depending 
on the size of the gel. The gels were finally incubated in an ethidium bromide bath (1 L 
ddH2O plus 1 ml 1 % ethidium bromide solution from AppliChem, Darmstadt, Germany) for 
15 – 20 min and photographed using a LAS-4000 imaging system (Fujifilm Life ScIence, 
USA). 
Purification of DNA from the agarose gel was performed using the QIAquick PCR purification 
Kit (Qiagen, Hilden, Germany). 
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2.5.5 Gateway cloning 
The gateway cloning system is based on the integration and excision mechanism of 
bacteriophage λ. A gene of interest (GOI) is amplified in a two-step PCR that includes the 
stepwise attachment of the attB recombination sites and the PCR product is then inserted in 
an entry vector containing a so-called gateway cassette. This cassette contains the toxic 
ccdB gene (Bernard and Couturier, 1992) that is exchanged during the recombination 
reaction with the gene of interest and so allows a selection step aside from the antibiotic 
resistance marker. In a second recombination reaction, the GOI can be shuttled in different 
destination vectors for expression in bacteria or eukaryotic cells. Further information on 
gateway cloning can be obtained from (Hartley et al., 2000) and the Gateway ® Technology 
Manual provided by Invitrogen. Exemplary BP and LR recombination reactions read as 
follows: 
 
BP  PCR product with attB sites  6 µl 
  5x BP buffer    2 µl 
  pDONR vector (entry vector)  1 µl (150 ng/µl) 
  BP clonase enzyme mix  1 µl 
 
LR  ddH2O    5 µl 
entry vector with GOI   1 µl 
destination vector   1 µl 
  5x LR buffer    2 µl 
  LR clonase enzyme mix  1 µl 
Usually both reactions are performed at 25 °C over night.  After completion 1 µl of 2 µg/µl 
Proteinase K is added and the reaction is incubated at 37 °C for 10 min to degrade the 
clonase. Finally 5 µl are transformed in competent E. coli cells.  
 
All cloning in the frame of this work was done using the gateway technology. The correctness 
of the entry clones and expression vectors was assessed by sequencing and BsrGI 
restriction, respectively. 
2.5.6 Restriction of DNA 
The restriction enzymes used in the context of this work are listed below. If not stated 
otherwise, enzymes and corresponding buffers were ordered from (New England Biolabs, 
Frankfurt am Main, Germany). 
 
Enzyme Source      Reaction temperature 
AflII  Anabaena flos-aquae           37 °C 
ApaI  Acetobacter pasteurianus          25 °C 
BsrGI  Bacillus stearothermophilus GR75         37 °C 
BamH1 Bacillus amyloliquefaciens          37 °C 
NotI  Nocardia otitidis-caviarum (ATCC 14630)        37 °C 
SpeI  Sphaerotilus species (ATCC 13923)         37 °C 
XhoI  Xanthomonas holcicola          37 °C 
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Standard DNA restriction was done in 15 µl total volume for 1 h, an exemplary restriction mix 
(BsrGI) reads as follows: 
 
BsrGI  Template DNA   200 ng – 1 µg 
  10x BSA    1.5 µl 
  10x NEBuffer (2 or 4)   1.5 µl 
  H2O     add up to 15 µl 
The quality of digestion was assessed using gel electrophoresis. 
2.5.7 Cloning and plasmid propagation in E. coli 
The strains E. coli DH5α, E. coli DH10B, E. coli TOP10 (Invitrogen, Karlsruhe) were used for 
standard cloning purposes, whereas propagation of Gateway® Vectors harbouring the ccdB 
gene was done in the strain E. coli DB3.1 (Invitrogen). 
2.5.7.1 Preparation and transformation of chemically competent E. coli cells 
A single E. coli colony was picked and grown in 50 ml LB medium over night at 37 °C and 
200 rpm. 500 ml LB were inoculated with this starter culture to an OD600 of 0.05 and grown 
for 2 – 3 h until an OD600 of 0.4 was reached. Then the culture was placed on ice for 30 min 
and harvested at 4000 rpm and 4 °C. Subsequently the medium was discarded and the pellet 
was washed with 25 ml of ice cold 100 mM CaCl2. Finally, the cells were resuspended in 5 ml 
ice cold 100 mM CaCl2 with glycerol (15 % v/v), divided in 50 µl aliquots and frozen in liquid 
nitrogen. The tubes can be stored at –80 °C for up to 1 year, afterwards the transformation 
efficiency decreases. 
For transformation, an aliquot of competent cells was thawed on ice for about 20 min, then 
5 µl of gateway recombination reaction or 1 µl of plasmid DNA were added and the cells 
were incubated for another 30 min on ice. Subsequently a heat shock was done at 42 °C for 
60 sec and the cells were cooled down on ice for another 2 min before 750 µl of room 
temperature LB medium were added followed by an incubation period of 1 h at 37 °C and 
700 rpm. Finally 100 µl of the cell suspension was plated on selective agar plates. 
2.5.7.2 Electrocompetent E. coli cells 
For the preparation of electrocompetent E. coli, 500 ml bacterial culture were grown to an 
OD600 of 0.5 as previously described for chemically competent E. coli and then placed on ice 
for 20 min. All subsequent steps were performed at 4 °C. The cells were harvested at 
4000 rpm for 15 min, washed in 250 ml sterile ice cold ddH2O and resuspended in 10 ml ice 
cold ddH2O with 10 % glycerol. Finally the cells were distributed in 50 µl aliquots into 
pre-chilled tubes, frozen in liquid nitrogen and stored at -80 °C. 
The transformation of pooled libraries that required increased transformation efficiency was 
done using electrocompetent E. coli. An aliquot of the cells was thawn on ice and mixed with 
1 µl (0.5 – 1 µg) plasmid DNA. Then the suspension was incubated on ice for 5 min, 
transferred into a precooled electroporation cuvette (1 mm electrode gap, Peqlab, Erlangen) 
and pulsed once at 1.8 kV with a MicroPulserTM (Bio-Rad Laboratories GmbH, München). 
Directly after electroporation, the bacteria were mixed with 750 µl of LB medium and 
incubated at 37 °C for 1 h at 700 rpm. Finally the cells were plated on selective medium. 
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2.5.8 Plasmid DNA preparation 
Preparation of plasmids from bacteria was done using the Qiagen Mini, Midi and Maxi 
plasmid kits (Qiagen, Hilden, Germany). The purity and concentration of DNA was 
determined using the NanoDrop Spectrophotometer (Thermo ScIentific, Wilmington, USA). 
2.5.9 DNA Precipitation 
The DNA was mixed with 0.1 volumes of 3 M sodium acetate (pH 5.2) and 2.7 volumes of ice 
cold ethanol, then incubated for at least 2 h at -20 °C and further centrifuged at 20,000 rpm 
and 4°C for 1 h. The pellet was washed with 800 µl of ice cold 70 % ethanol, dried for 15 min 
under sterile conditions and finally resuspended in an appropriate amount of ddH2O. 
2.6 Proteomics 
2.6.1 Yeast two-hybrid 
Yeast two-hybrid (Y2H) is a method to detect interactions between two proteins in a living 
cell. The method is based on a transcription factor (GAL4) split in its two domains that do not 
work independently. If these two domains, namely GAL4-DNA-binding-domain (GAL4-DBD) 
and GAL4-activation-domain (GAL4-AD), are expressed as fusion proteins with two proteins 
of interest (POI) having affinity for each other, the two parts of the split protein are 
recombined and its function is restored. 
Yeast two-hybrid can be used in large-scale to screen whole interactomes as well as in 
small-scale for the detection of binary protein-protein interactions (PPI). In this work, Y2H 
was used to identify unknown interaction partners of defined bait proteins by screening 
against pooled prey libraries and for the verification of identified binary protein-protein 
interactions. 
2.6.1.1 Yeast strains 
Bait:  
CG1945 MAT a, ura3-52, his3-200, ade2-101, lys2-801, trp1-901, leu2-3 112, gal4-542, 
gal80-538, cyhr2, LYS2::GAL1UAS-GAL1TATA-HIS3, URA3::GAL417mers(x3)-
CYC1TATA –lacZ 
AH109 MAT a, ura3-52,  his3-200,  trp1-90,  leu2-3 112, gal4  gal80 , 
LYS2::GAL1UAS-GAL1TATA-HIS3, GAL2UAS- GAL2TATA-ADE2, URA3::MEL1UAS-
MEL1TATA –lacZ, MEL1 
Prey:  
Y187 MAT alpha, ura3-52, his3-200, ade2-101, trp1-901, leu2-3, 112, gal4 , met-, 
gal80 , URA3::GAL1UAS-GAL1TATA -lacZ, MEL1 
2.6.1.2 Competent yeast cells and transformation 
This protocol was used to transform bait plasmids for Y2H pool screening and bait and prey 
plasmids for Y2H binary tests.  
An overnight culture of 5 to 10 ml in volume was grown at 30 °C in YPDA at 180 rpm (Infors 
HT Multitron Cell incubator), inoculated in 500 ml 1x YPDA (start OD600 ~0.3) and grown for 
another 2 to 3 h until an OD600 of 0.6 – 0.8 was reached (this equals roughly a cell density of 
0.6 – 0.8*107 yeast cells per ml). Then the cells were harvested at 2900 rpm (~1000x g) for 
2 min, washed with 0.5 volumes (250 ml) of Solution I and resuspended in 0.02 volumes 
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(10 ml) of Solution I. Finally the yeast cells were divided in 0.2 ml aliquots and slowly frozen 
at -80 °C. To maximise transformation efficiency, all steps before freezing were done at room 
temperature. 
For competent yeast transformation, salmon or herring sperm carrier DNA (10 mg/ml) was 
denaturated at 95 °C for 5 min and placed on ice immediately. One 0.2 ml yeast aliquot per 
plasmid was taken out of the -80 °C freezer and also placed on ice. Then 2 µg plasmid DNA 
and 5 µl of denaturated carrier DNA were added to the still frozen yeast suspension and the 
mix was incubated for 10 – 15 seconds at 37 °C. After that it was mixed until the melting was 
complete, then 1.4 ml Solution II were added and after thorough mixing the suspension was 
incubated at 30 °C for 1 h at 700 rpm in a Thermomixer comfort (Eppendorf, Hamburg). 
Finally the cells were spun down (3000 rpm for 10 sec), resuspended in 150 µl Solution III 
and plated on selective agar plates (SD-∆W or SD-∆L, depending on the selective marker of 
the transformed plasmid). 
2.6.1.3 Yeast two-hybrid library transformation 
A colony of the yeast prey strain Y187 was precultured in 5 ml YPDA over night at 30 °C and 
180 rpm. About 1 ml of the overnight culture was inoculated in 500 ml YPDA (start OD600 
~0.1) and grown until an OD600 of 0.6 was reached, then the cells were harvested at 
2900 rpm (~1000x g) for 2 min at room temperature and washed in 120 ml sterile ddH2O. A 
second washing step was performed with 50 ml lithium acetate solution before the pellet was 
resuspended in 5 ml lithium acetate solution. Subsequently the cell suspension was 
distributed in 4 aliquots into 50 ml Falcon tubes and the following transformation mixture was 
prepared for each: 
 
  yeast cell suspension   1250 µl 
carrier DNA        50 µl 
plasmid DNA (prey library)      12.5 µg  
40 % PEG solution         7.5 ml 
The solution was mixed well and incubated for 30 min at 30 °C, followed by a heat shock at 
42 °C for 15 min. After the heat shock, the cells were spun down at 2900 rpm for 2 min at 
room temperature and resuspended in 1 ml of selective medium per tube. The yeast 
suspension was then plated on one selective agar plate per tube (Bio-Assay dishes, 245 x 
245 x 25 mm, nunc, Thermo scientific, Langenselbold) and grown for 2 -3 days at 30 °C. The 
number of yeast colonies was determined and the yeast was washed from the agar plates 
using 15 ml YPDA with 15 % glycerol. The suspension was divided in 50 µl aliquots and 
slowly frozen at –80 °C. For a pooled ORF library containing 12,000 genes, at least 120,000 
yeast colonies should be harvested (equals a 10x coverage), whereas for a human cDNA 
library at least 5 million colonies are required.  
Before usage one 50 µl aliquot was taken from the -80 °C freezer, inoculated in 35 ml 
selective medium and grown over night at 30 °C and 180 rpm to an OD600 between 1.0 and 
3.0. 
2.6.1.4 Yeast two hybrid pooled libraries 
E. coli W3110 libraries  See (Rajagopala et al., 2010) for the origin of the clones. 
The library in pDEST22 and pGADT7g was provided by 
Peter Uetz and SV Rajagopala 
Universal human cDNA library ordered ready to use from Clontech 
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ORF.01/02 and ORF.03 collection of 12,000 human genes in gateway compatible 
pGAD424 (ORF.01/02) and pGADCg (ORF.03) bait 
vectors with amino- and carboxy-terminal GAL4-DBD, 
respectively 
 
The ORF libraries ORF.01/02 and ORF.03 both originate from the same human gene 
collection (Brasch et al., 2004; Lamesch et al., 2007; Temple et al., 2009) in pDONR223 
entry vector that was shuttled into amino- and carboxy-terminally tagged prey vectors. The 
ORF.01/02 was provided ready to use by M. Koegl, whereas the ORF.03 was produced by 
myself. 
2.6.1.5 Library screens 
A single yeast colony harbouring the bait plasmid to be tested and an aliquot of the 
corresponding library were inoculated in 12 ml of selective medium each and grown over 
night at 30 °C and 180 rpm until an OD600 of approximately 1.0 was reached. Note that bait 
and prey plasmids require distinct selection markers to allow control for successful mating. 
Then both were mixed in a 50 ml plastic tube (FalconTM) and spun down at 2900 rpm for 
2 min at room temperature. The supernatant was discarded, 24 ml of YPDA/PEG mating 
medium were added and the yeast suspension was mixed thoroughly. Yeast mating was 
performed at 30 °C and 100 rpm for exactly 3 h before the cells were harvested at 2900 rpm 
for 2 min at room temperature. Then the pellet was washed with 10 ml of ∆LWH selective 
medium and resuspended in 200 ml ∆LWH comprising 75 µl of 60 mM 4-Methylumbelliferyl-
alpha-D-galactoside (4Mu-X, Biosynth) and 80 µl of 1 M 3-AT (0.4 mM final concentration). 
For determination of the mating efficiency (= screening depth), 10 µl of yeast solution were 
diluted with 990 µl ∆LW and 100 µl of those were plated on an ∆LW agar plate. Colonies 
were counted after 2 days and the screening depth (in millions) was determined with the 
following formula:  
Screening depth in millions (for 200 ml suspension in total) = number of colonies x 0.2 
The number should be above 5 million. 
The remaining yeast suspension was distributed to 10 96-well plates (Flat-bottom 
transparent microtiter plates), 200 µl per well, and grown at 30 °C without shaking for 6 days. 
Then the fluorescence of the plates was measured at an excitation of 360 nm and an 
emission of 465 nm using the TECAN Infinite 200 Reader (equipped with stacker, automated 
loading system, and bar-code reader). All wells harbouring a yeast colony and revealing 
fluorescence at least two fold above that of the plate mean were seen as positive for an 
interaction. 10 µl of each positive yeast colony were then collected, re-arrayed on a fresh 96-
well microtiter plate harbouring 200 µl ∆LWH per well and grown for another two days. Finally 
the re-array plates were used as template for the previously described yeast colony PCR 
steps and the PCR product was sequenced (GATC, Konstanz, Germany) to identify the prey 
insert. A flow diagram visualizing the principle of Y2H pool screening is shown in figure 11. 
Further details can be obtained from (Mohr and Koegl, 2012). 
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2.6.1.6 Pairwise tests 
To test binary interactions in Y2H, a single bait and a single prey plasmid were transformed 
in bait and prey yeast strains (as previously described in ‘Competent yeast cells and 
transformation’), respectively. A colony of each was then grown over night in 1 ml selective 
medium at 30 °C and 180 rpm. Subsequently 500 µl of bait and prey were mixed, spun down 
at 2900 rpm for 2 min at room temperature and 1.5 ml YPDA/PEG mating medium were 
added. Cells and mating medium were mixed thoroughly and the mating was performed at 
30 °C and 100 rpm for 3 h. Then the cells were harvested at 2900 rpm for 2 min, washed 
with 2 ml ∆LW medium and resuspended in 1 ml ∆LW. The diploids were grown for 2 days in 
liquid ∆LW at 30 °C without shaking and then plated on selective agar plates (∆LWH). If bait 
and prey protein interact, visible colonies appear after 2 days. If required the stringency was 
adjusted by adding an appropriate amount of 3-AT to the selective agar plates. 
2.6.2 LUMIER assay 
Luminescence-based mammalian interactome mapping (LUMIER) was used to test for 
binary protein-protein interactions in 96-well format (Barrios-Rodiles et al., 2005; Pfefferle et 
al., 2011; Tahoun et al., 2011). The two proteins of interest, harbouring an N-terminal 
Staphylococcus aureus protein A and Renilla reniformis luciferase tag, respectively, were 
transiently expressed in HEK-293T cells. Roughly 40 h after transfection (see ‘Transient 
 
Figure 11. Flowchart visualising the principle (A) and procedure (B) of yeast two-hybrid pool 
screening. (A) The bait harbours a plasmid encoding a protein (protein of interest, POI) to be tested 
for interaction against a prey library containing several thousand different plasmids. Bait and prey 
library are mated to combine the bait protein with the library. If the bait found an interacting protein, the 
GAL4-DBD and the GAL4-AD fused to bait and prey protein, respectively, are joined leading to GAL4 
functioning as transcription factor and thus to GAL4-dependent expression of the selective markers 
HIS3 and MEL1. HIS3 encodes the imidazoleglycerol-phosphate dehydratase whose expression leads 
to histidine prototrophy. MEL1 encodes an α-galactosidase that cleaves 4-MU and thus generates 
measurable fluorescence when expressed. (B) Scheme of the different steps of the Y2H pool 
screening procedure. Further explanation can be obtained from the text. 
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transfection of human cell lines’), the medium was removed and 10 µl ice cold LUMIER lysis 
buffer, including the sheep anti-rabbit IgG-coated magnetic beads (Dynabeads M280, 
Invitrogen), were added to each well. The lysis was done for 15 min on ice and 100 µl of 1x 
PBS were added afterwards. 10 µl of the lysate were then placed in another plate to 
determine the total luciferase activity of each sample (lysate plate). The remaining 100 µl 
were washed five times with 1x PBS using a TECAN HydroFlexTM bead washer. The bead 
washer is set to leave 20 µl of 1x PBS in each well after the washing is completed. 
Luciferase activity of the washed beads as well as of the lysate plate was determined using a 
TECAN Infinite 200 Reader. 10 sec before measuring, the TECAN reader injected 70 µl of 
LUMIER Renilla buffer to each well to start the luciferase reaction.  
A vector harbouring a dimer of protein A was used as negative control and tested for binding 
to the Renilla reniformis luciferase tagged second protein. Also for the negative control both 
the lysate before washing and the washed beads were measured. This adds up to a total of 
four values measured for each protein pair to be tested for binary interaction. For data 
analysis, a signal to background ratio was determined as follows: 
(Signal of washed beads)/(signal of 10 µl of the lysate, non-washed) for both the interaction 
test (the two proteins to be tested for binary interaction) and the negative control (protein A 
dimer and the luciferase-tagged second protein) to obtain “signals normalised for expression 
levels”. The JUN/FOS protein pair was used as positive control. 
2.6.3 Detection of Caspase activity 
For the detection of caspase-9 activity in vitro, the Caspase-9 inhibitor screening kit 
(KA0763, Abnova, Taiwan) and the Caspase-Glo ® 9 assay (Promega, Madison, USA) were 
used. Detection of caspase-4 and -8 was done with the Caspase-4 and -8 inhibitor screening 
kits (KA0747 and KA0758, Abnova, Taiwan), respectively. All three Abnova caspase inhibitor 
screening kits provide active caspase along with the corresponding kit. Active caspase-9 and 
NleF (purity of both proteins >90 % per SDS page) were obtained from Proteros (Martinsried, 
Germany) as part of a cooperation project. Detection of caspase-9 activity in cell lasates was 
performed using the Apopcyto caspase-9 fluorometric assay kit (MBL, Massachusetts, USA). 
2.6.3.1 Caspase-9 activity in cell lysate 
3 h after splitting or 48 h after transfection, HeLa cells (6-well plates containing 300,000 cells 
in 3 ml culture medium) were treated with 25 ng/ml SuperKillerTrail (ENZO Life ScIences) or 
5 µM staurosporine (Roche Diagnostics) for 6 h. The medium was collected in 15 ml 
centrifuge tubes, the cells were washed with PBS and trypsinized with 200 µl of 0.05 % 
trypsin-EDTA (PAN Biotech). The washing buffer and the trypsinized cells were added to the 
previously collected medium, the tube was centrifuged at 300 rpm for 5 min and the 
supernatant was discarded. The cell pellet was placed on ice before 250 µl of ice cold lysis 
buffer (Apopcyto kit, MBL) were added. Lysis was performed for 10 min on ice. Subsequently 
the cell lysate was centrifuged at 10,000x g for 5 min at 4 °C and the supernatant was 
transferred into a new eppendorf tube and diluted with more lysis buffer (the lysate can be 
stored at -80 °C for up to 6 months). 25 µl of 2x reaction buffer (supplemented with 10 mM 
DTT) and 22.5 µl of the cell lysate were placed per well in a precooled black 96-well plate. 
0.5 µl of the LEHD-FMK caspase-9 inhibitor (1 mM stock, Apopcyto, MBL) were added to the 
negative control. For the determination of native caspase-9 activity in presence of purified 
NleF, 2.5 µg NleF were added. The reaction was started by adding 2 µl caspase-9 substrate 
(Apopcyto, MBL). Then the plate was incubated for 1 – 2 h at 37 °C before the fluorescence 
was measured at excitation 380 nm and emission 460 nm using a TECAN Infinite 200 
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Reader. Caspase-9 activity with and without NleF was compared for purified and expressed 
NleF.  
2.6.3.2 Caspase-4, -8 and -9 activity in vitro 
The activities of caspases 4, 8 and 9 were measured using the Abnova caspase inhibitor 
screening kits. For determination of the IC50 (caspases 4 and 8) 1:2 serial dilutions of NleF 
were prepared starting at a caspase:NleF ratio of 8:1 and ending at 1:256. Each row was 
done in triplicate and the whole plate was repeated twice or more. Usually the reaction was 
performed in a total volume of 50 µl comprising 0.5 units of caspase. Blank reactions were 
done without active caspase and specificity of measured activity was assessed by comparing 
wells containing 20 µM Z-VAD-FMK to inhibitor-free caspase reactions. The plate (black 
nunc, 96-well) was incubated for 1 – 2 h at 37 °C and measured with a TECAN Infinite 200 
Reader at 400 nm excitation and 505 nm emission. Further information can be obtained from 
the manufacturer’s instructions. 
The IC50 of caspase-9 was determined using the Caspase-Glo ® 9 assay (Promega, 
Madison, USA) and purified caspase-9 from Proteros (Martinsried, Germany). The serial 
dilutions of NleF were done as described for the Abnova assays, the reaction volumes were 
either 50 or 100 µl and between 1 and 5 units of active caspase-9 were used per reaction. 
The experimental procedure was performed following the manufacturers protocol. 
Luminescence was measured with a TECAN Infinite 200 Reader. 
Inactivation of purified NleF was done using 1 µl of Proteinase K (2 µg/µl) per 50 µg purified 
NleF in 10 µl 25 mM HEPES pH 7.5. The digestion was done for 30 min at 37 °C and the 
Proteinase K was then inactivated for 45 min at 85 °C. 
To determine the concentration of active sites of caspase-4, -8 and -9, the Z-VAD-FMK 
(Z-VAD-fluoromethylketone, non-omethylated, MP Biomedicals, Eschwege, Germany) 
inhibitor was used. 
2.7 Flow cytometry (FACS) 
HeLa or Caco-2 cells were transfected as previously described (6.4.3 Transient transfection 
of human cell lines) with pdEYFP-C1amp containing YFP-fusions of BCL2, Protein A, XIAP, 
NleF and different NleF fragments as well as mutagenized versions of NleF. Apoptosis was 
induced for 6h with 25 ng/ml SuperKillerTrail (ENZO Life ScIences) or 5 µM staurosporine 
(Roche Diagnostics), 48 hours after transfection. After apoptosis induction, the culture 
medium was collected in 15 ml plastic tubes, the cells were washed with 1x PBS and 
trypsinized with 200 µl of 0.05 % trypsin-EDTA (PAN Biotech). Washing buffer and 
trypsinized cells were collected together with the culture medium. The cells were spun down 
at 300 rpm for 5 min, the pellet was washed with 1 ml 1x PBS and resuspended in 100 µl 1x 
Annexin-V binding buffer (BD Pharmingen™). For staining necrotic and apoptotic cells, 5 µl 
of each, propidium iodide (PI) and Annexin-V-allophycocyanine (APC) (both BD Biosciences 
Pharmingen), were added. Subsequently the cells were incubated for 20 min in the dark on 
ice to allow binding of the dye and transferred to FACS tubes. Then 400 µl of 1x Annexin-V 
binding buffer was added. Flow cytometry was performed using the BD FACS Canto II flow 
cytometer with a 488 nm laser. PI, Annexin-APC and YFP were measured with a 670 nm 
long pass filter, a 660/20 nm and a 530/30 nm band pass filter, respectively. Blots were 
analyzed using the FACSDiva software (BD BioscIences). 
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2.8 Bioinformatic tools and web interfaces 
For the identification of protein domains, InterProScan (Quevillon et al., 2005) 
(http://www.ebi.ac.uk/Tools/pfa/iprscan/) was used. 
Predictions of intrinsic protein disorder and globularity were done with GlobPlot (Linding et 
al., 2003) (http://globplot.embl.de/). 
Interaction maps were generated using Cytoscape (Shannon et al., 2003) and published 
human interactions were retrieved from the BioGRID database (Stark et al., 2011) 
(thebiogrid.org). 
2.9 Data analysis 
Analysis of raw data was usually done using Microsoft Access and Excel (both, the 2003 and 
the 2010 versions). Significance of the results was assessed using the two-tailed unpaired    
Student’s t-test. * p<0.05; ** p<0.01; *** p<0.001; **** p<0.0001. 
 
RESULTS 
 
45
3 Results 
3.1 Part I: The EHEC-host interactome 
According to Tobe et al. 2006 enterohemorrhagic Escherichia coli  (EHEC) O157:H7 strain 
Sakai harbours more than 60 putative effector proteins out of which 39 were experimentally 
proven to be injected into human host cells (Tobe et al., 2006). In order to identify novel host 
interaction partners of these EHEC effector proteins, I cloned 34 out of the 39 effectors to 
screen them against three human libraries, namely the Universal human (Clontech), the 
ORF.01/02 and the ORF.03, using Y2H pool screening.  
3.1.1 Construction of a C-terminally tagged human prey library 
The ORF.03 library (carboxy-terminal GAL4-AD tag) was constructed mainly for this work, 
since screening a bait protein N- and C-terminally tagged against N- and C-terminally tagged 
libraries increases the number of detected interactors and thus the coverage of Y2H 
screening significantly (Stellberger et al., 2010).  
The pooled human ORF collection comprising roughly 12,000 human ORFs (Brasch et al., 
2004; Lamesch et al., 2007; Temple et al., 2009) was shuttled into the pGADCg prey vector 
(Stellberger et al., 2010) via six standard gateway LR reactions and transformed into E. coli. 
The transformation was done in six batches resulting in > 1.4 million harvested E. coli 
colonies. The plasmids of the pooled colonies were isolated and retransformed into the 
haploid yeast strain Y187, which in turn led to 776,759 yeast colonies in total. This exceeds 
the minimal coverage of pooled Y2H libraries (10x) by more than six times (see ‘Yeast two-
hybrid library transformation’ for details). 
3.1.2 Pool screens of EHEC effector proteins against human libraries 
The 34 EHEC effectors (see table 3 for a complete list) were cloned into a pDONR221 entry 
vector using the gateway technology and shuttled into pGBT9 and pGBKCg Y2H bait vectors 
harbouring an amino- and carboxy-terminal GAL4-DNA-binding domain, respectively.  
 
Table 3. Cloned and screened EHEC effector proteins. The columns ‘Hits’ and ‘Verifiable Hits’ 
state, if positive yeast colonies and verifiable interactors were identified in the Y2H pool screens. Out 
of the 34 EHEC effector proteins, 21 interacted with host proteins in Y2H screens, whereas for 15 
effectors one or more of these host interactors was detected repeatedly. The remaining 12 EHEC 
effectors did not give any hits, not even when screened at the lowest stringency (0 mM 3-AT). The 6 
effectors that only found single hits or promiscuous preys were categorized as putative random 
interactors and as such excluded from further evaluation. 
 EHEC str. Sakai effector protein ECs ID Effector family Hits Verifyable hits 
1 EspY1 ECs0061 SopD_Nterm yes yes 
2 NleC ECs0847 NleC yes yes 
3 NleH1-1 ECs0848 NleH yes - 
4 NleD ECs0850 NleD yes yes 
5 EspX2 ECs0876 PPR - - 
6 EspX7 ECs1560 PPR; LRR - - 
7 EspN ECs1561 CNF - - 
8 EspO1-1 ECs1567 OspE yes yes 
9 EspK ECs1568 LRR yes - 
10 NleA ECs1812 NleA yes yes 
RESULTS 
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 EHEC str. Sakai effector protein ECs ID Effector family Hits Verifyable hits 
11 NleH1-2 ECs1814 NleH yes yes 
12 NleF ECs1815 NleF yes yes 
13 NleG ECs1824 NleG yes - 
14 EspM1 ECs1825 IpgB - - 
15 NleG2-2 ECs1994 NleG yes - 
16 NleG6-1 ECs1995 NleG - - 
17 NleG5-1 ECs1996 NleG - - 
18 NleG2-3 ECs2156 NleG - - 
19 EspJ ECs2714 EspJ yes yes 
20 TccP ECs2715 EspF yes yes 
21 EspM2 ECs3485 IpgB - - 
22 NleG8-2 ECs3486 NleG - - 
23 EspW ECs3487 HopW - - 
24 EspL2 ECs3855 AR - - 
25 NleB1 ECs3857 NleB yes yes 
26 NleE ECs3858 NleE yes - 
27 EspF1 ECs4550 EspF yes yes 
28 EspB ECs4554 EspB yes yes 
29 TIR ECs4561 TIR yes yes 
30 Map ECs4562 IpgB yes yes 
31 EspH ECs4564 EspH yes - 
32 EspZ ECs4571 EspZ - - 
33 EspG ECs4590 EspG yes yes 
34 EspY4 ECs4653 SopD_Nterm -  - 
 
These effector proteins were screened as N- and C-terminally tagged bait proteins against 
three pooled Y2H prey libraries, namely a human cDNA-based library as well as the C-and 
N-terminally tagged libraries based on full length open reading frames. This resulted in the 
identification of 296 different human prey proteins and 328 interacting bait/prey pairs. 273 of 
the latter were single or unconfirmed hits, meaning these bait/prey pairs were found only 
once. Single hits may be artefacts, but may as well be real interactors. A final statement 
cannot be made, since weak or short-term interactions may also come up as single hits.  
56 interacting pairs were detected repeatedly, out of which 35 could be classified as high 
confidence hits. The latter are defined as non-promiscuous prey proteins found to interact 
repeatedly with the same bait protein. In addition 35 preys were classified as potentially 
promiscuous. See table 4 and figure 12 for a summary of the resulting screen data and a 
flowchart visualizing the sequence of the screening procedure, respectively.  
 
Table 4. Y2H data sheet. The total number of prey proteins, promiscuous preys, bait/prey pairs, 
single hits, repeatedly detected hits and high confidence hits found in the EHEC/host screens. 
Total number of identified human prey proteins 296   
Promiscuous human prey proteins 35  
Unique bait/prey pairs 328  
Single Hits 273  
Repeatedly detected hits 56  
High confidence hits 35   
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3.1.2.1 Identification of potentially promiscuous prey proteins 
False positive interactions are a long known problem in yeast two-hybrid screening 
(Serebriiskii and Golemis, 2001). To reduce potential sources of false positives, prey proteins 
were inspected for their likeliness to interact with different bait proteins. A prey protein was 
then tagged as potentially promiscuous, if it interacted with more than 1 % of all bait proteins 
screened via Y2H pool screening at the DKFZ Y2H core facility (Schwarz et al., 
unpublished). If a prey protein interacted with 1 % of all baits previously screened in the Y2H 
core facility, a promiscuity factor of 1 was assigned. The higher a preys promiscuity factor, 
the higher is its probability to be a random interactor and thus to be a false positive hit.  
 
Table 5. Promiscuous prey proteins. 35 human proteins found to interact with EHEC effectors were 
tagged as potentially promiscuous and thus as putative artefacts. The promiscuity factor equals the 
relative prey promiscuity in percent. 
  Prey gene symbol Promiscuity factor   Prey gene symbol Promiscuity factor 
1 CRX 23.0 19 VEGFB 1.3 
2 COPS5 18.3 20 ZNF343 1.3 
3 MEOX2 14.5 21 HBA1 1.2 
4 OTX2 9.2 22 MTMR9 1.2 
5 BEND7 5.3 23 PNMA1 1.2 
6 TIGD1 2.7 24 SEP15 1.2 
7 ALX1 2.5 25 URM1 1.2 
8 CTDSP2 2.5 26 CBX4 1.0 
9 HBA2 2.2 27 MCRS1 1.0 
10 PALLD 2.0 28 MPV17 1.0 
11 SNX3 2.0 29 NDUFV3 1.0 
12 RING1 1.8 30 NEK2 1.0 
13 RPL21 1.8 31 PTPN6 1.0 
14 EIF4B 1.7 32 SDHD 1.0 
15 CDCA4 1.5 33 SFRS3 1.0 
16 DNAJC7 1.5 34 TIMM8A 1.0 
17 XRCC6 1.5 35 TTC1 1.0 
18 BHMT 1.3      
 
 
Figure 12. Flowchart visualizing the 
Y2H pool screening procedure 
performed in this work. The 34 EHEC 
effector proteins were shuttled into two 
gateway compatible bait vectors using a 
gateway LR reaction. pGBT9 and 
pGBKCg harbour an amino- and 
carboxy-terminal GAL4-DBD, respectively. 
The resulting 68 clones were screened 
each against the following three libraries, 
a human cDNA-based library as well as 
the C-and N-terminally tagged libraries 
based on full length open reading frames. 
The human prey proteins detected in all 
three libraries were summarized and the 
total occurrence of each unique bait/prey 
pair was determined. 
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Preys with a promiscuity factor of ≥ 1 were marked as putative false positives and as a 
consequence excluded from further data analysis. The 35 human prey proteins found in the 
EHEC-host screens that were identified as promiscuous and its corresponding promiscuity 
factors can be obtained from table 5. 
3.1.2.2 EHEC-host protein-protein interactions 
A complete list of all EHEC-host interactions is provided in supplementary table 1 and a list 
of the 35 high confidence interactions is shown in table 6.  
 
Table 6. EHEC/host high confidence interactions. The column ‘Occurrence’ states the number of 
times a unique bait/prey pair was detected. For high confidence hits, this number is at least 2. 
   Bait name Bait ID Prey gene symbol Occurrence Prey gene ID   
1  EspB ECs4554 RBCK1 78 10616  
2  EspB ECs4554 STK16 48 8576  
3  EspF1 ECs4550 SNX33 16 257364  
4  EspF1 ECs4550 SNX9 2 51429  
5  EspG ECs4590 Hs.658052 3 100589704  
6  EspJ ECs2714 IFT20 20 90410  
7  EspJ ECs2714 RIC8A 15 60626  
8  EspJ ECs2714 CENPH 13 64946  
9  EspO1-1 ECs1567 FEM1B 2 10116  
10  EspY1 ECs0061 CDKN2AIPNL 51 91368  
11  EspY1 ECs0061 PIH1D1 6 55011  
12  EspY1 ECs0061 PSMC1 5 5700  
13  EspY1 ECs0061 CAPN3 3 825  
14  EspY1 ECs0061 PCID2 3 55795  
15  EspY1 ECs0061 DNAJC14 2 85406  
16  EspY1 ECs0061 ZNHIT1 2 10467  
17  Map ECs4562 SLC9A3R2 13 9351  
18  Map ECs4562 RHPN1 3 114822  
19  NleA ECs1812 DSCR4 2 10281  
20  NleB1 ECs3857 LRRC18 7 474354  
21  NleB1 ECs3857 DRG2 5 1819  
22  NleB1 ECs3857 POLR2E 3 5434  
23  NleC ECs0847 C8orf71 3 26138  
24  NleC ECs0847 CTDSPL2 3 51496  
25  NleD ECs0850 METTL2A 6 339175  
26  NleF ECs1815 CASP9 49 842  
27  NleF ECs1815 DHFR 21 1719  
28  NleH1-2 ECs1814 UFC1 2 51506  
29  TccP ECs2715 ZNF626 2 199777  
30  TIR ECs4561 HPCAL1 56 3241  
31  TIR ECs4561 STK16 11 8576  
32  TIR ECs4561 NCALD 7 83988  
33  TIR ECs4561 BAIAP2L1 5 55971  
34  TIR ECs4561 ARRB1 2 408  
35  TIR ECs4561 BAIAP2 2 10458   
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Four out of the 35 high confidence hits were previously published, namely TIR-BAIAP2 
(Weiss et al., 2009), TIR-BAIAP2L1 (Vingadassalom et al., 2009), EspF-SNX9 (Marches et 
al., 2006) and Map-NHERF2 (SLC9A3R2) (Martinez et al., 2010), the remaining 31 are novel 
interactions. The high confidence EHEC-host interactions are depicted in figure 13. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Only one human interaction partner revealed high confidence interactions with more than 
one EHEC effector protein, namely STK16, and there are no primary human interactors that 
bind to each other.  
To test if the EHEC effector proteins are connected to each other by secondary interactions, 
the published interaction partners of the human EHEC effector binders (direct interactors, 
blue nodes in figure 13) were retrieved from the BioGRID database and added to the network 
(figure 15; secondary interaction partners and corresponding annotations are shown in 
supplementary table 2). The network was then analyzed for the occurrence of connections 
between the effector proteins. A connection exists if two direct EHEC interaction partners 
both interact with a third human protein, a so-called secondary interactor. If the two direct 
interactors also bind the same effector protein, the connection was termed a loop. Examples 
for connections and loops are depicted in figure 14. 
 
Figure 13. EHEC-host high confidence network. The proteins are depicted as nodes. Edges 
represent protein-protein interactions. EHEC effectors and human proteins are colored in red and blue, 
respectively. Previously published interactions are represented as green lines. 
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In total 23 connections, including four loops, between 6 EHEC effector proteins were 
detected and involved 12 different secondarily interacting human proteins. A list of detected 
connections is shown in table 7. 
In addition to observed connections, the 6 effector proteins are interconnected over a varying 
amount of edges (see figure 15), which suggests that these effectors are part of a common 
protein complex or pathway 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 7. Indirect connections between EHEC effector proteins. The columns ‘Effector A’ and 
‘Effector B’ comprise the two EHEC effectors that are connected by their human interactors (‘Human 
direct A’ and ‘Human direct B’) over a common interaction with a third human protein (‘Human 
indirect’). 
Effector A Human direct A Human indirect Human direct B Effector B Loop? 
EspB RBCK1 IKBKG HPCAL1 TIR - 
EspB RBCK1 IKBKG POLR2E NleB1 - 
EspB RBCK1 UBC CASP9 NleF - 
EspB RBCK1 UBC PSMC1 EspY1 - 
EspB RBCK1 UBC ZNHIT1 EspY1 - 
EspB STK16 KCTD17 LRRC18 NleB1 - 
EspJ RIC8A TERF1 BAIAP2L1 TIR - 
EspY1 PSMC1 UBC ZNHIT1 EspY1 loop 
NleB1 POLR2E RPAP3 PIH1D1 EspY1 - 
NleB1 POLR2E RUVBL2 PIH1D1 EspY1 - 
NleF CASP9 UBC PSMC1 EspY1 - 
NleF CASP9 UBC ZNHIT1 EspY1 - 
NleF DHFR TP53 ZNHIT1 EspY1 - 
 
Figure 14. Connections and loops between EHEC effector proteins. A connection takes place 
between two different EHEC effectors, whereas within a loop, an effector protein is connected with 
itself. The edges involved in connections and loops are depicted in green. EHEC proteins, human 
direct interactors and human indirect interactors are shown in red, dark blue and light blue, 
respectively. 
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Effector A Human direct A Human indirect Human direct B Effector B Loop? 
NleF DHFR UBC CASP9 NleF loop 
NleF DHFR UBC PSMC1 EspY1 - 
NleF DHFR UBC ZNHIT1 EspY1 - 
NleF DHFR UBC RBCK1 EspB - 
TIR ARRB1 CDC42 BAIAP2 TIR loop 
TIR ARRB1 ITCH POLR2E NleB1 - 
TIR ARRB1 MDM2 DHFR NleF - 
TIR ARRB1 NEDD4 POLR2E NleB1 - 
TIR HPCAL1 DTX2 NCALD TIR loop 
TIR HPCAL1 IKBKG POLR2E NleB1 - 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.1.3 EHEC effector TIR interacts with 8 host proteins 
As a part of the yeast two-hybrid EHEC-host interactome, 8 human proteins were detected 
as binding partners of the EHEC translocated intimin receptor (TIR), namely HPCAL1, 
STK16, NCALD, BAIAP2L1, ARRB1, BAIAP2, HPCAL4 and PDE6D. Among them, two 
single hits and six high confidence interactions, whereas two of the latter were published 
previously.  
 
Figure 15. EHEC-host network including indirect interactions. EHEC proteins, human direct 
interactors and human indirect interactors are shown in red, dark blue and light blue, respectively. 
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3.1.3.1 LUMIER assays of EHEC TIR and its host interaction partners 
To verify the TIR interactions, LUMIER assays of the human TIR interactors were performed 
against full-length TIR as well as against its amino-and carboxy-terminal intracellular 
fragments (see table 8 for details).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16. LUMIER assay testing the eight human TIR interaction partners previously identified 
in yeast two-hybrid pool screens against full-length TIR and its N-and C-terminal intracellular 
domains. All human proteins tested interact with full-length TIR. To test if calcium affects the binding 
ability of the three calcium binding proteins, HPCAL1, HPCAL4 and NCALD, an equivalent assay was 
done with 1 mM CaCl2 (bottom) instead of 10 mM EDTA (top), but the two assays revealed no 
significant differences in TIR binding. TIR C: TIR C-terminus, amino acids 333-559; TIR N: TIR N-
terminus, amino acids 1-267; TIR full: full-length TIR. 
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These revealed that all eight human proteins interact clearly with full-length TIR. None of the 
TIR fragments interacted with ARRB1, BAIAP2 and BAIAP2L1, whereas HPCAL1, HPCAL4, 
NCALD and STK16 exhibited a tendency to interact with the N-terminal TIR fragment. The 
PDE6D clearly interacted with the TIR N-terminus. 
Since three of the eight human interaction partners identified were calcium-binding proteins, 
namely HPCAL1, HPCAL4 and NCALD, it was determined if calcium would alter their binding 
abilities. A standard LUMIER assay was performed with the only difference that the 10 mM 
EDTA, usually removing the Ca+2 ions from the HEK-293T cell lysate, were substituted with 
1 mM CaCl2. However, a comparison of both LUMIER assays only revealed minor variations 
in the binding strength, but no significant differences. The results are depicted in figure 16. 
3.1.3.2 Comparison of EHEC and EPEC TIR interactions  
EPEC harbours a TIR protein homologous to that of EHEC, but despite their similarity, EHEC 
and EPEC TIR employ different pathways for pedestal formation in host cells (Wong et al., 
2011). Both proteins harbour several identical parts, but also some regions with lower 
similarity in the carboxy-terminus (see figure 17 for a clustal W alignment of EPEC and 
EHEC TIR). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17. Clustal W alignment of EPEC and EHEC TIR. Identical amino acids are shaded blue. 
The two transmembrane domains are framed with black boxes.
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In order to figure out to what extent EPEC TIR is able to bind the eight human proteins 
previously detected as EHEC TIR interactors, EPEC TIR was cloned full-length from the 
EPEC strain O127:H6 E2348/69 and comparable C- and N-terminal fragments were 
produced. A list of all EHEC and EPEC variations and the bait vectors they were shuttled into 
is provided in table 8. The eight human prey proteins were obtained with and without native 
stop codon from the human ORF collection that was also used for the construction of the 
C-terminally tagged Y2H library. 
 
Table 8. EPEC and EHEC TIR fragments used in this work. AA: amino acids 
No. Taxonomy Name Description AA Stop codon Bait vector Vectot ID 
1 EHEC TIR full full-length TIR 1-558 yes pGBT9 v0012 
2 EHEC TIR C carboxy terminus 333-558 yes pGBT9 v0012 
3 EHEC TIR N amino terminus 1-267 yes pGBT9 v0012 
4 EHEC TIR full full-length TIR 1-558 no pGBKCg v0034 
5 EHEC TIR C carboxy terminus 333-558 no pGBKCg v0034 
6 EHEC TIR N amino terminus 1-267 no pGBKCg v0034 
1 EPEC TIR full full-length TIR 1-550 yes pGBT9 v0012 
2 EPEC TIR C carboxy terminus 338-550 yes pGBT9 v0012 
3 EPEC TIR N amino terminus 1-270 yes pGBT9 v0012 
4 EPEC TIR full full-length TIR 1-550 no pGBKCg v0034 
5 EPEC TIR C carboxy terminus 338-550 no pGBKCg v0034 
6 EPEC TIR N amino terminus 1-270 no pGBKCg v0034 
 
To exclude non-specific interactions, all EHEC and EPEC TIR variants were subjected in one 
to one Y2H interaction tests against the prey vectors used in this study, namely pGADCg and 
pGAD424, revealing that none of the TIR variants interacted with plain prey vector. The 
results are depicted in figure 18, the plate layout is shown in table 9. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18. Paiwise tests of EHEC and EPEC baits against pure prey vecor. The columns 
1 + 3 and 2 + 4 harbour plain pGAD424 and pGADCg as preys, respectively. The plate 
layout for the baits can be obtained from table 9. The picture on the left is the mating control 
on LW selective medium. The other three are the interaction tests done with increasing 3-AT 
concentrations as indicated. 
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Table 9. Plate layout of the EHEC and EPEC baits in figure 18. 
BAIT    
  1 2 3 4 
A EHEC TIR full w/o Stop EHEC TIR full w/o Stop EPEC TIR full w/o Stop EPEC TIR full w/o Stop
B EHEC TIR N w/o Stop EHEC TIR N w/o Stop EPEC TIR N w/o Stop EPEC TIR N w/o Stop 
C EHEC TIR full Stop EHEC TIR full Stop EPEC TIR full Stop EPEC TIR full Stop 
D EHEC TIR N Stop EHEC TIR N Stop EPEC TIR N Stop EPEC TIR N Stop 
E EHEC TIR C Stop EHEC TIR C Stop EPEC TIR C Stop EPEC TIR C Stop 
F EHEC TIR C w/o Stop EHEC TIR C w/o Stop EPEC TIR C w/o Stop EPEC TIR C w/o Stop 
 
For the pairwise tests against the human interactors, full-length EHEC and EPEC TIR as well 
as the C- and N-terminal intracellular fragments were tested as C- and N-terminal tagged 
proteins against the human preys. The human prey proteins were also shuttled in C- and N-
terminal tagged prey vectors, namely pGADCg and pGAD424. Diploids were selected on 
∆LWH agarose plates at varying stringencies. The results obtained for all stringencies were 
documented photographically. The complete results are depicted in supplementary figure 1. 
Not all bait and prey vectors or combinations were equally functional. Bait or prey protein 
fusions that did not find any interactions or seemed to interact randomly were not considered. 
Figure 19 shows the most informative results of the obtained data.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
As previously published, BAIAP2 and BAIAP2L1 bound full-length TIR and the carboxy-
terminal fragment of both, EHEC and EPEC TIR, proving functionality of both TIR proteins 
and their C-terminal fragments. Though clearly interacting with full-length EHEC TIR in 
LUMIER assay, the PDE6D did not reveal any interaction with EPEC or with EHEC TIR in 
the pairwise Y2H tests. At stringencies lower than 10 mM 3-AT, diploid yeast colonies 
appeared at random. A possible explanation might be that the protein is instable in yeast or 
does not function well when fused to GAL4. HPCAL1 and NCALD bound to the amino-
terminal fragment of EPEC and EHEC TIR, though the binding to EHEC TIR seems to be 
slightly weaker than that to EPEC TIR. The STK16 bound to the C-terminal fragment of both 
TIR proteins. Differences between EPEC and EHEC TIR were only found for ARRB1 and 
HPCAL4. Both human prey proteins do not bind EPEC TIR. ARRB1 only bound the carboxy-
Figure 19. Pairwise Y2H tests of EHEC and EPEC baits against human prey proteins. ARRB1, 
BAIAP2, BAIAP2L1 and HPCAL4: prey vector pGADCg, bait vector pGBT9, stringency 1 mM 3-AT; 
HPCAL1: prey vector pGAD424, bait vector pGBKCg, stringency 10 mM 3-AT; NALD: prey vector 
pGADCg, bait vector pGBT9, stringency 15 mM 3-AT; PDE6D: prey vector pGAD424, bait vector 
pGBT9, stringency 10 mM 3-AT and STK16: prey vector pGADCg, bait vector pGBKCg, stringency 
25 mM 3-AT. 
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terminus of TIR EHEC. HPCAL4 clearly interacted with full-length and the N-terminal 
fragment of the latter. 
3.1.4 NleF – host interactions 
As previously shown in table 6 and figure 13, the non-LEE (locus of enterocyte effacement) 
encoded EHEC effector protein F (NleF) interacts with caspase-9. The NleF-CASP9 unique 
pair was isolated 49 times in two Y2H pool screens indicating that this interaction is highly 
reproducible. In addition, caspase-9 exhibits a very low promiscuity factor of 0.2, which 
qualifies it as a reliable prey and thus makes the NleF/caspase-9 interaction favourable for 
further investigation. 
3.1.4.1 NleF interacts with caspases in LUMIER assay 
To verify the NleF/CASP9 interaction with an independent method, LUMIER assays in 
HEK-293T cells were performed. Further interaction tests with NleF against other human 
caspases, namely caspase-1, -2, -3, -4, -6, -7, -8, -10, and -14, led to the identification of 
caspase-4 and -8 as additional interaction partners. The LUMIER results are depicted in 
figure 20. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.1.4.2 NleF fragments are incapable of caspase binding 
NleF is non-functional when fused to a tag at the carboxy-terminus. Prediction of potential 
globular domains performed with GlobPlot predicts an amino-terminal globular domain and a 
disordered region at the C-terminus. This suggested a potential role of the NleF carboxy-
terminus in caspase binding.  
To examine this, I made four different fragments of NleF, namely NleF 1-145, NleF 1-160, 
NleF 144-189 and NleF 161 189 (numbers referring to amino acids, full length being 189). 
LUMIER assays of these fragments against caspase 4, -8 and -9 revealed that none of the 
NleF fragments was capable of caspase binding. The results are depicted in figure 21. 
 
 
 
 
Figure 20. LUMIER assay NleF with 
human caspases. NleF was tested for 
interaction with the human caspases -
1, -2, -3, -4, -6, -7, -8, -9, -10 and -14 
in LUMIER assay. Each NleF/caspase 
pair was done in triplicate. All signals 
above the dotted line are positive for 
interaction. JUN and FOS were used 
as a positive control. 
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3.1.4.3 Caspase inhibition by NleF and IC50 in vitro 
Caspases are cysteine proteases that play substantial roles in a number of cellular 
processes, among them inflammation and apoptosis (Alnemri et al., 1996). As initiator 
caspases of the extrinsic and intrinsic apoptosis pathway, caspase-8 and -9 are of special 
importance for the initiation of programmed cell death, which can be induced e.g. as a 
response to pathogen infestation or cell damage (Munoz-Pinedo, 2012). In the literature two 
biological roles are discussed for caspase-4, namely as an initiator caspase responding to 
ER stress (Hitomi et al., 2004) and as an inflammatory caspase (Martinon and Tschopp, 
2007). Considering their roles, all three caspases might be relevant targets for EHEC. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To test if NleF is able to inhibit the caspases 4, 8 and 9, their activity was assessed in vitro. 
1.5 µg of purified NleF was mixed with one unit of active caspase and its proteolytic activity 
was measured. The data were compared with NleF-free samples, samples harbouring the 
 
Figure 22. In vitro inhibition of caspases -4, -8 and -9 by NleF, the small molecule inhibitor 
Z-VAD-FMK and inactivated NleF. The significance was determined by two-tailed unpaired Student’s 
t-test. **** p<0.0001 
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Figure 21. LUMIER assay of the four NleF fragments against the caspases 4, 8 and 9. None of 
the four fragments, NleF 1-145, 1-160, 144-189 and 161-189 is capable of caspase binding, whereas 
full-length NleF (189 amino acids, wild type) clearly interacts with all three caspases. JUN and FOS 
are the positive control. 
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known caspase inhibitor Z-VAD-FMK and samples with an equivalent amount of inactivated 
NleF (inactivation was done by proteinase K digestion and subsequent heat inactivation of 
the protease). This resulted in a potent inhibition of all three caspases in presence of NleF, 
but not inactivated NleF (see figure 22). 
 
To measure the efficiency of caspase inhibition by NleF, the half maximal inhibitory 
concentration (IC50) of NleF required to inhibit the caspases was determined. For the 
caspases 4 and 8 the corresponding caspase inhibitor kits and 0.5 units of caspase-4 (~208 
nM) and caspase-8 (~72 nM) were used per well, respectively. Caspase-9 was measured 
with the Caspase-Glo ® 9 luminescence assay and 1100 nM active caspase-9 matching 5 
units were used per well. The NleF dilutions were started with an NleF/caspase molar ratio of 
8:1, 80:1 and 3:1 for caspase-4, -8 and -9, respectively, and continued as 1:2 dilution rows. 
These resulted in an IC50 of 14 nM, 40 nM and 83 nM NleF for the caspases 4, 8 and 9, 
respectively. The results are graphed in figure 23. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To determine if the molar concentration of caspases 4, 8 and 9 in the assay correlates with 
the concentration of caspase active sites, active site titration with the kovalent pan-caspase 
inhibitor Z-VAD-FMK was performed. FMK inhibitors form covalent adducts with active 
caspases, whereas one molecule of inhibitor inactivates one active site.  
This leads to a linear connection between the applied concentrations of caspase and 
inhibitor. The concentration of caspase active sites can be obtained from the intercept with 
the X axis (Stennicke and Salvesen, 1999). As depicted in figure 24, the total concentration 
of active sites was determined to be 200 nM, 68 nM and 1.1 µM for caspase-4, -8 and -9, 
respectively. This correlates well with the estimated caspase concentrations of 208 nM, 
72 nM and 1.1 µM for caspase-4, -8 and -9, respectively. 
 
 
 
 
 
 
 
 
 
 
Figure 23. Dose-dependent inhibition of purified caspases by NleF. The Y-axis represents the 
caspase activity in percent and the X-axis the logarithmic molar concentration of purified NleF. For 
caspase-4, caspase-8 and caspase-9, an IC50 of 14 nM, 40 nM and 83 nM NleF was observed, 
respectively. 
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3.1.4.4 Ex vivo inhibition of caspase activity 
Human enterocytes, the primary host cells of EHEC, are so-called type II cells that rely on 
the mitochondrial pathway and thus on caspase-9 activation for apoptosis induction (Kantari 
and Walczak, 2011). To determine if NleF is able to inhibit cellular caspases, caspase activity 
was determined in HeLa cell lysate. This was done in two different ways: 1. HeLa cells 
expressing YFP-tagged NleF, an inactive NleF fragment (NleF 1-160) and protein A 
(Staphylococcus aureus), respectively, were treated with TRAIL (Tumor Necrosis Factor 
Related Apoptosis Inducing Ligand) for apoptosis induction, lysed and caspase-9 activity was 
assessed in the lysate.  
2. TRAIL treated HeLa cells were lysed and purified NleF or an equivalent amount of 
inactivated NleF was added, respectively. The results are depicted in figure 25. 
In both cases caspase-9 activity is significantly increased in TRAIL treated cells that 
expressed Protein A, the negative control, and NleF 1-160, an inactive NleF fragment, when 
compared to untreated samples, respectively (figure 25 A). This indicates that TRAIL-treated 
cells entered apoptosis as expected. In HeLa cells expressing wild type NleF or BCL2, a 
known inhibitor of apoptosis, caspase-9 activity in TRAIL treated samples was reduced by 
half. When purified NleF was added to HeLa cell lysate that exhibited native caspase-9 
activity after apoptosis induction, caspase-9 activity was decreased by more that two thirds. 
The addition of an equivalent amount of inactivated NleF had no effect on caspase-9 activity 
(figure 25 B). 
In summary, naturally expressed and purified NleF are both able to decrease caspase-9 
activity significantly in cell lysates. 
 
 
 
 
 
 
Figure 24. Active site titration  of caspases 4, 
8 and 9 using the Z-VAD-FMK pan-caspase 
inhibitor. The active site concentration was 
determined to be 200 nM, 68 nM and 1.1 µM for 
caspase-4, caspase-8 and caspase-9, 
respectively. The Y and X axis represent 
caspase activity in raw fluorescence or 
luminescence units and molar concentration of 
Z-VAD-FMK inhibitor, respectively. 
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3.1.4.5 NleF inhibits apoptosis in HeLa and Caco-2 cells 
To test if NleF is not only capable of inhibiting caspase activity, but can also prevent human 
cells from entering apoptosis, the effect of expressed NleF on HeLa cells that were exposed 
to apoptotic stimuli was assessed.  
NleF, Protein A and NleF 1-160 as well as known inhibitors of apoptosis, namely XIAP and 
BCL2, were transiently expressed as YFP fusion proteins in HeLa cells. XIAP as an inhibitor 
of the initiator caspase 9 and the effector caspases 3 and 7 (Deveraux and Reed, 1999) and 
BCL2 as a known inhibitor of apoptosis were employed for comparison with NleF. The 
percentage of apoptotic cells was determined using FACS before and after TRAIL treatment 
revealing a significantly decreased number of apoptotic cells in samples expressing XIAP 
(6.1 %) , BCL2 (13.4 %) and NleF (6.5 %), but not in the controls expressing Protein A (42.8 
%) and NleF 1-160 (37.4 %), respectively (Figure 26 A and C). Thus, NleF is capable of 
inhibiting TRAIL-induced apoptosis in HeLa cells just as efficient as XIAP and BCL2. 
Since HeLa cells are not the native host cells of EHEC, I tested if apoptosis inhibition by NleF 
is just as efficient in Caco-2 cells. Caco-2 are epithelial colorectal adenocarcinoma cells and 
as such closer to human enterocytes than HeLa cells. After TRAIL-treatment, NleF and 
Protein A expressing Caco-2 cells revealed 7.0 % and 25.2 % of apoptotic cells, respectively 
(see Figure 26 B), confirming, that NleF can prevent apoptosis in Caco-2 cells as well.  
TRAIL binds to the death receptors DR4 and DR5 leading to the recruitment and activation of 
caspase-8 and thus to the induction of apoptosis through the extrinsic pathway (Song and 
Lee, 2008). As mentioned previously, in case of type II cells (HeLa and Caco-2 are both 
type II), apoptosis induction through the extrinsic pathway also requires caspase-9. Still it 
would be interesting to know if NleF prevents apoptosis induced through the intrinsic 
pathway, with caspase-9 and not caspase-8 being the first caspase activated, just as efficient 
as TRAIL-induced apoptosis. To test this, apoptosis was induced in HeLa cells with 
staurosporine, a global protein kinase inhibitor produced by Streptomyces staurosporeus, 
that incuces intrinsic apoptosis as a consequence of cellular damage done by non-specific 
 
Figure 25. NleF inhibits caspase-9 in HeLa cell lysate. (A) Caspase-9 activity in apoptotic HeLa cell 
extracts expressing Protein A, an inactive fragment of NleF (amino acids 1-160), wild type NleF or 
BCL2, respectively. (B) Recombinant NleF inhibits caspase-9 activity in lysates of apoptotic cells. 
HeLa cells were induced to enter apoptosis by treatment with TRAIL for four hours (black bars) or left 
untreated (striped bars) before preparation of lysates and measurement of cellular caspase-9 activity 
in the absence or presence of purified NleF. Significance was determined using the two-tailed 
unpaired Student’s  t-test.  * p<0.05; *** p<0.001 
RESULTS 
 
61
kinase inhibition. As depicted in Figure 26 D and E, samples expressing NleF and Protein A 
revealed 3.7 % and 49.9 % apoptotic cells after staurosporine treatment, respectively.  
Thus NleF decreases the number of apoptotic cells in staurosporine treated samples at least 
as efficiently as in TRAIL treated ones and as a consequence prevents apoptosis entered via 
the intrinsic as well as via the extrinsic pathway. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.1.4.6 Mutagenesis of the NleF C-terminus 
In the frame of a collaboration with Holger Steuber from Proteros (Martinsried, Germany), the 
structural basis of the caspase-9/NleF complex was solved by co-crystallization. The 
structure revealed that in addition to other minor contacts, the carboxy-terminal amino acids 
G189, C188, Q187 and L186 anchor NleF to the S1, S2, S3, and S4 pockets of caspase-9, 
Figure 26. NleF inhibits apoptosis induced by TRAIL and staurosporine. (A) HeLa cells 
expressing wild type NleF, XIAP and BCL2, respectively, exhibited decreased apoptosis in comparison 
to cells expressing Protein A or the inactive NleF 1-160 fragment after TRAIL treatment. Squares: 
percentage of apoptotic cells (three independent experiments); bars: average. (B) Caco-2 cells 
expressing NleF and Protein A, respectively. Significance (t-test): * P < 0.05.  (C and E) 
Representative FACS counts of HeLa cells expressing indicated constructs. Cells that stained positive 
for annexin V- allophycocyanine (APC+) but negative for propidium iodide were counted as apoptotic 
cells. (D) Percentage of apoptotic HeLa cells in staurosporine treated (+) and untreated (-) samples 
expressing NleF and Protein A, respectively. 
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respectively. The occupancy of the substrate binding pockets of caspase-9 is a likely 
explanation for the effective inhibition of caspase-9 activity by NleF.  
To test if changes of the last four amino acids of NleF may impair its binding to the caspases 
4, 8 and 9, I constructed seven versions of NleF with altered C-termini. These involve 
NleF +1, NleF -1, NleF -4, NleF L186A, NleF Q187A, NleF C188A and NleF G189A. NleF +1 
harbours an extra alanine, NleF -1 and NleF -4 lack 1 and 4 carboxy-terminal amino acids, 
respectively, and the remaining four are substitutions of L, Q, C and G to alanine (see figure 
27 for details). 
LUMIER assays of all NleF versions against caspases 4, 8 and 9 revealed different binding 
profiles. Caspase-9 still bound, though weaker than wild type NleF, four out of the seven 
NleF versions, namely NleF -1, NleF L186A, C188A and G189A. Caspase-4 was only able to 
bind NleF C188A, whereas caspase-8 was unable to bind any of the mutagenized NleF 
versions.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
When tested for their ability to prevent apoptosis as transiently expressed YFP-fusions in 
HeLa cells, NleF +1 and NleF -4 revealed a complete loss of apoptosis inhibition. This 
indicates that the caspase-9 P1 pocket is unable to tolerate an additional amino acid, which 
as a consequence leads to a complete loss of NleF +1 function. Since NleF -4 lacks the four 
carboxy-terminal amino acids predicted to be responsible for caspase-9 inhibition, its inability 
to prevent apoptosis was expected. NleF -1, NleF L186A, Q187A, C188A and G189A were 
still able to decrease the number of apoptotic cells significantly, but none did as efficient as 
wild type NleF. The results are depicted in figure 28. 
 
 
 
Figure 27. NleF versions with altered carboxy-terminus. Amino acids 1-185 are constant in all 
NleF versions. NleF +1, NleF -1 and NleF -4 harbour an extra alanine and lack 1 and 4 C-terminal 
amino acids, respectively. NleF L186A, Q187A, C188A and G189A are substitutions of leucine, 
glutamine, cysteine and glycine to alanine. 
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Figure 28. Caspase 
binding and apoptosis 
inhibition by modified 
versions of NleF. (A) 
Caspase-4, (B) caspase-8 
and (C) caspase-9-binding of 
different versions of NleF 
assessed by LUMIER 
assays. (D) Percentage of 
apoptotic HeLa cells 
expressing different versions 
of NleF after induction with 
staurosporine. NleF +1: NleF 
with an additional C-terminal 
alanine; NleF -1 and NleF -4: 
NleF with the terminal 1 and 
4 amino acids removed, 
respectively; NleF L186A, 
NleF Q187A, NleF C188A 
and NleF G189A: NleF 
versions with indicated 
amino acids substituted by 
alanine; NleF +18: NleF with 
additional 18 amino acids. 
The last version of NleF 
lacks its native stop codon. 
The additional 18 amino 
acids originate from the 
LUMIER vector pcDNA3-
Rluc-GW.  
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3.2 Part II: The phage lambda-E. coli interactome 
As customary for viruses, phage lambda completely relies on its host’s cellular machinery for 
propagation. It can ‘choose’ out of two ways to propagate, namely to grow lytically by 
producing a large number of virions and killing its host as a consequence or to insert in 
chromosomal DNA and duplicate with each cell division performed by the host bacterium. 
Regardless which way is chosen, protein-protein interactions between phage and host are 
indispensable either way.  
To identify novel interactions between phage lambda and E. coli, I analysed 68 phage 
lambda proteins by Y2H screening against an E. coli ORF library. The phage lambda clones 
and the E. coli library originate from (Rajagopala et al., 2011) and (Rajagopala et al., 2010), 
respectively.  
3.2.1 Procedure of the phage lambda/host screens 
For the performance of the Y2H pool and arrayed pool screens, the 68 phage lambda clones 
in the bait vectors pGBKT7g and pDEST32 were screened against the E. coli W3110 library 
in the prey vectors pGADT7g and pDEST22, respectively. The screens were performed in 
three runs, each including the screening of the phage lambda baits once or more against one 
library using one screening method (see table 10 for details). 
 
Table 10. Overview summarizing the screening procedures and properties of the lambda baits 
and the E. coli prey libraries. 
Baits Bait vector Prey libraries Prey vector Properties Screen procedure 
Lambda ORFs pGBKT7g E. coli W3110 pGADT7g high copy vector arrayed pool 
screens 
Lambda ORFs pGBKT7g E. coli W3110 pGADT7g high copy vector pool screens 
Lambda ORFs pDEST32 E. coli W3110 pDEST22 low copy vector pool screens 
 
Arrayed pool screens were done using the whole E. coli pGADT7g library arranged on two 
plates, each well containing a separate prey pool. Each bait was mated with each prey pool 
and the diploids were arrayed on selective agarose plates. A flowchart of the procedure is 
provided in figure 29.  
The pGBKT7g/pGADT7g and pDEST32/22 vector systems differ mainly by copy number and 
thus in the amount of protein present in the yeast cell. As previously shown by (Rajagopala 
et al., 2009), the number of obtained screening hits varies clearly between the vector 
systems and the overlap of unique pairs detected in both systems is usually low. However, 
the two vector systems complement each other and thus screening with both leads to an 
increase in identified protein-protein interactions.  
The lambda-host screens resulted in the identification of 294 E. coli proteins and 631 unique 
bait/prey pairs in total. 573 pairs were found in the pGBKT7g/pGADT7g vector system and 
56 in the pDEST32/22 system. Two were found in both systems, namely lambda G – E. coli 
clpP and lambda A – E. coli nohB. 
In total 334 pairs were identified as single hits, 103 were found repeatedly in one screen and 
54 repeatedly in 2 or more independent screens. 25 potentially promiscuous preys were 
identified that were involved in 218 lambda/host interactions. The numeric results of the 
phage lambda-host pool screens are summarized in table 11. 
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Table 11. Numeric results of the phage lambda/host pool screens. 
Identified E. coli prey proteins: Total number 294
  Promiscuous  25
Unique bait/prey pairs: Total number 631
 Single hits 334
 High-confidence hits 161
  with promiscuous preys 218
Unique bait/prey pairs, pDEST32/22 only: Total number 56
 Single hits 38
  High-confidence hits 18
Unique bait/prey pairs, pGBKT7g/pGADT7g only: Total number 573
 Single hits 296
  High-confidence hits 141
Unique bait/prey pairs found in both pDEST32/22 and 
pGBKT7g/pGADT7g   2
 
3.2.1.1 Promiscuous preys 
A prey protein was considered promiscuous or ‘sticky’ if it interacted with 5 or more different 
lambda baits and/or if it interacted randomly or excessively in pairwise yeast two-hybrid tests. 
At the time the phage lambda-host screens were done, the E. coli library had not been used 
extensively, so the main source for the evaluation of preys that behave sticky in this library 
 
Figure 29. Arrayed pool screens. (A) Flowchart visualizing the procedure of arrayed pool screening 
and (B) exemplary array plates. The positive yeast colonies are indicated by arrows. The plates are in 
384-format and each prey pool is pinned as quadruplicate. 
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were previously described lambda-host screens. A list of potential promiscuous preys and 
the number of phage lambda baits they interacted with is provided in table 12. 
 
Table 12. List of E. coli prey proteins tagged as promiscuous. The column ‘Number of baits’ 
states the number of phage lambda baits a prey protein was found to interact with. LeuB was found to 
interact randomly in the pDEST vector system. PhoB was identified as sticky in the pairwise tests. 
  Prey gene symbol ECK ID JW ID b ID Number of baits   
1 ynjB ECK1752 JW5284 b1754 20  
2 yiaF ECK3541 JW5655 b3554 16  
3 flxA ECK1560 JW1558 b1566 15  
4 spr ECK2169 JW2163 b2175 13  
5 mltB ECK2696 JW2671 b2701 12  
6 ydaW ECK1359 JW5211 b1361 11  
7 ynfO ECK1542 JW5251 b4533 11  
8 dicB ECK1569 JW1566 b1575 10  
9 fliA ECK1921 JW1907 b1922 10  
10 metN ECK0199 JW0195 b0199 10  
11 tyrS ECK1633 JW1629 b1637 8  
12 phnG ECK4094 JW4062 b4101 7  
13 ydcE ECK1455 JW1456 b1461 7  
14 ygiT ECK3012 JW2989 b3021 7  
15 yihD ECK3850 JW3830 b3858 7  
16 insN ECK0257 JW5024 b0255 6  
17 tbpA ECK0069 JW0067 b0068 6  
18 yajI ECK0406 JW5056 b0412 6  
19 yjgZ ECK4267 JW4236 b4277 6  
20 yjhV ECK4276 JW4246 b4286 6  
21 fixX ECK0045 JW0043 b0044 5  
22 wza ECK2056 JW2047 b2062 5  
23 ydaL ECK1337 JW1334 b1340 5  
24 phoB ECK0393 JW0389 b0399 4  
25 leuB ECK0075 JW5807 b0073 1   
 
PhoB was only found to interact with 4 different lambda baits in the pool screens. However, 
when tested in binary yeast two-hybrid assays it revealed interactions with 27 phage lambda 
baits. LeuB appeared randomly in screens with the pDEST32/22 vector system. If it was 
detected, the screens were mostly overgrown and had to be removed. It only came up once 
in a pool screen.  
Most promiscuous preys concerned the pGBKT7g/pGADT7g vector system. The pDEST 
system revealed only interactions with two sticky proteins, namely leuB and yajI. 
3.2.1.2 Promiscuous baits 
Potentially promiscuous baits were identified using two different approaches:  
1. Binary tests of all baits against the empty prey vector. 
2. Identification of baits that revealed non-specific interaction patterns in yeast two-
hybrid pool screens and/or binary tests. 
In the first approach, the lambda baits in pGBKT7g vector were screened against the empty 
pGADT7g vector at increasing stringencies. Four baits activated the Y2H reporter when 
combined with empty vector at stringencies up to 20 mM 3-AT, namely lambdap18, 
lambdap29, lambdap47 and lambdap67. Even though the signal was lost at 50 mM 3-AT, no 
usable results were obtained for these baits. Some other baits revealed background signals 
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at lower stringencies, which did not affect the screening, since the selection of diploid yeast 
cells was done using a standard stringency of 3 mM 3-AT. 
 
The baits in pDEST32 were only tested at the standard stringency of 3 mM 3-AT, revealing 
background growth for five baits when tested with pDEST22 vector, namely lambdap05, 
lambdap06, lambdap29, lambdap47 and lambdap67. The latter three were also identified in 
the pGBKT7g vector. The plate is depicted in figure 30.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
As a consequence, the six baits interacting with plain vector, lambdap05, 06, 18, 29, 47 and 
67 were excluded from further evaluations. 
 
In the second approach, pairwise tests of the phage lambda bait proteins in pGBKT7g 
against different prey proteins revealed lambdap16 (H), lambdap36 (ea8.5), lambdap45 
(ea10), lambdap65 (NinD) and lambda83 (ea22) as putative non-specific interactors. When 
screened repeatedly, these bait proteins continued to find novel interactors in each screen. 
Therefore I decided to include only interactors of the concerning baits if they were found at 
least in three independent screens or binary tests. 
3.2.1.3 Verification of single hits by pairwise Y2H assays 
334 unique pairs were only found once, as single hits and out of these, 256 involved non-
promiscuous prey proteins. To test if these interactions are reproducible, binary tests were 
performed. Out of 256, 25 were not retested and 139 revealed no interactions with the 
corresponding prey. However, 92 unique pairs could be confirmed in the pairwise Y2H tests.  
3.2.2 The phage lambda-E. coli interactome 
The procedure of Y2H screening and filtering resulted in 144 validated phage lambda-host 
interactions in total. See figure 31 for a visualization of the process.  
A list of the final 144 phage lambda interactions is provided in table 13. A complete list of all 
interactions obtained, including the ones involving promiscuous baits and preys as well as 
single hits, can be obtained from supplementary table 3. 
 
 
 
Figure 30. Binary tests of 
pDEST32 baits against pure 
pDEST22 vector. The 
selection was done at ∆LWH at 
a stringency of 3 mM 3-AT. 
Five baits revealed interactions 
with pure prey vector (indicated 
by white squares). 
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Table 13. Phage lambda-E. coli interactome. Hits states the number of times a unique pair was 
detected during the phage-host screens. 
Locus tag Lambda Bait E. coli prey Hits ECK ID Annotation 
lambdap01 nu1 dcrB 2 ECK3456 protein DcrB 
lambdap02 A nohA 9 ECK1541 bacteriophage DNA packaging 
protein 
lambdap02 A nohB 4 ECK0552 bacteriophage DNA packaging 
protein 
lambdap09 Fi ydgH 4 ECK1599 protein YdgH 
lambdap09 Fi fixB 3 ECK0043 protein FixB 
 
Figure 31. Procedure of phage lambda/host screens and filtering of obtained interactions. From 
the 631 interactions received in the Y2H pool screens, 218 were removed due to the involvement of 
promiscuous prey proteins. 164 were unconfirmed single hits and another 105 were removed, since 
the bait protein exhibited a high bait promiscuity and the corresponding interactions were only found 
twice or less times in one screen. 
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lambdap09 Fi smpA 2 ECK2613 small protein A 
lambdap09 Fi cchB 1 ECK2451 ethanolamine utilization protein EutN 
lambdap09 Fi minE 2 ECK1162 cell division topological specificity 
factor MinE 
lambdap14 G ycbQ 4 ECK0929 fimbrial subunit 
lambdap14 G ycgE 48 ECK1149 HTH-type transcriptional regulator 
MlrA 
lambdap14 G chaC 4 ECK1212 cation transport protein ChaC 
lambdap14 G yliL 3 ECK0805 b0816 hypothetical protein (yliL) 
lambdap14 G clpP 43 ECK0431 ATP-dependent Clp protease, 
proteolytic subunit ClpP 
lambdap14 G fdoH 8 ECK3886 formate dehydrogenase, beta subunit
lambdap14 G proQ 3 ECK1830 ProP effector 
lambdap14 G yceK 2 ECK1036 lipoprotein, putative 
lambdap14 G ykgL 2 ECK0294 hypothetical protein (ykgL) 
lambdap14 G fhuF 21 ECK4357 ferric iron reductase protein FhuF 
lambdap14 G yohN 5 ECK2100 conserved hypothetical protein 
lambdap16 H sfmA 2 ECK0523 type-1 fimbrial protein, A chain 
lambdap16 H sfmF 3 ECK0527 major fimbrial subunit 
lambdap16 H dnaN 3 ECK3693 DNA polymerase III, beta subunit 
lambdap16 H ECK1157 3 ECK1157 putative ATP-binding component of a 
transport system 
lambdap16 H hyfG 3 ECK2483 hydrogenase-4 component G 
lambdap16 H ynfC 3 ECK1580 lipoprotein YnfC 
lambdap16 H yehD 3 ECK2104 fimbrial protein 
lambdap16 H yraH 3 ECK3130 fimbrial protein 
lambdap16 H ycbQ 4 ECK0929 fimbrial subunit 
lambdap16 H yfcQ 4 ECK2328 conserved hypothetical protein 
lambdap16 H yohH 4 ECK2132 YohH 
lambdap16 H yeiW 4 ECK2164 proteinase inhibitor 
lambdap16 H ybgD 4 ECK0708 fimbrial protein 
lambdap16 H ymjB 4 ECK1314 putative ATP-binding component of a 
transport system 
lambdap16 H acpS 5 ECK2561 holo-(acyl-carrier-protein) synthase 
lambdap16 H yliL 10 ECK0805 b0816 hypothetical protein (yliL) 
lambdap27 orf-401 stfR 89 ECK1367 putative membrane protein 
lambdap28 orf-314 tfaR 152 ECK1368 tail fiber assembly protein 
lambdap28 orf-314 tfaQ 2 ECK1539 tail fiber assembly protein 
lambdap28 orf-314 clpP 7 ECK0431 ATP-dependent Clp protease, 
proteolytic subunit ClpP 
lambdap28 orf-314 ycgE 4 ECK1149 HTH-type transcriptional regulator 
MlrA 
lambdap33 int nohB 7 ECK0552 bacteriophage DNA packaging 
protein 
lambdap33 int paaC 6 ECK1387 phenylacetate-CoA oxygenase, PaaI 
subunit 
lambdap33 int nlpI 6 ECK3151 lipoprotein NlpI 
lambdap36 ea8.5 minE 2 ECK1162 cell division topological specificity 
factor MinE 
lambdap36 ea8.5 yeiW 2 ECK2164 proteinase inhibitor 
lambdap36 ea8.5 yjdI 3 ECK4119 conserved hypothetical protein 
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lambdap37 orf61 yqhC 3 ECK3002 putative HTH-type transcriptional 
regulator YqhC 
lambdap37 orf61 yjdI 2 ECK4119 conserved hypothetical protein 
lambdap37 orf61 yheL 2 ECK3330 sulfur relay protein TusD/DsrH 
lambdap38 orf63 yqhC 4 ECK3002 putative HTH-type transcriptional 
regulator YqhC 
lambdap45 ea10 rpmA 8 ECK3174 ribosomal protein L27 
lambdap45 ea10 ycbG 3 ECK0947 protein YcbG 
lambdap45 ea10 frvA 43 ECK3893 phosphoenolpyruvate-dependent 
sugar phosphotransferase system, 
eiia 2, putative 
lambdap45 ea10 rmf 17 ECK0944 b0953 ribosome modulation factor 
(rmf) 
lambdap45 ea10 yliL 8 ECK0805 b0816 hypothetical protein (yliL) 
lambdap45 ea10 rpsG 7 ECK3328 ribosomal protein S7 
lambdap45 ea10 cedA 5 ECK1729 conserved hypothetical protein 
lambdap45 ea10 soxS 3 ECK4054 regulatory protein SoxS 
lambdap45 ea10 yqjI 63 ECK3061 transcriptional regulator, PadR family 
protein 
lambdap45 ea10 yjiR 5 ECK4331 aminotransferase, classes I and II 
superfamily 
lambdap45 ea10 priC 4 ECK0461 primosomal replication protein N 
lambdap45 ea10 rpsS 4 ECK3303 30S ribosomal protein S19 
lambdap45 ea10 ypjJ 4 ECK2641 hypothetical protein (ypjJ) 
lambdap45 ea10 cobB 3 ECK1106 NAD-dependent deacetylase 
lambdap48 lambdap48 pntA 1 ECK1598 NAD(P) transhydrogenase, alpha 
subunit 
lambdap49 N nusA 1 ECK3158 transcription elongation protein NusA
lambdap49 N yicI 4 ECK3646 alpha-glucosidase 
lambdap49 N hcr 3 ECK0863 NADH oxidoreductase hcr 
lambdap49 N ego 2 ECK1506 putative ABC transporter ATP-
binding protein ego 
lambdap49 N ppc 2 ECK3947 phosphoenolpyruvate carboxylase 
lambdap49 N secB 3 ECK3599 protein-export chaperone SecB 
lambdap49 N nuoG 2 ECK2277 NADH-quinone oxidoreductase, 
chain g 
lambdap49 N yebR 2 ECK1831 protein YebR 
lambdap49 N yjeP 2 ECK4155 BspA protein 
lambdap49 N rpoS 1 ECK2736 RNA polymerase sigma factor RpoS 
lambdap49 N envR 1 ECK3251 probable acrEF/envCD operon 
repressor 
lambdap49 N minC 1 ECK1164 septum site-determining protein MinC
lambdap49 N ycbG 1 ECK0947 protein YcbG 
lambdap49 N ydiT 1 ECK1698 conserved hypothetical protein 
lambdap49 N yfhL 1 ECK2560 iron-sulfur cluster-binding protein 
lambdap49 N yiiF 1 ECK3883 conserved hypothetical protein 
lambdap49 N nohA 2 ECK1541 bacteriophage DNA packaging 
protein 
lambdap49 N ybeB 1 ECK0630 iojap-like ribosome-associated 
protein 
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lambdap61 P ycbG 2 ECK0947 protein YcbG 
lambdap61 P eutC 2 ECK2435 ethanolamine ammonia-lyase, light 
chain 
lambdap61 P atpC 3 ECK3724 ATP synthase F1, epsilon subunit 
lambdap61 P yqhC 2 ECK3002 putative HTH-type transcriptional 
regulator YqhC 
lambdap61 P ydaG 2 ECK1353 conserved hypothetical protein 
lambdap61 P fliM 2 ECK1943 flagellar motor switch protein FliM 
lambdap63 NinB rpsE 2 ECK3290 ribosomal protein S5 
lambdap63 NinB yqjI 6 ECK3061 transcriptional regulator, PadR family 
protein 
lambdap65 NinD ydiT 6 ECK1698 conserved hypothetical protein 
lambdap65 NinD minE 4 ECK1162 cell division topological specificity 
factor MinE 
lambdap65 NinD pyrF 5 ECK1276 orotidine 5'-phosphate decarboxylase
lambdap65 NinD yfiM 5 ECK2584 conserved hypothetical protein 
lambdap65 NinD yhdW 5 ECK3255 general L-amino acid-binding 
periplasmic protein AapJ 
lambdap65 NinD slp 4 ECK3490 outer membrane protein slp 
lambdap65 NinD csrA 3 ECK2691 carbon storage regulator 
lambdap65 NinD HycG 3 ECK2714 hydrogenase-4 component I 
lambdap65 NinD sdiA 3 ECK1915 regulatory protein SdiA 
lambdap65 NinD soxS 3 ECK4054 regulatory protein SoxS 
lambdap65 NinD smpA 4 ECK2613 small protein A 
lambdap65 NinD yjdI 4 ECK4119 conserved hypothetical protein 
lambdap65 NinD yebR 3 ECK1831 protein YebR 
lambdap66 NinE nlpI 3 ECK3151 lipoprotein NlpI 
lambdap71 Q nlpI 4 ECK3151 lipoprotein NlpI 
lambdap71 Q yqhC 2 ECK3002 putative HTH-type transcriptional 
regulator YqhC 
lambdap71 Q glyQ 2 ECK3548 glycyl-tRNA synthetase, alpha 
subunit 
lambdap71 Q ybeB 1 ECK0630 iojap-like ribosome-associated 
protein 
lambdap71 Q rfaD 1 ECK3609 ADP-L-glycero-D-manno-heptose-6-
epimerase 
lambdap71 Q paaC 1 ECK1387 phenylacetate-CoA oxygenase, PaaI 
subunit 
lambdap71 Q yibA 2 ECK3583 protein YibA 
lambdap75 R fhuF 10 ECK4357 ferric iron reductase protein FhuF 
lambdap75 R caiF 3 ECK0035 transcriptional activatory protein CaiF
lambdap75 R ydcK 1 ECK1421 conserved hypothetical protein 
lambdap78 orf_78 ispB 4 ECK3176 octaprenyl-diphosphate synthase 
lambdap79 orf_79 ybcW 1 ECK0551 conserved hypothetical protein 
lambdap80 ea47 yjiT 4 ECK4333 conserved hypothetical protein 
lambdap80 ea47 sucC 2 ECK0716 succinyl-CoA synthetase beta chain 
lambdap80 ea47 ubiH 2 ECK2902 2-polyprenyl-6-methoxyphenol 4-
hydroxylase 
lambdap80 ea47 hybO 1 ECK2991 [Ni/Fe] hydrogenase, small subunit 
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lambdap80 ea47 modC 1 ECK0754 molybdate ABC transporter, ATP-
binding protein 
lambdap80 ea47 thiF 1 ECK3984 thiazole biosynthesis 
adenylyltransferase ThiF 
lambdap80 ea47 ycdC 1 ECK1004 HTH-type transcriptional regulator 
RutR 
lambdap80 ea47 yqhC 1 ECK3002 putative HTH-type transcriptional 
regulator YqhC 
lambdap83 ea22 ybiS 2 ECK0809 protein YbiS 
lambdap83 ea22 soxS 3 ECK4054 regulatory protein SoxS 
lambdap83 ea22 yliL 4 ECK0805 b0816 hypothetical protein (yliL) 
lambdap83 ea22 norR 26 ECK2704 anaerobic nitric oxide reductase 
transcription regulator NorR 
lambdap88 cI pldB 3 ECK3819 lysophospholipase L2 
lambdap88 cI mdtE 2 ECK3497 multidrug resistance protein MdtE 
lambdap88 cI smpA 2 ECK2613 small protein A 
lambdap88 cI eutC 2 ECK2435 ethanolamine ammonia-lyase, light 
chain 
lambdap88 cI fliM 2 ECK1943 flagellar motor switch protein FliM 
lambdap88 cI rseB 2 ECK2569 sigma-E factor regulatory protein 
RseB 
lambdap88 cI ydiT 2 ECK1698 conserved hypothetical protein 
lambdap89 O clpP 1 ECK0431 ATP-dependent Clp protease, 
proteolytic subunit ClpP 
lambdap89 O ppk 15 ECK2497 polyphosphate kinase 
lambdap89 O yjhP 15 ECK4296 conserved hypothetical protein 
lambdap89 O tfaQ 3 ECK1539 tail fiber assembly protein 
lambdap89 O mviM 2 ECK1053 putative Virulence factor MviM 
homolog 
lambdap90 orf206b prfH 3 ECK0237 putative peptide chain release factor 
H 
lambdap90 orf206b yjbF 2 ECK4019 YmcC 
lambdap90 orf206b ypfJ 2 ECK2471 neutral zinc metallopeptidase family 
 
3.2.2.1 Functional groups 
All phage lambda proteins and corresponding E. coli interactors were assigned to 9 and 14 
different functional groups, respectively. For phage lambda, these were virion head, virion 
tail, superinfection exclusion, transcription, replication, recombination, lysis, inhibition of host 
replication and proteins of unknown function. The categories for E. coli involve biosynthesis 
of cofactors prosthetic groups and carriers, cell envelope, phage origin, cellular processes, 
DNA metabolism, energy metabolism, fimbrial proteins, protein fate, protein synthesis, 
regulatory functions, transcription, transport and binding proteins, 
unknown/uncharacterized/hypothetical proteins and others with known function. The phage 
lambda (L) and host (Eco) proteins along with their assigned functional groups can be 
obtained from table 14. 
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Table 14. Functional groups of phage lambda (L) and E. coli proteins (Eco). biosynth - 
biosynthesis of cofactors, prosthetic groups, and carriers; cenv - cell envelope; phage - phage origin; 
cellProc - cellular processes; DNAmeta - DNA metabolism; enMeta - energy metabolism; fimProt - 
fimbrial protein; protFate - protein fate; protSynth - protein synthesis; regFunc - regulatory functions; 
trx - transcription; transBind - transport and binding proteins; unc/unk/hyp - 
unknown/uncharacterized/hypothetical protein; other - other; tail - virion tail; sep - superinfection 
exclusion; trx - transcription; repl - replication; unk - unknown; rec - recombination; lysis - lysis; ihr - 
inhibition of host replication; head - virion head. 
Gene Organism Function Gene Organism Function 
A L head cobB Eco other 
Fi L head ppk Eco other 
nu1 L head acpS Eco other 
ea8.5 L ihr pldB Eco other 
R L lysis pyrF Eco other 
NinB L rec frvA Eco other 
int L rec tfaQ Eco phage 
orf63 L rec tfaR Eco phage 
ea10 L repl nohA Eco phage 
O L repl nohB Eco phage 
P L repl stfR Eco phage 
SieB (orf48) L sep ybcW Eco phage 
orf-401 L tail ydaG Eco phage 
orf-314 L tail clpP Eco protFate 
G L tail secB Eco protFate 
H L tail yeiW Eco protFate 
cI L trx ypfJ Eco protFate 
Q L trx glyQ Eco protSynth 
N L trx prfH Eco protSynth 
orf_78 L unk rmf Eco protSynth 
NinE L unk rpmA Eco protSynth 
NinD L unk rpsE Eco protSynth 
orf206b L unk rpsG Eco protSynth 
orf_79 L unk rpsS Eco protSynth 
orf61 L unk yheL Eco protSynth 
ea47 L unk caiF Eco regFunc 
ea22 L unk envR Eco regFunc 
ispB Eco biosynth rseB Eco regFunc 
thiF Eco biosynth sdiA Eco regFunc 
ubiH Eco biosynth soxS Eco regFunc 
fliM Eco cellProc ycdC Eco regFunc 
mdtE Eco cellProc ycgE Eco regFunc 
minC Eco cellProc yqhC Eco regFunc 
minE Eco cellProc yqjI Eco regFunc 
mviM Eco cellProc chaC Eco transBind 
proQ Eco cellProc ECK1157 Eco transBind 
nlpI Eco cenv ego Eco transBind 
rfaD Eco cenv fhuF Eco transBind 
slp Eco cenv modC Eco transBind 
yceK Eco cenv ydgH Eco transBind 
yjeP Eco cenv yhdW Eco transBind 
dnaN Eco DNAmeta ymjB Eco transBind 
priC Eco DNAmeta nusA Eco trx 
atpC Eco enMeta rpoS Eco trx 
cchB Eco enMeta cedA Eco unc/unk/hyp 
csrA Eco enMeta dcrB Eco unc/unk/hyp 
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Gene Organism Function Gene Organism Function 
eutC Eco enMeta smpA Eco unc/unk/hyp 
fdoH Eco enMeta ybeB Eco unc/unk/hyp 
fixB Eco enMeta ybiS Eco unc/unk/hyp 
hcr Eco enMeta ycbG Eco unc/unk/hyp 
hybO Eco enMeta ydcK Eco unc/unk/hyp 
HycG Eco enMeta ydiT Eco unc/unk/hyp 
hyfG Eco enMeta yebR Eco unc/unk/hyp 
norR Eco enMeta yfcQ Eco unc/unk/hyp 
nuoG Eco enMeta yfiM Eco unc/unk/hyp 
paaC Eco enMeta yibA Eco unc/unk/hyp 
pntA Eco enMeta yiiF Eco unc/unk/hyp 
ppc Eco enMeta yjbF Eco unc/unk/hyp 
sucC Eco enMeta yjdI Eco unc/unk/hyp 
yfhL Eco enMeta yjhP Eco unc/unk/hyp 
yicI Eco enMeta yjiT Eco unc/unk/hyp 
sfmA Eco fimProt ykgL Eco unc/unk/hyp 
sfmF Eco fimProt yliL Eco unc/unk/hyp 
ybgD Eco fimProt ynfC Eco unc/unk/hyp 
ycbQ Eco fimProt yohH Eco unc/unk/hyp 
yehD Eco fimProt yohN Eco unc/unk/hyp 
yraH Eco fimProt ypjJ Eco unc/unk/hyp 
yjiR Eco other       
 
To observe which functional categories of E. coli proteins are targeted most frequently by 
phage lambda, the interactions occurring between functional groups of phage proteins and 
functional groups of host proteins were examined.  
The results were dissimilar, depending on which functional groups were observed (see figure 
32). A highly specific group was the E. coli group ‘transcription’ that was only targeted by 
phage lambda proteins involved in transcription, whereas the phage lambda transcription 
category targeted 11 out of 14 host functional groups. However, the most proteins involved in 
phage transcription interact with host proteins of the functional group energy metabolism.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Interestingly, another group, the E. coli fimbrial proteins, interacted exclusively with phage 
lambda proteins involved in virion tail formation, especially with the lambda protein gpH, the 
tape measure protein. Even though no similarities between the protein sequences of host 
fimbrial proteins with phage lambda proteins were detected, it seems as if the tape measure 
 
Figure 32. Interactions between the functional groups of phage lambda and its host E. coli. 
See text for further explanations. 
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protein is capable to selectively target host fimbrial proteins. However, if these interactions 
play a role in vivo is still obscure. A similar statement can be made for phage lambda 
proteins interacting with E. coli proteins of prophage origin (functional group: Phage). 
Altogether seven different E. coli proteins of phage origin were involved in 10 phage host 
interactions, out of which 6 proteins were highly homologous to phage lambda proteins (see 
table 15). It has been shown previously that lambda gpA interacts with nu1 and orf_79 with 
itself (Rajagopala et al., 2011), so it is no surprise that these proteins also interact with 
homologues of nu1 (E. coli nohA and nohB) and orf_79 (E. coli ybcW), respectively. The nu1 
homologue nohA was also found to interact with the phage antiterminator gpN. Even though 
the biological relevance of this interaction is not fully clear, binding of gpN to lambda nu1 was 
previously found by (Rajagopala et al., 2011). 
Also conceivable are the interactions of the phage lambda defective tail fiber proteins orf-314 
and orf-401 with the tail fiber assembly proteins tfaR and tfaQ and the tail fiber protein stfR, 
respectively. On the other hand the biological relevance of interactions like lambda 
integrase/E. coli nohB, lambda gpO/ E. coli tfaQ and lambda gpP/ E. coli ydaG is obscure, 
especially since phage lambda has no homologues of ydaG, which is a protein of Rac 
prophage origin. 
 
Table 15. Lambda targets E. coli proteins of phage origin. The column ‘lambda homologue’ states 
the lambda protein which is homologous to the E. coli prey. 
Lambda bait E. coli preys Lambda homologue Description of E. coli prey 
A nohA nu1 bacteriophage DNA packaging protein 
N nohA nu1 bacteriophage DNA packaging protein 
int nohB nu1 DLP12 prophage, DNA packaging protein 
A nohB nu1 DLP12 prophage, DNA packaging protein 
orf-401 stfR orf-314 Rac prophage; predicted tail fiber protein 
O tfaQ orf-194 Qin prophage; predicted tail fibre assembly protein 
orf-314 tfaQ orf-194 Qin prophage; predicted tail fibre assembly protein 
orf-314 tfaR orf-194 Rac prophage; predicted tail fiber assembly protein 
orf_79 ybcW orf_79 DLP12 prophage; predicted protein 
P ydaG - Rac prophage; predicted protein 
 
Eight interactions were found for the E. coli group ‘protein synthesis’ that was targeted mainly 
by one phage lambda protein involved in replication, namely the putative single strand 
binding protein ea10. It bound the three ribosomal proteins rpmA, rpsG and rpsS as well as 
the ribosome modulation factor rmf. The host group ‘transport and binding’ interacted mainly 
with virion tail proteins, namely with gpG and gpH.  
Remarkably, on both sides, phage and host, proteins of unknown function (or hypothetical 
proteins) were involved in interactions with several functional categories, but mainly with 
other proteins of unknown function. 
3.2.2.2 Phage lambda – host interaction network 
The 144 phage lambda – host interactions were combined in a complete network (see figure 
33). Two interactions, namely lambda gpN/E. coli nusA (Friedman and Court, 2001) and 
lambda gpO/ E. coli clpP (Kobiler et al., 2004) were published previously (depicted as bold 
lines in green). The phage lambda-host interactions concerning E. coli proteins of phage 
origin (depicted in light pink in figure 33) were not considered as published interactions, since 
the interactions published by (Rajagopala et al., 2011) involve homologous proteins. 
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Figure 33. The protein interaction network of phage lambda with its host E. coli. The nodes 
represent proteins and are colored according to their functional class; quadratic and circular 
shapes stand for phage and host proteins, respectively. Protein-protein interactions are 
depicted as edges. Published interactions are depicted in green. The network contains the 
144 phage/host interactions found in this study. 
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4 Discussion 
4.1 The EHEC-host interactome 
The EHEC-host interactome presented in this study was done to discover novel human 
interactors of both well-studied and lesser-known EHEC effector proteins. I chose the EHEC 
effector protein – host interactome for the following two reasons:  
1. 39 EHEC effectors were experimentally shown to be secreted by the T3SS (Tobe et al., 
2006) and were as such likely to reveal interactions with host proteins and  
2. in contrast to extracellular and surface proteins that may also reveal interspecies 
interactions, soluble proteins with an intracellular localization are more likely to be functional 
in the yeast two-hybrid system. 
4.1.1 Data quality and limits of the yeast two-hybrid system 
In total 35 non-promiscuous interactions of 15 effectors with 34 human proteins were 
detected reproducibly. The 273 single hits also found in this study are unconfirmed yeast 
two-hybrid interacting pairs. They may be real interactions, but it is just as well possible that 
they arose through different technical artefacts such as more than one prey plasmid per cell, 
two or more yeast colonies per well or spontaneous mutations, which makes them highly 
unreliable (Mohr and Koegl, 2012). In addition their frequency of occurrence in pooled library 
screens is much higher (about 8 times in this study) than that of high-confidence hits, 
previously published interactions are rarely found among them and most single hits cannot 
be confirmed with alternate methods (other than yeast two-hybrid). As a consequence I 
decided to exclude the single hits from further network analysis. 
For EHEC effectors, about 60 human putative and known interactors are described in the 
literature to date (reviewed in (Wong et al., 2011), out of which four were also discovered in 
this study. These involve TIR-BAIAP2 (Weiss et al., 2009), TIR-BAIAP2L1 (Vingadassalom 
et al., 2009), EspF-SNX9 (Marches et al., 2006) and Map-NHERF2 (SLC9A3R2) (Martinez et 
al., 2010). In general, this seems like a low overlap with published data, but since many 
pathogen-host interactions are rather of regulatory than of structural nature, the interactions 
may be only temporary and as such less stable. This makes discovery via Y2H screening 
more difficult. Yeast two-hybrid interactomes focussing on interactions between structural 
proteins such as (Rajagopala et al., 2011), who mapped the intraviral interactions of 
bacteriophage lambda, usually reveal a much higher overlap with literature data. Especially 
the hardwearing interactions of tail and capsid are highly reproducible. 
Another limit of yeast two-hybrid is its restriction to direct protein-protein interactions. In the 
human cell, many proteins are organized into multimeric protein complexes. This allows not 
only direct, but also indirect protein-protein interactions involving one or more so-called linker 
proteins as connection(s) between the two indirect interactors. Both, indirect and direct PPIs 
can be detected with cell based assays such as LUMIER (Luminescence-based mammalian 
interactome mapping), since in contrast to yeast, mammalian cells can provide missing linker 
proteins. On the other hand a restriction to direct PPIs can also be advantageous, especially 
for the generation of interactomes and the distinction between direct and indirect interactors 
in protein complexes. 
Other challenges include that some proteins require the aid of chaperones for efficient folding 
or only bind when folded into certain spatial conformations, depending on interactions with 
third proteins or on post translational modifications. Both EHEC effectors and human host 
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proteins are expressed in a non-natural environment and as such may reveal altered post 
translational modifications that interfere with their binding capabilities (Koegl and Uetz, 
2007). However, despite these odds, most proteins are capable of folding correctly in the 
environment of the yeast nucleus and these show, as demonstrated by the discovery of 
previously known interactors, their natural interaction patterns. 
Regarding the obtained 35 high confidence hits, it can be estimated, that the majority of 
these interactions are true interactions. The only exceptions may be NleH-UFC1 and 
TccP/EspFU-ZNF626, since for both NleH and TccP/EspFU these interactions are the only 
high confidence hits among more than 27 single hits. Although these interactions may be 
less reliable compared to the other 33 high confidence hits, they are nevertheless 
reproducible PPIs and as such included in the EHEC-host network. 
Potential yeast two-hybrid artefacts, also called promiscuous proteins were already removed 
from the high confidence dataset during the process of data analysis. The identification of 
putative artefacts relies very much on the threshold set for prey promiscuity. In our system of 
automated pool screening, which was applied for the generation of the EHEC-host 
interactome, a conservative specificity cut-off of 1% relative prey promiscuity was chosen. 
This means, a prey protein that was found to interact with one or more percent of all 
screened bait proteins was tagged as a potential artefact. Since our human cDNA libraries 
and ORF collections are also used by the yeast two-hybrid screening service facility of the 
DKFZ core facilities, a more comprehensive dataset was available for the identification of 
putative false-positive interactors. This allows an improved distinction between potential 
artefacts and high-confidence interactions, which corresponds well with the fact that the list 
of potential promiscuous prey proteins remained widely constant despite the ongoing 
increase of our dataset (internal data, unpublished). Still not all proteins tagged as 
promiscuous in our system are indeed artefacts. Some proteins such as TP53 that naturally 
exhibit a large number of different interactors (465 unique interactors are listed for TP53 in 
the BioGRID database, state 09/2012) may be sorted out in error. However, the majority of 
preys tagged erroneously as artefacts cannot be discovered due to the lack of published 
interaction data. 
It is hard to estimate the recall, of our screens, i.e., the percentage of interactions recovered 
of all the ones that actually occur in nature. Taken the fact that the majority of detected 
EHEC-host interactions, namely 31, are novel ones, it can be concluded that many 
interactions between EHEC and its human host cells are not yet discovered. 
4.1.2 Connections between effector proteins 
The EHEC-host interactome generated within this study revealed several connections 
between EHEC effectors over indirectly interacting human proteins. These connections 
include so-called loops, which terms connections between two human interactors of one 
effector protein and their shared human interaction partner. Connections and loops indicate 
that the corresponding EHEC effectors are part of the same protein complex or pathway, or 
at least are in spatial proximity to each other. On the other hand, several of the connections 
and loops contain ubiquitin (UBC) or ubiquitin ligases (namely DTX2, ITCH, MDM2 and 
NEDD4) as connecting proteins. This may indicate that the human interactors are tagged 
(e.g. for degradation) by the same enzyme(s). Other connections seem to be more 
interesting, for example the one between NleF and EspY1 over their direct interactors DHFR 
and ZNHIT1 as well as the common indirect interactor TP53, or a trimeric connection 
between the EHEC effectors TIR, NleB1 and EspB over the common indirect interactor 
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IKBKG (see figure 34 A). IKBKG (NEMO) is the regulatory subunit of the IKK (inhibitor of 
kappaB kinase) complex and essential in activation of NF-kB. 
A recently published study found that TIR can inhibit NF-kB activation via a direct or indirect 
interaction of TIR with TRAF2 (Ruchaud-Sparagano et al., 2011). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In this study I found no direct interaction of TIR with the adaptor protein TRAF2, only an 
indirect connection over IKBKG, a direct interactor of TRAF2 (Tang et al., 2003). This 
connection links not only TIR, but also EspB and NleB1 to IKBKG and thus TRAF2. A finding 
 
Figure 34. Indirect connections of EHEC effectors. A, EHEC TIR, EspB and NleB1 interact 
indirectly with IKBKG. B, NleB and TIR putatively inhibit NF-kB signalling at the level of TRAF2, figure 
modified after (Newton et al., 2010). C, Connections between EHEC effectors and TRAF2 (green 
node). EHEC effectors, direct and indirect interactors (human) are depicted in red, blue and light blue, 
respectively. IKBKG is framed in green and TNF is depicted in yellow. 
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that corresponds well with the observation that NleB1 can inhibit TNFα induced NF-kB 
activation (Newton et al., 2010). However, NleB1 is connected to IKBKG by an interaction 
with POLR2E, a subunit of the human RNA polymerase II, which is an unusual adaptor 
protein. It remains to be shown if this connection is of relevance in vivo. 
TIR- and NleB-dependent inhibition of NF-kB signalling and connections between EHEC 
effector proteins and human TRAF2 illustrated as network are depicted in figure 34 B and C, 
respectively. 
4.1.3 TIR-host interaction patterns 
The EHEC-host network includes two single hits and six high confidence human interactors 
for EHEC TIR, namely ARRB1, BAIAP2, BAIAP2L1, HPCAL1, HPCAL4, NCALD, PDE6D 
and STK16. HPCAL4 and PDE6D were found as single hits and BAIAP2 and BAIAP2L1 
were published previously (Vingadassalom et al., 2009; Weiss et al., 2009). All eight 
inteactions could be confirmed by LUMIER assays.  
Three out of the eight human interactors, namely HPCAL1, HPCAL4 and NCALD, are 
homologous calcium binding proteins, which may suggest the assumption that their ability to 
bind EHEC TIR varies depending on their calcium binding state. Nevertheless, LUMIER 
assays with 1 mM CaCl2 instead of 10 mM EDTA revealed that TIR binding does not 
dependent on the availability of calcium. However, it cannot be excluded that the cellular 
calcium levels regulate binding through translocalization of these proteins from the cytosol to 
the plasma membrane, an observation previously published for bovine recoverin, a 
homologous protein (Zozulya and Stryer, 1992). 
The eight human interactors found for EHEC TIR were systematically tested for interactions 
with the homologous EPEC TIR via binary yeast two-hybrid assays. This revealed that five of 
the eight proteins also interacted with EPEC TIR. Only ARRB1, HPCAL4 and PDE6D did not 
display interaction signals. However PDE6D was found as single hit in a Y2H pool screen 
and clearly interacted with EHEC TIR in LUMIER assay. Either it only interacts under certain 
circumstances or it is an indirect interactor that requires cellular factors for successful 
binding. 
It can be concluded that, despite some differences, the interaction patterns of EHEC and 
EPEC TIR are similar. However, if ARRB1 and HPCAL4 do indeed only bind to EHEC TIR 
needs to be validated in functional assays. 
4.1.4 NleF, caspase inhibition and apoptosis subversion 
NleF was previously shown to be a substrate of the type III secretion system to be injected 
into human gut cells (Tobe et al., 2006). Within the host cell it localizes to the cytoplasm and 
experiments in mice and gnotobiotic piglets suggested a contribution of NleF to gut 
colonization (Echtenkamp et al., 2008). However, no study approaching NleF’s role in the 
host cell has been published to date.  
NleF is a 21.4 kDa protein, which is present in many different EHEC and EPEC strains in 
highly similar versions; often these versions reveal an amino acid identity of 100% (Bugarel 
et al., 2011; Echtenkamp et al., 2008). Aside from that, there are only few other proteins that 
reveal similarities with EHEC/EPEC NleF (Echtenkamp et al., 2008), e.g. SDY_P223, an 
effector protein from Shigella dysenteriae, which is 45 amino acids in length and reveals 
homologies to the EHEC NleF C-terminus 
In this study I discovered that human caspases 4, 8 and 9 are direct interaction partners of 
EHEC NleF. NleF was shown to inhibit caspase activity in vitro and in HeLa cell lysate and 
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further to decrease TRAIL and staurosporine-mediated apoptosis induction in HeLa and 
Caco-2 cells. This allots NleF a role in apoptosis inhibition, a strategy frequently used by viral 
and bacterial pathogens to preserve their biological niche (Behar et al., 2011; Brune, 2010). 
Whereas in viruses apoptosis regulation is a long known phenomenon (Richard and Tulasne, 
2012), the first antiapoptotic type III effector of an animal pathogen, namely SopB of 
Salmonella, was discovered in 2005 (Knodler et al., 2005). Soon after, antiapoptotic T3SS 
secreted effectors were identified in other pathogens, also in EHEC and EPEC. With NleF 
and the previously published antiapoptotic EHEC effectors NleD and NleH (Baruch et al., 
2011; Hemrajani et al., 2010), there are now three known EHEC effectors that inhibit 
apoptosis by subversion of distinct apoptotic pathways. This suggests the assumption that 
the need for such countermeasures may be crucial to pathogenic E. coli, especially since the 
bundle-forming pili and some effectors expressed by EPEC and/or EHEC, e.g. EspF and 
Map, have been demonstrated to induce apoptosis in host cells (Abul-Milh et al., 2001; 
Barnett Foster et al., 2000; Nougayrede and Donnenberg, 2004; Nougayrede et al., 2007). 
Despite the presence of these proapoptotic factors, a decrease in normal apoptotic rates was 
observed upon infection of rabbits with a related REPEC O103 strain, which contains an 
NleF similar to that of EHEC and EPEC (93 % amino acid identity) (Heczko et al., 2001).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 35. The EHEC effector protein NleF inhibits the caspases 4, 8 and 9. This leads to 
decreased apoptosis induction through subsequent impairment of the extrinsic and intrinsic (caspases 
8 and 9 dependent) apoptosis pathways. The role of NleF dependent caspase-4 inhibition was not 
clarified. It may either contribute to this phenotype by prevention of ER stress induced apoptosis, or 
prevent processes involved in inflammation. 
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By inhibiting the two initiator caspases 8 and 9 of the extrinsic and intrinsic apoptosis 
pathways, respectively, NleF is likely to add to this phenotype. To what extent caspase-4 
inhibition by NleF contributes to apoptosis inhibition is still unclear at present. The role of 
caspase-4 is controversial; it has been associated with ER stress-induced apoptosis (Hitomi 
et al., 2004), which was later challenged by (Obeng and Boise, 2005), but could not be 
disproved to date. A recent publication revealed a novel ER stress-induced apoptotic 
pathway in which caspase-4 directly activates caspase-9 (Yamamuro et al., 2011). 
However, less controversial is an involvement of caspase-4 in inflammation via 
inflammasome activation and NF-kB regulation (Martinon and Tschopp, 2007; Nickles et al., 
2012; Sollberger et al., 2012). Whether NleF is able to inhibit NF-kB activation or prevent 
caspase-4 dependent caspase-1 activation was not tested in the frame of this study. The 
suggested role of NleF in apoptosis regulation is schematized in figure 35. 
4.1.4.1 NleF binding site and efficiency 
A collaboration with Proteros (Martinsried, Germany), led to the co-crystallization of the 
NleF/CASP9 complex. The structure revealed that in addition to some other contact points 
between the two proteins, the carboxy-terminal four amino acids Gly189, Cys188, Gln187 
and Leu186 of NleF occupy the caspase-9 S1, S2, S3 and S4 pockets, respectively. When 
the findings of the structure are compared to the results I obtained for the NleF versions with 
mutagenized carboxy-termini, it can be concluded that the very same amino acids are not 
only responsible for caspase binding, but also for apoptosis inhibition in host cells. Deletion 
of the NleF carboxy-terminal 4 amino acids abolishes both, its ability to bind caspase-9 and 
its ability to prevent apoptosis induction. A similar result was obtained for an NleF version 
with an extra carboxy-terminal alanine. The results for the NleF substitution mutants were not 
so clear: Alanine substitutions of Leu186, Gln187, Cys188 and Gly189 tend to show 
impairment in caspase-9 binding and apoptosis inhibition. However, while caspase-9 binding 
varies between ‘similar to wild type’ (Cys188Ala) and ‘almost no caspase-9 binding 
detectable’ (Gln187Ala), the apoptosis inhibition is highly similar between the four 
substitution mutants. It lies at 10 % apoptotic cells 6 h after apoptosis induction (wild type 
NleF: ~3-4 %, negative control protein A is over 60 %). Possibly the interactions of the NleF 
substitutions with caspases are less stable than those of wild type NleF and thus give weaker 
signals in co-precipitation assays such as LUMIER. This may only have a minor effect on 
their ability to inhibit apoptosis. A picture of the NleF/CASP9 structure is shown in figure 36. 
 
Regarding both, the results of the NleF versions with altered carboxy-termini and the 
caspase-9/NleF crystal structure, it can be said that NleF binds and blocks the active center 
of caspase-9 and probably also of caspase-4 and -8 with its carboxy-terminal four amino 
acids. However, the efficiency with which NleF inhibits caspase-9 is higher than expected: 
According to the NleF/caspase-9 structure, a 1:1 mode of caspase-9 inhibition by NleF has to 
be expected, since one NleF carboxy-terminus blocks one catalytic site. Nevertheless, the 
IC50 values obtained for NleF-dependent caspase-9 and also caspase-4 inhibition are much 
lower than expected. The lower limit for an IC50 is 1/2 the enzyme concentration (Copeland, 
2002), the IC50 of NleF in caspase-4 and -9 inhibition are less than 1/10. Thus NleF must be 
able to inhibit more than one caspase-9 (and -4) catalytic site. Since NleF has no catalytic 
activity which could contribute to caspase inactivation (data not shown), it either inhibits 
whole caspase multimers or it decreases caspase activity by reducing the caspase dimers in 
solution and thus caspase activity. 
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4.1.4.2 Role of NleF and occurrence in bacteria 
Many EPEC and EHEC strains harbouring a type III secretion system and effector proteins 
possess a highly similar or identical NleF (Echtenkamp et al., 2008). In other bacteria, the 
occurrence of proteins homologous to NleF is a rarity. The few exceptions include 
Providencia rustigianii, Yersinia pseudotuberculosis, Shigella dysenteriae and S. boydii. All 
 
Figure 36. Crystal structure of the caspase-9/NleF complex (Holger Steuber, Proteros). 
Illustration A depicts the caspase-9/NleF complex consisting of two caspase-9 protease monomers 
(magenta and yellow) and two NleF effector proteins attached to them (green). The caspase-9 active 
site cysteins are represented by red sticks. B shows the four NleF C-terminal amino acids Gly189, 
Cys188, Gln187 and Leu186 in the caspase-9 S1-4 pockets. The grey boxes state the effect on 
caspase-9 binding and apoptosis inhibition when these residues are substituted by alanine. 
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are pathogens with a type III secretion system. The NleFs of these bacteria differ significantly 
from those of EPEC and EHEC. Interestingly the ones from Shigella are truncated and 
contain only the carboxy-terminal 45 amino acids (see figure 37 for an alignment). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Whether these NleF homologues are functional in apoptosis inhibition or caspase-binding 
was not tested in this study. It is reasonable to expect that at least the NleF versions with 
similar carboxy-termini are functional. The NleF substitution mutants revealed that a 
Cys188Ala substitution had only minor effects on caspase-9 binding and apoptosis inhibition, 
which is in conformance with the rather low degree of conservation found for Cys188 in the 
NleF homologues of other bacteria. The Gln187 and Gly189 residues are highly conserved in 
all NleF versions depicted in figure 37 and are involved in NleF functionality. 
Another possibility may be that NleF fulfills functions other than apoptosis inhibition in these 
bacteria. An option supported by the fact that NleF also interacts with human dihydrofolate 
reductase (DHFR). However, the biological function of this interaction was not examined in 
this study. 
 
Figure 37. Alignment showing the NleF homologues of different bacteria. The amino acids are 
colored after conservation. The carboxy-terminal four amino acids involed in caspase binding are 
framed in red. 
DISCUSSION 
 
85
4.2 The phage lambda-host interactome 
In the frame of this study, the first systematic interactome between phage lambda and its 
host E. coli was generated. The 631 interactions first discovered in the yeast two-hybrid 
screens were reduced to 144 interactions after quality filtering. The 144 final pathogen-host 
intercations include two previously published ones and a number of phage proteins binding 
to E. coli proteins of prophage origin. Many of these interactions are homologous to phage 
lambda intraspecies interactions (Rajagopala et al., 2011).  
4.3 Outlook 
The generation of interactomes usually involves the production of large datasets. As a 
consequence, detailed analysis can only be realised for a small number of interactions. The 
role of interactomes can be seen as a data-rich resource, which provides the foundation for 
further research. The EHEC-host network definitely contains, aside from NleF/caspase-9, 
many more interesting interactions worth to follow up experimentally in future studies. 
It is planned to use the phage lambda-E. coli dataset for the identification of pathways that 
play essential roles in phage infection. In addition the comparison of the lambda-host 
interaction network to other phage-host interactomes may reveal distinct interaction patterns 
among different phages, e.g. between temperate and lythic phages. Such comparisons of 
whole interactomes are facilitated by the permanently increasing amount of phage-host 
interaction data available in the literature (Hauser et al., 2012). 
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Supplementary figure 1. Binary yeast two hybrid tests of EHEC and EPEC TIR against the 
human proteins ARRB1, BAIAP2, BAIAP2L1, HPCAL1, HPCAL4, NCALD, PDE6D and STK16 
at different 3-AT concentrations. N – amino-terminal TIR fragment; C – carboxy-terminal TIR 
fragemnt; full – full length TIR; v0011 – pGAD424; v0012 – pGBT9; v0034 – pGBKCg; v0035 – 
pGADCg. 
APPENDIX 
 
104
Supplementary table 1. Complete list of detected EHEC/host interactions. 3’UTR – hit was in the 
3’UTR and did not contain coding sequence; Prey prom – prey promiscuity assessed as total number 
of different baits the respective prey was found to interact with (raw counts), if the number is 6 or 
above, the prey is tagged as promiscuous. 
Bait ID EHEC 
bait 
Prey gene 
symbol 
Prey 
count
3'UTR Prey 
prom 
Description GeneID
ECs0061 EspY1 CDKN2AIPNL 51 0 2 CDKN2A interacting 
protein N-terminal like 
91368 
ECs0061 EspY1 RING1 19 0 11 ring finger protein 1 6015 
ECs0061 EspY1 PIH1D1 6 0 2 PIH1 domain containing 1 55011 
ECs0061 EspY1 PSMC1 5 0 4 proteasome (prosome, 
macropain) 26S subunit, 
ATPase, 1 
5700 
ECs0061 EspY1 CAPN3 3 0 3 calpain 3, (p94) 825 
ECs0061 EspY1 PCID2 3 0 4 PCI domain-containing 
protein 2 (CSN12-like 
protein). 
55795 
ECs0061 EspY1 DNAJC14 2 0 3 DnaJ (Hsp40) homologue, 
subfamily C, member 14 
85406 
ECs0061 EspY1 ZNHIT1 2 0 5 zinc finger, HIT type 1 10467 
ECs0061 EspY1 CLK1 1 0 3 CDC-like kinase 1 1195 
ECs0847 NleC C8orf71 3 0 1 chromosome 8 open 
reading frame 71 
26138 
ECs0847 NleC CTDSPL2 3 0 1 CTD (carboxy-terminal 
domain, RNA polymerase 
II, polypeptide A) small 
phosphatase like 2 
51496 
ECs0847 NleC CREM 1 0 1 cAMP responsive element 
modulator 
1390 
ECs0847 NleC CBWD1 1 0 1 COBW domain containing 
1 
55871 
ECs0847 NleC LCP2 1 0 1 lymphocyte cytosolic 
protein 2 (SH2 domain 
containing leukocyte 
protein of 76kDa) 
3937 
ECs0847 NleC MCART1 1 0 1 mitochondrial carrier triple 
repeat 1 
92014 
ECs0847 NleC ZC3H14 1 0 2 zinc finger CCCH-type 
containing 14 
79882 
ECs0847 NleC HEPH 1 0 2 hephaestin 9843 
ECs0847 NleC FKBP3 1 0 3 FK506 binding protein 3, 
25kDa 
2287 
ECs0847 NleC YLPM1 1 0 4 YLP motif containing 1 56252 
ECs0847 NleC ADRBK2 1 1 1 adrenergic, beta, receptor 
kinase 2 
157 
ECs0847 NleC NEBL 1 1 1 nebulette 10529 
ECs0847 NleC PPP3R2 1 1 1 protein phosphatase 3 
(formerly 2B), regulatory 
subunit B, beta isoform 
5535 
ECs0847 NleC RIN2 1 1 1 Ras and Rab interactor 2 54453 
ECs0847 NleC ZFYVE16 1 1 1 zinc finger, FYVE domain 
containing 16 
9765 
ECs0847 NleC SLC31A2 1 1 2 solute carrier family 31 
(copper transporters), 
member 2 
1318 
ECs0847 NleC ZRANB2 1 1 2 zinc finger, RAN-binding 
domain containing 2 
9406 
ECs0847 NleC CYB5B 1 1 3 cytochrome b5 type B 
(outer mitochondrial 
membrane) 
80777 
ECs0847 NleC NOMO1 1 1 4 NODAL modulator 1 23420 
ECs0847 NleC PTPN6 1 0 6 protein tyrosine 
phosphatase 
5777 
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ECs0847 NleC DNAJC7 1 0 9 DnaJ (Hsp40) homolog, 
subfamily C, member 7 
7266 
ECs0847 NleC RPL21 1 0 11 ribosomal protein L21 6144 
ECs0847 NleC BHMT 1 1 8 betaine-homocysteine 
methyltransferase 
635 
ECs0847 NleC EIF4B 1 1 10 eukaryotic translation 
initiation factor 4B 
1975 
ECs0848 NleH1-1 ENSG0000020
6444 
1 0 1 CDNA FLJ46428 fis, 
clone THYMU3014173, 
moderately similar to HLA 
class I histocompatibility 
antigen, alpha chain 
E*0101/E*0102. 
  
ECs0848 NleH1-1 ENSG0000020
6507 
1 0 1 CDNA FLJ46428 fis, 
clone THYMU3014173, 
moderately similar to HLA 
class I histocompatibility 
antigen, alpha chain 
E*0101/E*0102. 
  
ECs0848 NleH1-1 TYRO3 1 0 1 TYRO3 protein tyrosine 
kinase 
7301 
ECs0848 NleH1-1 ACP5 1 0 1 acId phosphatase 5, 
tartrate resistant 
54 
ECs0848 NleH1-1 ATP6V1D 1 0 1 ATPase, H+ transporting, 
lysosomal 34kDa, V1 
subunit D 
51382 
ECs0848 NleH1-1 C12orf72 1 0 1 chromosome 12 open 
reading frame 72 
254013 
ECs0848 NleH1-1 C20orf196 1 0 1 chromosome 20 open 
reading frame 196 
149840 
ECs0848 NleH1-1 C3orf38 1 0 1 chromosome 3 open 
reading frame 38 
285237 
ECs0848 NleH1-1 CADM3 1 0 1 cell adhesion molecule 3 57863 
ECs0848 NleH1-1 CALML4 1 0 1 calmodulin-like 4 91860 
ECs0848 NleH1-1 CCDC102A 1 0 1 coiled-coil domain 
containing 102A 
92922 
ECs0848 NleH1-1 CYB561D2 1 0 1 cytochrome b-561 domain 
containing 2 
11068 
ECs0848 NleH1-1 DNAJC24 1 0 1 DnaJ (Hsp40) homolog, 
subfamily C, member 24 
120526 
ECs0848 NleH1-1 DNAJC3 1 0 1 DnaJ (Hsp40) homolog, 
subfamily C, member 3 
5611 
ECs0848 NleH1-1 ERGIC2 1 0 1 ERGIC and golgi 2 51290 
ECs0848 NleH1-1 FGL2 1 0 1 fibrinogen-like 2 10875 
ECs0848 NleH1-1 FXC1 1 0 1 fracture callus 1 homolog 
(rat) 
26515 
ECs0848 NleH1-1 GZMB 1 0 1 granzyme B (granzyme 2, 
cytotoxic T-lymphocyte-
assocIated serine 
esterase 1) 
3002 
ECs0848 NleH1-1 ICT1 1 0 1 immature colon 
carcInoma transcript 1 
3396 
ECs0848 NleH1-1 LOC10029445
9 
1 0 1 similar to immunoglobulin 
lambda-like polypeptide 1 
100294459 
ECs0848 NleH1-1 LOC643406 1 0 1 hypothetical protein 
LOC643406 
643406 
ECs0848 NleH1-1 LYSMD3 1 0 1 LysM, putative 
peptidoglycan-binding, 
domain containing 3 
116068 
ECs0848 NleH1-1 NDUFAF4 1 0 1 NADH dehydrogenase 1 
alpha subcomplex, 
assembly factor 4 
29078 
ECs0848 NleH1-1 OR2L13 1 0 1 olfactory receptor, family 
2, subfamily L, member 
13 
284521 
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ECs0848 NleH1-1 PDHB 1 0 1 pyruvate dehydrogenase 
(lipoamide) beta 
5162 
ECs0848 NleH1-1 PEX16 1 0 1 peroxisomal biogenesis 
factor 16 
9409 
ECs0848 NleH1-1 PLA2G16 1 0 1 phospholipase A2, group 
XVI 
11145 
ECs0848 NleH1-1 PODXL2 1 0 1 podocalyxin-like 2 50512 
ECs0848 NleH1-1 PRSS35 1 0 1 protease, serine, 35 167681 
ECs0848 NleH1-1 RPL13AP17 1 0 1 ribosomal protein L13a 
pseudogene 17 
399670 
ECs0848 NleH1-1 SCGB2A1 1 0 1 secretoglobin, family 2A, 
member 1 
4246 
ECs0848 NleH1-1 SPATA1 1 0 1 spermatogenesis 
assocIated 1 
64173 
ECs0848 NleH1-1 SPATA3 1 0 1 spermatogenesis 
assocIated 3 
130560 
ECs0848 NleH1-1 SPINLW1 1 0 1 serine peptidase inhibitor-
like, with Kunitz and WAP 
domains 1 (eppin) 
57119 
ECs0848 NleH1-1 TM4SF18 1 0 1 transmembrane 4 L six 
family member 18 
116441 
ECs0848 NleH1-1 TMEM180 1 0 1 transmembrane protein 
180 
79847 
ECs0848 NleH1-1 TMEM184B 1 0 1 transmembrane protein 
184B 
25829 
ECs0848 NleH1-1 TYMP 1 0 1 thymidine phosphorylase 1890 
ECs0848 NleH1-1 UBE2D1 1 0 1 ubiquitin-conjugating 
enzyme E2D 1 (UBC4/5 
homolog, yeast) 
7321 
ECs0848 NleH1-1 ZNF385C 1 0 1 zinc finger protein 385C 201181 
ECs0848 NleH1-1 AATF 1 0 2 apoptosis antagonizing 
transcription factor 
26574 
ECs0848 NleH1-1 ASCC3 1 0 2 activating signal 
cointegrator 1 complex 
subunit 3 
10973 
ECs0848 NleH1-1 COX7B2 1 0 2 cytochrome c oxidase 
subunit VIIb2 
170712 
ECs0848 NleH1-1 DCUN1D1 1 0 2 DCN1, defective in cullin 
neddylation 1, domain 
containing 1 (S. 
cerevisiae) 
54165 
ECs0848 NleH1-1 DDX54 1 0 2 DEAD (Asp-Glu-Ala-Asp) 
box polypeptide 54 
79039 
ECs0848 NleH1-1 HSBP1 1 0 2 heat shock factor binding 
protein 1 
3281 
ECs0848 NleH1-1 IL24 1 0 2 interleukin 24 11009 
ECs0848 NleH1-1 LRTM1 1 0 2 leucIne-rich repeats and 
transmembrane domains 
1 
57408 
ECs0848 NleH1-1 PARL 1 0 2 presenilin assocIated, 
rhomboid-like 
55486 
ECs0848 NleH1-1 RNASE6 1 0 2 ribonuclease, RNase A 
family, k6 
6039 
ECs0848 NleH1-1 SYNJ2BP 1 0 2 synaptojanin 2 binding 
protein 
55333 
ECs0848 NleH1-1 IFI27 1 0 3 interferon, alpha-inducIble 
protein 27 
3429 
ECs0848 NleH1-1 NDUFV3 1 0 6 NADH dehydrogenase 
(ubiquinone) flavoprotein 
3, 10kDa 
4731 
ECs0848 NleH1-1 NEK2 1 0 6 NIMA (never in mitosis 
gene a)-related kinase 2 
4751 
ECs0848 NleH1-1 HBA1 1 0 7 hemoglobin, alpha 1 3039 
ECs0848 NleH1-1 SEP15 1 0 7 15 kDa selenoprotein 9403 
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ECs0848 NleH1-1 HBA2 1 0 13 hemoglobin, alpha 2 3040 
ECs0848 NleH1-1 LOC10017093
9 
1 0 3 glucuronidase, beta 
pseudogene 
100170939 
ECs0848 NleH1-1 LOC653391 1 0 3 glucuronidase, beta 
pseudogene 
653391 
ECs0848 NleH1-1 RBMS2 1 0 3 RNA binding motif, single 
stranded interacting 
protein 2 
5939 
ECs0848 NleH1-1 RPL14 1 0 3 ribosomal protein L14 9045 
ECs0848 NleH1-1 PSMB2 1 0 4 proteasome (prosome, 
macropain) subunit, beta 
type, 2 
5690 
ECs0848 NleH1-1 RPL37A 1 0 5 ribosomal protein L37a 6168 
ECs0848 NleH1-1 DUSP13 1 1 1 dual specIficIty 
phosphatase 13 
51207 
ECs0848 NleH1-1 FOXN3 1 1 2 forkhead box N3 1112 
ECs0848 NleH1-1 PRKCH 1 1 2 protein kinase C, eta 5583 
ECs0848 NleH1-1 STK10 1 1 5 serine/threonine kinase 
10 
6793 
ECs0850 NleD METTL2A 6 0 1 methyltransferase like 2A 339175 
ECs0850 NleD OTX2 3 0 55 orthodenticle homeobox 2 5015 
ECs0850 NleD MEOX2 3 0 87 mesenchyme homeobox 
2 
4223 
ECs0850 NleD CRX 3 0 138 cone-rod homeobox 1406 
ECs0850 NleD ATP5G1 1 0 2 ATP synthase, H+ 
transporting, 
mitochondrial F0 complex, 
subunit C1 (subunit 9) 
516 
ECs0850 NleD XRCC6 1 0 9 X-ray repair 
complementing defective 
repair in Chinese hamster 
cells 6 (Ku autoantigen, 
70kDa) 
2547 
ECs1567 EspO1-1 FEM1B 2 0 4 fem-1 homolog b (C. 
elegans) 
10116 
ECs1567 EspO1-1 Hs.722170 1 0 1     
ECs1567 EspO1-1 SSFA2 1 0 5 sperm specIfic antigen 2 6744 
ECs1567 EspO1-1 CCDC117 1 1 1 coiled-coil domain 
containing 117 
150275 
ECs1567 EspO1-1 IPO7 1 1 1 importin 7 10527 
ECs1567 EspO1-1 ZFPM2 1 1 1 zinc finger protein, 
multitype 2 
23414 
ECs1567 EspO1-1 DNAJB9 1 1 2 DnaJ (Hsp40) homolog, 
subfamily B, member 9 
4189 
ECs1567 EspO1-1 SFRS6 1 1 2 splicIng factor, 
arginine/serine-rich 6 
6431 
ECs1567 EspO1-1 CALU 1 1 3 calumenin 813 
ECs1567 EspO1-1 COL5A2 1 1 3 collagen, type V, alpha 2 1290 
ECs1568 EspK GAS1 1 1 5 growth arrest-specIfic 1 2619 
ECs1812 NleA CDCA4 10 0 9 cell division cycle 
assocIated 4 
55038 
ECs1812 NleA DSCR4 2 0 2 Down syndrome critical 
region gene 4 
10281 
ECs1812 NleA FRMD3 1 0 1 FERM domain containing 
3 
257019 
ECs1812 NleA PENK 1 0 2 proenkephalin 5179 
ECs1812 NleA PTP4A1 1 0 2 protein tyrosine 
phosphatase type IVA, 
member 1 
7803 
ECs1812 NleA SDHD 1 0 6 succInate dehydrogenase 
complex, subunit D 
6392 
ECs1814 NleH1-2 UFC1 2 0 2 ubiquitin-fold modifier 51506 
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conjugating enzyme 1 
ECs1814 NleH1-2 DNAJC12 1 0 1 DnaJ (Hsp40) homolog, 
subfamily C, member 12 
56521 
ECs1814 NleH1-2 EIF1AY 1 0 1 eukaryotic translation 
initiation factor 1A, Y-
linked 
9086 
ECs1814 NleH1-2 MITD1 1 0 1 MIT, microtubule 
interacting and transport, 
domain containing 1 
129531 
ECs1814 NleH1-2 RNF181 1 0 1 ring finger protein 181 51255 
ECs1814 NleH1-2 HS3ST5 1 0 1 Heparan sulfate 
glucosamine 3-O-
sulfotransferase  
222537 
ECs1814 NleH1-2 MTHFD2L 1 0 1 methylenetetrahydrofolate 
dehydrogenase (NADP+ 
dependent) 2-like 
441024 
ECs1814 NleH1-2 Hs.677634 1 0 1     
ECs1814 NleH1-2 AGXT2 1 0 1 alanine-glyoxylate 
aminotransferase 2 
64902 
ECs1814 NleH1-2 CDK13 1 0 1 CDK13 cyclin-dependent 
kinase 13 [ 
8621 
ECs1814 NleH1-2 PLEKHA9 1 0 1 pleckstrin homology 
domain containing, family 
A (phosphoinositide 
binding specIfic) member 
9 
51054 
ECs1814 NleH1-2 PWP1 1 0 1 PWP1 homolog (S. 
cerevisiae) 
11137 
ECs1814 NleH1-2 RBM5 1 0 1 RNA binding motif protein 
5 
10181 
ECs1814 NleH1-2 ZNF287 1 0 1 zinc finger protein 287 57336 
ECs1814 NleH1-2 COPS2 1 0 2 COP9 constitutive 
photomorphogenic 
homolog subunit 2 
(Arabidopsis) 
9318 
ECs1814 NleH1-2 HEPH 1 0 2 hephaestin 9843 
ECs1814 NleH1-2 PSMA4 1 0 3 proteasome (prosome, 
macropain) subunit, alpha 
type, 4 
5685 
ECs1814 NleH1-2 ATP2C1 1 1 1 ATPase, Ca++ 
transporting, type 2C, 
member 1 
27032 
ECs1814 NleH1-2 BBS10 1 1 1 Bardet-Biedl syndrome 10 79738 
ECs1814 NleH1-2 CCDC50 1 1 1 coiled-coil domain 
containing 50 
152137 
ECs1814 NleH1-2 CDK17 1 1 1 CDK17 cyclin-dependent 
kinase 17 
5128 
ECs1814 NleH1-2 L3MBTL4 1 1 1 l(3)mbt-like 4 (Drosophila) 91133 
ECs1814 NleH1-2 MAML3 1 1 1 mastermind-like 3 55534 
ECs1814 NleH1-2 VPS13D 1 1 1 vacuolar protein sorting 
13 homolog D 
55187 
ECs1814 NleH1-2 BAG5 1 1 2 BCL2-assocIated 
athanogene 5 
9529 
ECs1814 NleH1-2 C6orf62 1 1 2 chromosome 6 open 
reading frame 62 
81688 
ECs1814 NleH1-2 PPP1CC 1 1 2 protein phosphatase 1, 
catalytic subunit, gamma 
isoform 
5501 
ECs1814 NleH1-2 RAB31 1 1 2 RAB31, member RAS 
oncogene family 
11031 
ECs1814 NleH1-2 UBE2E2 1 1 2 ubiquitin-conjugating 
enzyme E2E 2 (UBC4/5 
homolog, yeast) 
7325 
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ECs1814 NleH1-2 HSP90AA1 1 1 3 heat shock protein 90kDa 
alpha (cytosolic), class A 
member 1 
3320 
ECs1814 NleH1-2 PCSK6 1 1 3 proprotein convertase 
subtilisin/kexin type 6 
5046 
ECs1814 NleH1-2 VAMP2 1 1 3 vesicle-assocIated 
membrane protein 2 
(synaptobrevin 2) 
6844 
ECs1814 NleH1-2 ZBTB44 1 1 3 zinc finger and BTB 
domain containing 44 
29068 
ECs1814 NleH1-2 GMFB 1 1 5 glia maturation factor, 
beta 
2764 
ECs1814 NleH1-2 SFRS3 1 1 6 splicIng factor, 
arginine/serine-rich 3 
6428 
ECs1814 NleH1-2 CTDSP2 1 1 15 CTD (carboxy-terminal 
domain, RNA polymerase 
II, polypeptide A) small 
phosphatase 2 
10106 
ECs1815 NleF CASP9 49 0 1 caspase 9, apoptosis-
related cysteine peptidase 
842 
ECs1815 NleF DHFR 21 0 1 dihydrofolate reductase 1719 
ECs1815 NleF BEND7 4 0 32 BEN domain containing 7 222389 
ECs1815 NleF FAM13A 1 0 1 family with sequence 
similarity 13, member A 
10144 
ECs1815 NleF FAM181B 1 0 1 family with sequence 
similarity 181, member B 
220382 
ECs1815 NleF WFDC2 1 0 1 WAP four-disulfide core 
domain 2 
10406 
ECs1815 NleF ERI3 1 0 2 ERI3 exoribonuclease 3 [ 
Homo sapiens ] 
79033 
ECs1815 NleF GUSBL1 1 0 2 glucuronidase, beta-like 1 387036 
ECs1815 NleF HMGN2 1 0 2 high-mobility group 
nucleosomal binding 
domain 2 
3151 
ECs1815 NleF LMO4 1 0 2 LIM domain only 4 8543 
ECs1815 NleF LOC10017093
9 
1 0 3 glucuronidase, beta 
pseudogene 
100170939 
ECs1815 NleF LOC653391 1 0 3 glucuronidase, beta 
pseudogene 
653391 
ECs1815 NleF TRNT1 1 0 3 tRNA nucleotidyl 
transferase, CCA-adding, 
1 
51095 
ECs1815 NleF TIMM8A 1 0 6 translocase of inner 
mitochondrial membrane 
8 homolog A (yeast) 
1678 
ECs1815 NleF CDCA4 1 0 9 cell division cycle 
assocIated 4 
55038 
ECs1815 NleF TIGD1 1 0 15 tigger transposable 
element derived 1 
200765 
ECs1824 NleG ZNF343 15 0 8 zinc finger protein 343 79175 
ECs1824 NleG OTX2 7 0 55 orthodenticle homeobox 2 5015 
ECs1824 NleG CRX 5 0 138 cone-rod homeobox 1406 
ECs1824 NleG ALX1 4 0 15 ALX homeobox 1 8092 
ECs1824 NleG MEOX2 2 0 87 mesenchyme homeobox 
2 
4223 
ECs1824 NleG PILRB 1 0 1 paired immunoglobin-like 
type 2 receptor beta 
29990 
ECs1824 NleG METTL8 1 0 1 methyltransferase like 8 79828 
ECs1824 NleG CNN3 1 0 1 calponin 3, acIdic 1266 
ECs1824 NleG CXCL10 1 0 1 chemokine (C-X-C motif) 
ligand 10 
3627 
ECs1824 NleG CYFIP2 1 0 1 cytoplasmic FMR1 
interacting protein 2 
26999 
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ECs1824 NleG DKC1 1 0 1 dyskeratosis congenita 1, 
dyskerin 
1736 
ECs1824 NleG ENOSF1 1 0 1 enolase superfamily 
member 1 
55556 
ECs1824 NleG GGCT 1 0 1 gamma-glutamyl 
cyclotransferase 
79017 
ECs1824 NleG MMP28 1 0 1 matrix metallopeptidase 
28 
79148 
ECs1824 NleG MPPED2 1 0 1 metallophosphoesterase 
domain containing 2 
744 
ECs1824 NleG RASGEF1C 1 0 1 RasGEF domain family, 
member 1C 
255426 
ECs1824 NleG RMI1 1 0 1 RMI1, RecQ mediated 
genome instability 1, 
homolog (S. cerevisiae) 
80010 
ECs1824 NleG RUVBL2 1 0 1 RuvB-like 2 (E. coli) 10856 
ECs1824 NleG SNX31 1 0 1 sorting nexin 31 169166 
ECs1824 NleG TFB1M 1 0 1 transcription factor B1, 
mitochondrial 
51106 
ECs1824 NleG WIPI1 1 0 1 WD repeat domain, 
phosphoinositide 
interacting 1 
55062 
ECs1824 NleG ZNF37A 1 0 1 zinc finger protein 37A 7587 
ECs1824 NleG TOMM7 1 0 2 translocase of outer 
mitochondrial membrane 
7 homolog (yeast) 
54543 
ECs1824 NleG LOC284912 1 0 2 hypothetical gene 
supported by BC001801 
284912 
ECs1824 NleG DDX54 1 0 2 DEAD (Asp-Glu-Ala-Asp) 
box polypeptide 54 
79039 
ECs1824 NleG SLC4A2 1 0 2 solute carrier family 4, 
anion exchanger, member 
2 (erythrocyte membrane 
protein band 3-like 1) 
6522 
ECs1824 NleG SNRNP25 1 0 2 SNRNP25 small nuclear 
ribonucleoprotein 25kDa 
(U11/U12) 
79622 
ECs1824 NleG TBXAS1 1 0 2 thromboxane A synthase 
1 (platelet, cytochrome 
P450, family 5, subfamily 
A) 
6916 
ECs1824 NleG DEXI 1 0 3 dexamethasone-induced 
transcript 
28955 
ECs1824 NleG HLA-DPB1 1 0 3 major histocompatibility 
complex, class II, DP beta 
1 
3115 
ECs1824 NleG SPINK2 1 0 3 serine peptidase inhibitor, 
Kazal type 2 (acrosin-
trypsin inhibitor) 
6691 
ECs1824 NleG TALDO1 1 0 3 transaldolase 1 6888 
ECs1824 NleG FBXO8 1 0 4 F-box protein 8 26269 
ECs1824 NleG OLA1 1 0 4 Obg-like ATPase 1 29789 
ECs1824 NleG PSMC1 1 0 4 proteasome (prosome, 
macropain) 26S subunit, 
ATPase, 1 
5700 
ECs1824 NleG PARP14 1 1 2 poly (ADP-ribose) 
polymerase family, 
member 14 
54625 
ECs1824 NleG CBX4 1 0 6 chromobox homolog 4 (Pc 
class homolog, 
Drosophila) 
8535 
ECs1824 NleG SDHD 1 0 6 succInate dehydrogenase 
complex, subunit D 
6392 
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ECs1824 NleG TIMM8A 1 0 6 translocase of inner 
mitochondrial membrane 
8 homolog A (yeast) 
1678 
ECs1994 NleG2-2 Hs.575672 1 0 1     
ECs1994 NleG2-2 Hs.722049 1 0 1     
ECs1994 NleG2-2 ALDH7A1 1 0 1 aldehyde dehydrogenase 
7 family, member A1 
501 
ECs1994 NleG2-2 FLJ43950 1 0 1 FLJ43950 protein 347127 
ECs1994 NleG2-2 KIF2B 1 0 1 kinesin family member 2B 84643 
ECs1994 NleG2-2 OR7E156P 1 0 1 olfactory receptor, family 
7, subfamily E, member 
156 pseudogene 
283491 
ECs1994 NleG2-2 RBM6 1 0 1 RNA binding motif protein 
6 
10180 
ECs1994 NleG2-2 SERPINI1 1 0 1 serpin peptidase inhibitor, 
clade I (neuroserpin), 
member 1 
5274 
ECs1994 NleG2-2 THAP10 1 0 1 THAP domain containing 
10 
56906 
ECs1994 NleG2-2 GHITM 1 0 2 growth hormone inducIble 
transmembrane protein 
27069 
ECs1994 NleG2-2 ANK3 1 0 4 ankyrin 3, node of Ranvier 
(ankyrin G) 
288 
ECs1994 NleG2-2 ARAP3 1 1 1 ARAP3 ArfGAP with 
RhoGAP domain, ankyrin 
repeat and PH domain 3 
64411 
ECs1994 NleG2-2 RRAS2 1 1 1 related RAS viral (r-ras) 
oncogene homolog 2 
22800 
ECs1994 NleG2-2 RYK 1 1 2 RYK receptor-like tyrosine 
kinase 
6259 
ECs1994 NleG2-2 STX7 1 1 2 syntaxin 7 8417 
ECs1994 NleG2-2 GAS1 1 1 5 growth arrest-specIfic 1 2619 
ECs1994 NleG2-2 MTMR9 1 1 7 myotubularin related 
protein 9 
66036 
ECs2714 EspJ IFT20 20 0 2 intraflagellar transport 20 
homolog 
(Chlamydomonas) 
90410 
ECs2714 EspJ RIC8A 15 0 5 resistance to inhibitors of 
cholinesterase 8 homolog 
A (C. elegans) 
60626 
ECs2714 EspJ CENPH 13 0 1 centromere protein H 64946 
ECs2714 EspJ CETN1 1 0 1 centrin, EF-hand protein, 
1 
1068 
ECs2714 EspJ MRFAP1L1 1 0 2 Morf4 family assocIated 
protein 1-like 1 
114932 
ECs2715 TccP ZNF626 2 0 2 zinc finger protein 626 199777 
ECs2715 TccP Hs.595320 1 0 1     
ECs2715 TccP Hs.686358 1 0 1     
ECs2715 TccP CCDC45 1 0 1 coiled-coil domain 
containing 45 
90799 
ECs2715 TccP CES1 1 0 1 carboxylesterase 1 
(monocyte/macrophage 
serine esterase 1) 
1066 
ECs2715 TccP MIOS 1 0 1 MIOS missing oocyte, 
meiosis regulator, 
homolog (Drosophila) 
54468 
ECs2715 TccP MYO5B 1 0 1 myosin VB 4645 
ECs2715 TccP SNHG10 1 0 1 small nucleolar RNA host 
gene 10 (non-protein 
coding) 
283596 
ECs2715 TccP DBNDD2 1 0 2 dysbindin (dystrobrevin 
binding protein 1) domain 
containing 2 
55861 
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ECs2715 TccP ATP5B 1 0 2 ATP synthase, H+ 
transporting, 
mitochondrial F1 complex, 
beta polypeptide 
506 
ECs2715 TccP KIAA2026 1 0 2 KIAA2026 158358 
ECs2715 TccP OGT 1 0 2 O-linked N-
acetylglucosamine 
(GlcNAc) transferase 
(UDP-N-
acetylglucosamine:polype
ptide-N-
acetylglucosaminyl 
transferase) 
8473 
ECs2715 TccP SH3GLB1 1 0 2 SH3-domain GRB2-like 
endophilin B1 
51100 
ECs2715 TccP SH3BGRL 1 0 3 SH3 domain binding 
glutamic acId-rich protein 
like 
6451 
ECs2715 TccP CCDC80 1 0 3 coiled-coil domain 
containing 80 
151887 
ECs2715 TccP RNF6 1 0 3 ring finger protein 
(C3H2C3 type) 6 
6049 
ECs2715 TccP TTC29 1 0 3 tetratricopeptide repeat 
domain 29 
83894 
ECs2715 TccP IMMT 1 0 5 inner membrane protein, 
mitochondrial (mitofilin) 
10989 
ECs2715 TccP RAB11A 1 0 5 RAB11A, member RAS 
oncogene family 
8766 
ECs2715 TccP ANKIB1 1 1 1 ankyrin repeat and IBR 
domain containing 1 
54467 
ECs2715 TccP FGF13 1 1 1 fibroblast growth factor 13 2258 
ECs2715 TccP IFT80 1 1 1 intraflagellar transport 80 
homolog 
(Chlamydomonas) 
57560 
ECs2715 TccP KTELC1 1 1 1 KTEL (Lys-Tyr-Glu-Leu) 
containing 1 
56983 
ECs2715 TccP SLC35E2 1 1 1 solute carrier family 35, 
member E2 
9906 
ECs2715 TccP UBQLN2 1 1 1 ubiquilin 2 29978 
ECs2715 TccP SGCB 1 1 2 sarcoglycan, beta (43kDa 
dystrophin-assocIated 
glycoprotein) 
6443 
ECs2715 TccP LAMP2 1 1 4 lysosomal-assocIated 
membrane protein 2 
3920 
ECs2715 TccP MPV17 1 0 6 MpV17 mitochondrial 
inner membrane protein 
4358 
ECs2715 TccP PALLD 1 1 12 palladin, cytoskeletal 
assocIated protein 
23022 
ECs3857 NleB1 ZNF343 98 0 8 zinc finger protein 343 79175 
ECs3857 NleB1 XRCC6 7 0 9 X-ray repair 
complementing defective 
repair in Chinese hamster 
cells 6 (Ku autoantigen, 
70kDa) 
2547 
ECs3857 NleB1 LRRC18 7 0 2 leucIne rich repeat 
containing 18 
474354 
ECs3857 NleB1 DRG2 5 0 4 developmentally regulated 
GTP binding protein 2 
1819 
ECs3857 NleB1 POLR2E 3 0 1 polymerase (RNA) II 
(DNA directed) 
polypeptide E, 25kDa 
5434 
ECs3857 NleB1 CDRT4 1 0 1 CMT1A duplicated region 
transcript 4 
284040 
ECs3857 NleB1 GUSBP3 1 0 1 GUSBP3 glucuronidase, 
beta pseudogene 3 
653188 
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ECs3857 NleB1 LOC10028704
6 
1 0 1 glucuronidase, beta 
pseudogene 
100287046 
ECs3857 NleB1 LOC10028707
8 
1 0 1     
ECs3857 NleB1 PCGF1 1 0 1 polycomb group ring 
finger 1 
84759 
ECs3857 NleB1 SLC6A13 1 0 1 solute carrier family 6 
(neurotransmitter 
transporter, GABA), 
member 13 
6540 
ECs3857 NleB1 YPEL3 1 0 2 yippee-like 3 (Drosophila) 83719 
ECs3857 NleB1 MGC4294 1 0 2 hypothetical protein 
MGC4294 
79160 
ECs3857 NleB1 GOSR2 1 0 3 golgi SNAP receptor 
complex member 2 
9570 
ECs3857 NleB1 LOC10017093
9 
1 0 3 glucuronidase, beta 
pseudogene 
100170939 
ECs3857 NleB1 LOC653391 1 0 3 glucuronidase, beta 
pseudogene 
653391 
ECs3857 NleB1 TTC29 1 0 3 tetratricopeptide repeat 
domain 29 
83894 
ECs3857 NleB1 PCID2 1 0 4 PCI domain-containing 
protein 2 (CSN12-like 
protein). 
55795 
ECs3857 NleB1 TTC19 1 0 4 tetratricopeptide repeat 
domain 19 
54902 
ECs3857 NleB1 TIGD1 1 0 15 tigger transposable 
element derived 1 
200765 
ECs3857 NleB1 BEND7 1 0 32 BEN domain containing 7 222389 
ECs3858 NleE ZNF343 11 0 8 zinc finger protein 343 79175 
ECs3858 NleE ADIG 1 0 1 adipogenin 149685 
ECs3858 NleE LRRC18 1 0 2 leucIne rich repeat 
containing 18 
474354 
ECs4550 EspF1 SNX33 16 0 1 sorting nexin 33 257364 
ECs4550 EspF1 SNX9 2 0 1 sorting nexin 9 51429 
ECs4550 EspF1 MAD2L2 1 0 2 MAD2 mitotic arrest 
deficIent-like 2 (yeast) 
10459 
ECs4554 EspB RBCK1 78 0 5 RanBP-type and C3HC4-
type zinc finger containing 
1 
10616 
ECs4554 EspB STK16 48 0 3 serine/threonine kinase 
16 
8576 
ECs4554 EspB VEGFB 9 0 8 vascular endothelial 
growth factor B 
7423 
ECs4554 EspB SNX3 3 0 12 sorting nexin 3 8724 
ECs4554 EspB SNAPC5 1 0 1 small nuclear RNA 
activating complex, 
polypeptide 5, 19kDa 
10302 
ECs4554 EspB PCID2 1 0 4 PCI domain-containing 
protein 2 (CSN12-like 
protein). 
55795 
ECs4554 EspB URM1 1 0 7 ubiquitin related modifier 
1 homolog (S. cerevisiae) 
81605 
ECs4561 TIR HPCAL1 56 0 4 hippocalcIn-like 1 3241 
ECs4561 TIR MCRS1 33 0 6 microspherule protein 1 10445 
ECs4561 TIR STK16 11 0 3 serine/threonine kinase 
16 
8576 
ECs4561 TIR NCALD 7 0 1 neurocalcIn delta 83988 
ECs4561 TIR TIGD1 6 0 16 tigger transposable 
element derived 1 
200765 
ECs4561 TIR BAIAP2L1 5 0 1 BAI1-assocIated protein 
2-like 1 
55971 
ECs4561 TIR TTC1 3 0 6 tetratricopeptide repeat 
domain 1 
7265 
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ECs4561 TIR ARRB1 2 0 2 arrestin, beta 1 408 
ECs4561 TIR BAIAP2 2 0 3 BAI1-assocIated protein 2 10458 
ECs4561 TIR HPCAL4 1 0 1 hippocalcIn like 4 51440 
ECs4561 TIR RPAP3 1 1 1 RNA polymerase II 
assocIated protein 3 
79657 
ECs4561 TIR PDE6D 1 0 3 phosphodiesterase 6D, 
cGMP-specIfic, rod, delta 
5147 
ECs4562 Map PNMA1 22 0 7 paraneoplastic antigen 
MA1 
9240 
ECs4562 Map RING1 15 0 11 ring finger protein 1 6015 
ECs4562 Map SLC9A3R2 13 0 2 solute carrier family 9 
(sodium/hydrogen 
exchanger), member 3 
regulator 2 
9351 
ECs4562 Map RHPN1 3 0 2 rhophilin, Rho GTPase 
binding protein 1 
114822 
ECs4562 Map BEND7 1 0 32 BEN domain containing 7 222389 
ECs4562 Map CLK1 1 0 3 CDC-like kinase 1 1195 
ECs4562 Map DSCR4 1 0 2 Down syndrome critical 
region gene 4 
10281 
ECs4562 Map GALNT10 1 0 1 UDP-N-acetyl-alpha-D-
galactosamine:polypeptid
e N-
acetylgalactosaminyltrans
ferase 10 (GalNAc-T10) 
55568 
ECs4562 Map SDHD 1 0 6 succInate dehydrogenase 
complex, subunit D, 
integral membrane protein 
6392 
ECs4562 Map TIGD1 1 0 15 tigger transposable 
element derived 1 
200765 
ECs4564 EspH ABCG2 1 0 2 ATP-binding cassette, 
sub-family G (WHITE), 
member 2 
9429 
ECs4564 EspH COPS5 1 0 110 COP9 constitutive 
photomorphogenic 
homolog subunit 5 
(Arabidopsis) [Homo 
sapiens] 
10987 
ECs4590 EspG Hs.658052 3 0 1   100589704 
ECs4590 EspG NMI 1 0 1 N-myc (and STAT) 
interactor 
9111 
ECs4590 EspG NCOA3 1 0 2 nuclear receptor 
coactivator 3 
8202 
ECs4590 EspG C5orf15 1 1 1 chromosome 5 open 
reading frame 15 
56951 
ECs4590 EspG COL5A2 1 1 3 collagen, type V, alpha 2 1290 
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Supplementary table 2. Published intraspecies interactions of the human interaction 
partners of EHEC effectors. The column ‘Direct’ contains the human interactors of EHEC 
effector proteins, whereas the column ‘Indirect’ contains published intraspecies interactions 
of these proteins. 
No. Direct Description Indirect Description
1 ARRB1 arrestin, beta 1 ADRB1 adrenergic, beta-1-, receptor 
2 ARRB1 arrestin, beta 1 AP3B1 adaptor-related protein complex 3, beta 
1 subunit 
3 ARRB1 arrestin, beta 1 ARF6 ADP-ribosylation factor 6 
4 ARRB1 arrestin, beta 1 ARR3 arrestin 3, retinal (X-arrestin) 
5 ARRB1 arrestin, beta 1 ARRB2 arrestin, beta 2 
6 ARRB1 arrestin, beta 1 BOP1 block of proliferation 1 
7 ARRB1 arrestin, beta 1 CCL14 chemokine (C-C motif) ligand 14 
8 ARRB1 arrestin, beta 1 CCR5 chemokine (C-C motif) receptor 5 
9 ARRB1 arrestin, beta 1 CDC42 cell division cycle 42 (GTP binding 
protein, 25kDa) 
10 ARRB1 arrestin, beta 1 CHD1 chromodomain helicase DNA binding 
protein 1 
11 ARRB1 arrestin, beta 1 CMBL carboxymethylenebutenolidase homolog 
(Pseudomonas) 
12 ARRB1 arrestin, beta 1 CSK c-src tyrosine kinase 
13 ARRB1 arrestin, beta 1 CSNK2A1 casein kinase 2, alpha 1 polypeptide 
14 ARRB1 arrestin, beta 1 CXCR2 chemokine (C-X-C motif) receptor 2 
15 ARRB1 arrestin, beta 1 CYTH2 cytohesin 2 
16 ARRB1 arrestin, beta 1 DDX27 DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 27 
17 ARRB1 arrestin, beta 1 DVL1 dishevelled, dsh homolog 1 (Drosophila) 
18 ARRB1 arrestin, beta 1 DVL2 dishevelled, dsh homolog 2 (Drosophila) 
19 ARRB1 arrestin, beta 1 GNMT glycine N-methyltransferase 
20 ARRB1 arrestin, beta 1 HDGFRP2 hepatoma-derived growth factor-related 
protein 2 
21 ARRB1 arrestin, beta 1 ITCH itchy E3 ubiquitin protein ligase homolog 
(mouse) 
22 ARRB1 arrestin, beta 1 JAK1 Janus kinase 1 (a protein tyrosine 
kinase) 
23 ARRB1 arrestin, beta 1 JUN jun oncogene 
24 ARRB1 arrestin, beta 1 KHK ketohexokinase (fructokinase) 
25 ARRB1 arrestin, beta 1 KPNA3 karyopherin alpha 3 (importin alpha 4) 
26 ARRB1 arrestin, beta 1 MAPK10 mitogen-activated protein kinase 10 
27 ARRB1 arrestin, beta 1 MDM2 Mdm2 p53 binding protein homolog 
(mouse) 
28 ARRB1 arrestin, beta 1 NEDD4 neural precursor cell expressed, 
developmentally down-regulated 4 
29 ARRB1 arrestin, beta 1 NOLC1 nucleolar and coiled-body 
phosphoprotein 1 
30 ARRB1 arrestin, beta 1 NSF N-ethylmaleimide-sensitive factor 
31 ARRB1 arrestin, beta 1 OPRD1 opioid receptor, delta 1 
32 ARRB1 arrestin, beta 1 PES1 pescadillo homolog 1, containing BRCT 
domain (zebrafish) 
33 ARRB1 arrestin, beta 1 PTHLH parathyroid hormone-like hormone 
34 ARRB1 arrestin, beta 1 RALGDS ral guanine nucleotide dissociation 
stimulator 
35 ARRB1 arrestin, beta 1 RPL7L1 ribosomal protein L7-like 1 
36 ARRB1 arrestin, beta 1 RTF1 Rtf1, Paf1/RNA polymerase II complex 
component, homolog (S. cerevisiae) 
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37 ARRB1 arrestin, beta 1 SREBF2 sterol regulatory element binding 
transcription factor 2 
38 ARRB1 arrestin, beta 1 TCOF1 Treacher Collins-Franceschetti 
syndrome 1 
39 ARRB1 arrestin, beta 1 ZBTB43 zinc finger and BTB domain containing 
43 
40 ARRB1 arrestin, beta 1 ZRANB2 zinc finger, RAN-binding domain 
containing 2 
41 BAIAP2 BAI1-associated protein 2 ATN1 atrophin 1 
42 BAIAP2 BAI1-associated protein 2 C14orf1 chromosome 14 open reading frame 1 
43 BAIAP2 BAI1-associated protein 2 CDC42 cell division cycle 42 (GTP binding 
protein, 25kDa) 
44 BAIAP2 BAI1-associated protein 2 ENAH enabled homolog (Drosophila) 
45 BAIAP2 BAI1-associated protein 2 EPS8 epidermal growth factor receptor 
pathway substrate 8 
46 BAIAP2 BAI1-associated protein 2 NCKIPSD NCK interacting protein with SH3 
domain 
47 BAIAP2 BAI1-associated protein 2 PAK1 p21 protein (Cdc42/Rac)-activated 
kinase 1 
48 BAIAP2 BAI1-associated protein 2 RAC1 ras-related C3 botulinum toxin substrate 
1 (rho family, small GTP binding protein 
Rac1) 
49 BAIAP2 BAI1-associated protein 2 SHANK1 SH3 and multiple ankyrin repeat 
domains 1 
50 BAIAP2 BAI1-associated protein 2 WASF1 WAS protein family, member 1 
51 BAIAP2 BAI1-associated protein 2 WASF2 WAS protein family, member 2 
52 BAIAP2 BAI1-associated protein 2 YWHAG tyrosine 3-monooxygenase/tryptophan 
5-monooxygenase activation protein, 
gamma polypeptide 
53 BAIAP2L1 BAI1-associated protein 2-like 1 PRKAA2 protein kinase, AMP-activated, alpha 2 
catalytic subunit 
54 BAIAP2L1 BAI1-associated protein 2-like 1 PRKAB2 protein kinase, AMP-activated, beta 2 
non-catalytic subunit 
55 BAIAP2L1 BAI1-associated protein 2-like 1 TERF1 telomeric repeat binding factor (NIMA-
interacting) 1 
56 BAIAP2L1 BAI1-associated protein 2-like 1 TERF2 telomeric repeat binding factor 2 
57 CAPN3 calpain 3, (p94) FLNC filamin C, gamma (actin binding protein 
280) 
58 CAPN3 calpain 3, (p94) NECAB2 N-terminal EF-hand calcium binding 
protein 2 
59 CAPN3 calpain 3, (p94) TTN titin 
60 CASP9 caspase 9, apoptosis-related 
cysteine peptidase 
APAF1 apoptotic peptidase activating factor 1 
61 CASP9 caspase 9, apoptosis-related 
cysteine peptidase 
BCL2L1 BCL2-like 1 
62 CASP9 caspase 9, apoptosis-related 
cysteine peptidase 
BIRC2 baculoviral IAP repeat-containing 2 
63 CASP9 caspase 9, apoptosis-related 
cysteine peptidase 
BIRC3 baculoviral IAP repeat-containing 3 
64 CASP9 caspase 9, apoptosis-related 
cysteine peptidase 
BIRC5 baculoviral IAP repeat-containing 5 
65 CASP9 caspase 9, apoptosis-related 
cysteine peptidase 
BIRC6 baculoviral IAP repeat-containing 6 
66 CASP9 caspase 9, apoptosis-related 
cysteine peptidase 
BIRC7 baculoviral IAP repeat-containing 7 
67 CASP9 caspase 9, apoptosis-related 
cysteine peptidase 
BIRC8 baculoviral IAP repeat-containing 8 
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68 CASP9 caspase 9, apoptosis-related 
cysteine peptidase 
CASP10 caspase 10, apoptosis-related cysteine 
peptidase 
69 CASP9 caspase 9, apoptosis-related 
cysteine peptidase 
CASP2 caspase 2, apoptosis-related cysteine 
peptidase 
70 CASP9 caspase 9, apoptosis-related 
cysteine peptidase 
CASP8 caspase 8, apoptosis-related cysteine 
peptidase 
71 CASP9 caspase 9, apoptosis-related 
cysteine peptidase 
DCC deleted in colorectal carcinoma 
72 CASP9 caspase 9, apoptosis-related 
cysteine peptidase 
MAPK1 mitogen-activated protein kinase 1 
73 CASP9 caspase 9, apoptosis-related 
cysteine peptidase 
NAIP NLR family, apoptosis inhibitory protein 
74 CASP9 caspase 9, apoptosis-related 
cysteine peptidase 
NLRP1 NLR family, pyrin domain containing 1 
75 CASP9 caspase 9, apoptosis-related 
cysteine peptidase 
NOD1 nucleotide-binding oligomerization 
domain containing 1 
76 CASP9 caspase 9, apoptosis-related 
cysteine peptidase 
RNF2 ring finger protein 2 
77 CASP9 caspase 9, apoptosis-related 
cysteine peptidase 
UBC ubiquitin C 
78 CASP9 caspase 9, apoptosis-related 
cysteine peptidase 
XIAP X-linked inhibitor of apoptosis 
79 CENPH centromere protein H CENPA centromere protein A 
80 CENPH centromere protein H CENPH centromere protein H 
81 CENPH centromere protein H KIF2C kinesin family member 2C 
82 CENPH centromere protein H PMVK phosphomevalonate kinase 
83 DHFR dihydrofolate reductase FKBP1A FK506 binding protein 1A, 12kDa 
84 DHFR dihydrofolate reductase HSPD1 heat shock 60kDa protein 1 (chaperonin)
85 DHFR dihydrofolate reductase MDM2 Mdm2 p53 binding protein homolog 
(mouse) 
86 DHFR dihydrofolate reductase THBS1 thrombospondin 1 
87 DHFR dihydrofolate reductase TP53 tumor protein p53 
88 DHFR dihydrofolate reductase SUMO2 SMT3 suppressor of mif two 3 homolog 
2 (S. cerevisiae) 
89 DHFR dihydrofolate reductase UBC ubiquitin C 
90 DNAJC14 DnaJ (Hsp40) homolog, subfamily 
C, member 14 
DRD1 dopamine receptor D1 
91 DNAJC14 DnaJ (Hsp40) homolog, subfamily 
C, member 14 
LYST lysosomal trafficking regulator 
92 DRG2 developmentally regulated GTP 
binding protein 2 
RWDD1 RWD domain containing 1 
93 FEM1B fem-1 homolog b (C. elegans) COPS6 COP9 constitutive photomorphogenic 
homolog subunit 6 (Arabidopsis) 
94 HPCAL1 hippocalcin-like 1 DTX2 deltex homolog 2 (Drosophila) 
95 HPCAL1 hippocalcin-like 1 HMG20A high-mobility group 20A 
96 HPCAL1 hippocalcin-like 1 IKBKG inhibitor of kappa light polypeptide gene 
enhancer in B-cells, kinase gamma 
97 IFT20 intraflagellar transport 20 homolog 
(Chlamydomonas) 
ABI2 abl interactor 2 
98 IFT20 intraflagellar transport 20 homolog 
(Chlamydomonas) 
C19orf50 chromosome 19 open reading frame 50 
99 IFT20 intraflagellar transport 20 homolog 
(Chlamydomonas) 
EXOC7 exocyst complex component 7 
100 IFT20 intraflagellar transport 20 homolog 
(Chlamydomonas) 
FBF1 Fas (TNFRSF6) binding factor 1 
101 IFT20 intraflagellar transport 20 homolog 
(Chlamydomonas) 
TREX1 three prime repair exonuclease 1 
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102 LRRC18 leucine rich repeat containing 18 KCTD17 potassium channel tetramerisation 
domain containing 17 
103 NCALD neurocalcin delta ACTB actin, beta 
104 NCALD neurocalcin delta DTX2 deltex homolog 2 (Drosophila) 
105 PCID2 PCI domain containing 2 NEK6 NIMA (never in mitosis gene a)-related 
kinase 6 
106 PCID2 PCI domain containing 2 SHFM1 split hand/foot malformation 
(ectrodactyly) type 1 
107 PIH1D1 PIH1 domain containing 1 C8orf41 chromosome 8 open reading frame 41 
108 PIH1D1 PIH1 domain containing 1 FBL fibrillarin 
109 PIH1D1 PIH1 domain containing 1 GPN1 GPN-loop GTPase 1 
110 PIH1D1 PIH1 domain containing 1 RPAP2 RNA polymerase II associated protein 2 
111 PIH1D1 PIH1 domain containing 1 RPAP3 RNA polymerase II associated protein 3 
112 PIH1D1 PIH1 domain containing 1 RUVBL1 RuvB-like 1 (E. coli) 
113 PIH1D1 PIH1 domain containing 1 RUVBL2 RuvB-like 2 (E. coli) 
114 PIH1D1 PIH1 domain containing 1 TSC22D4 TSC22 domain family, member 4 
115 PIH1D1 PIH1 domain containing 1 TTI1 TELO2 interacting protein 1 
116 POLR2E polymerase (RNA) II (DNA 
directed) polypeptide E, 25kDa 
C19orf2 chromosome 19 open reading frame 2 
117 POLR2E polymerase (RNA) II (DNA 
directed) polypeptide E, 25kDa 
GTF2F2 general transcription factor IIF, 
polypeptide 2, 30kDa 
118 POLR2E polymerase (RNA) II (DNA 
directed) polypeptide E, 25kDa 
IKBKG inhibitor of kappa light polypeptide gene 
enhancer in B-cells, kinase gamma 
119 POLR2E polymerase (RNA) II (DNA 
directed) polypeptide E, 25kDa 
INTS3 integrator complex subunit 3 
120 POLR2E polymerase (RNA) II (DNA 
directed) polypeptide E, 25kDa 
INTS5 integrator complex subunit 5 
121 POLR2E polymerase (RNA) II (DNA 
directed) polypeptide E, 25kDa 
INTS6 integrator complex subunit 6 
122 POLR2E polymerase (RNA) II (DNA 
directed) polypeptide E, 25kDa 
ITCH itchy E3 ubiquitin protein ligase homolog 
(mouse) 
123 POLR2E polymerase (RNA) II (DNA 
directed) polypeptide E, 25kDa 
LZTR1 leucine-zipper-like transcription regulator 
1 
124 POLR2E polymerase (RNA) II (DNA 
directed) polypeptide E, 25kDa 
MED1 mediator complex subunit 1 
125 POLR2E polymerase (RNA) II (DNA 
directed) polypeptide E, 25kDa 
MED10 mediator complex subunit 10 
126 POLR2E polymerase (RNA) II (DNA 
directed) polypeptide E, 25kDa 
MED12 mediator complex subunit 12 
127 POLR2E polymerase (RNA) II (DNA 
directed) polypeptide E, 25kDa 
MED19 mediator complex subunit 19 
128 POLR2E polymerase (RNA) II (DNA 
directed) polypeptide E, 25kDa 
MED26 mediator complex subunit 26 
129 POLR2E polymerase (RNA) II (DNA 
directed) polypeptide E, 25kDa 
MED28 mediator complex subunit 28 
130 POLR2E polymerase (RNA) II (DNA 
directed) polypeptide E, 25kDa 
MED29 mediator complex subunit 29 
131 POLR2E polymerase (RNA) II (DNA 
directed) polypeptide E, 25kDa 
MED9 mediator complex subunit 9 
132 POLR2E polymerase (RNA) II (DNA 
directed) polypeptide E, 25kDa 
NEDD4 neural precursor cell expressed, 
developmentally down-regulated 4 
133 POLR2E polymerase (RNA) II (DNA 
directed) polypeptide E, 25kDa 
PML promyelocytic leukemia 
134 POLR2E polymerase (RNA) II (DNA 
directed) polypeptide E, 25kDa 
POLR1A polymerase (RNA) I polypeptide A, 
194kDa 
135 POLR2E polymerase (RNA) II (DNA 
directed) polypeptide E, 25kDa 
POLR2A polymerase (RNA) II (DNA directed) 
polypeptide A, 220kDa 
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136 POLR2E polymerase (RNA) II (DNA 
directed) polypeptide E, 25kDa 
POLR2B polymerase (RNA) II (DNA directed) 
polypeptide B, 140kDa 
137 POLR2E polymerase (RNA) II (DNA 
directed) polypeptide E, 25kDa 
POLR2C polymerase (RNA) II (DNA directed) 
polypeptide C, 33kDa 
138 POLR2E polymerase (RNA) II (DNA 
directed) polypeptide E, 25kDa 
POLR2E polymerase (RNA) II (DNA directed) 
polypeptide E, 25kDa 
139 POLR2E polymerase (RNA) II (DNA 
directed) polypeptide E, 25kDa 
POLR2F polymerase (RNA) II (DNA directed) 
polypeptide F 
140 POLR2E polymerase (RNA) II (DNA 
directed) polypeptide E, 25kDa 
POLR2G polymerase (RNA) II (DNA directed) 
polypeptide G 
141 POLR2E polymerase (RNA) II (DNA 
directed) polypeptide E, 25kDa 
POLR2H polymerase (RNA) II (DNA directed) 
polypeptide H 
142 POLR2E polymerase (RNA) II (DNA 
directed) polypeptide E, 25kDa 
POLR2J polymerase (RNA) II (DNA directed) 
polypeptide J, 13.3kDa 
143 POLR2E polymerase (RNA) II (DNA 
directed) polypeptide E, 25kDa 
POLR2K polymerase (RNA) II (DNA directed) 
polypeptide K, 7.0kDa 
144 POLR2E polymerase (RNA) II (DNA 
directed) polypeptide E, 25kDa 
POLR2L polymerase (RNA) II (DNA directed) 
polypeptide L, 7.6kDa 
145 POLR2E polymerase (RNA) II (DNA 
directed) polypeptide E, 25kDa 
POLR3D polymerase (RNA) III (DNA directed) 
polypeptide D, 44kDa 
146 POLR2E polymerase (RNA) II (DNA 
directed) polypeptide E, 25kDa 
RPAP3 RNA polymerase II associated protein 3 
147 POLR2E polymerase (RNA) II (DNA 
directed) polypeptide E, 25kDa 
RUVBL2 RuvB-like 2 (E. coli) 
148 POLR2E polymerase (RNA) II (DNA 
directed) polypeptide E, 25kDa 
STAP1 signal transducing adaptor family 
member 1 
149 POLR2E polymerase (RNA) II (DNA 
directed) polypeptide E, 25kDa 
TAF10 TAF10 RNA polymerase II, TATA box 
binding protein (TBP)-associated factor, 
30kDa 
150 POLR2E polymerase (RNA) II (DNA 
directed) polypeptide E, 25kDa 
TAF15 TAF15 RNA polymerase II, TATA box 
binding protein (TBP)-associated factor, 
68kDa 
151 POLR2E polymerase (RNA) II (DNA 
directed) polypeptide E, 25kDa 
TRIM29 tripartite motif-containing 29 
152 POLR2E polymerase (RNA) II (DNA 
directed) polypeptide E, 25kDa 
USP11 ubiquitin specific peptidase 11 
153 POLR2E polymerase (RNA) II (DNA 
directed) polypeptide E, 25kDa 
XRCC5 X-ray repair complementing defective 
repair in Chinese hamster cells 5 
(double-strand-break rejoining) 
154 POLR2E polymerase (RNA) II (DNA 
directed) polypeptide E, 25kDa 
ZSCAN1 zinc finger and SCAN domain containing 
1 
155 PSMC1 proteasome (prosome, macropain) 
26S subunit, ATPase, 1 
ATG4C ATG4 autophagy related 4 homolog C 
(S. cerevisiae) 
156 PSMC1 proteasome (prosome, macropain) 
26S subunit, ATPase, 1 
ATXN7 ataxin 7 
157 PSMC1 proteasome (prosome, macropain) 
26S subunit, ATPase, 1 
CCDC85B coiled-coil domain containing 85B 
158 PSMC1 proteasome (prosome, macropain) 
26S subunit, ATPase, 1 
PAAF1 proteasomal ATPase-associated factor 1
159 PSMC1 proteasome (prosome, macropain) 
26S subunit, ATPase, 1 
PMS1 PMS1 postmeiotic segregation 
increased 1 (S. cerevisiae) 
160 PSMC1 proteasome (prosome, macropain) 
26S subunit, ATPase, 1 
PMS2 PMS2 postmeiotic segregation 
increased 2 (S. cerevisiae) 
161 PSMC1 proteasome (prosome, macropain) 
26S subunit, ATPase, 1 
PSMC2 proteasome (prosome, macropain) 26S 
subunit, ATPase, 2 
162 PSMC1 proteasome (prosome, macropain) 
26S subunit, ATPase, 1 
PSMC4 proteasome (prosome, macropain) 26S 
subunit, ATPase, 4 
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163 PSMC1 proteasome (prosome, macropain) 
26S subunit, ATPase, 1 
PSMC5 proteasome (prosome, macropain) 26S 
subunit, ATPase, 5 
164 PSMC1 proteasome (prosome, macropain) 
26S subunit, ATPase, 1 
PSMD10 proteasome (prosome, macropain) 26S 
subunit, non-ATPase, 10 
165 PSMC1 proteasome (prosome, macropain) 
26S subunit, ATPase, 1 
PSMD13 proteasome (prosome, macropain) 26S 
subunit, non-ATPase, 13 
166 PSMC1 proteasome (prosome, macropain) 
26S subunit, ATPase, 1 
PSMD14 proteasome (prosome, macropain) 26S 
subunit, non-ATPase, 14 
167 PSMC1 proteasome (prosome, macropain) 
26S subunit, ATPase, 1 
PSMD2 proteasome (prosome, macropain) 26S 
subunit, non-ATPase, 2 
168 PSMC1 proteasome (prosome, macropain) 
26S subunit, ATPase, 1 
PSMD5 proteasome (prosome, macropain) 26S 
subunit, non-ATPase, 5 
169 PSMC1 proteasome (prosome, macropain) 
26S subunit, ATPase, 1 
PSMD6 proteasome (prosome, macropain) 26S 
subunit, non-ATPase, 6 
170 PSMC1 proteasome (prosome, macropain) 
26S subunit, ATPase, 1 
PSMD7 proteasome (prosome, macropain) 26S 
subunit, non-ATPase, 7 
171 PSMC1 proteasome (prosome, macropain) 
26S subunit, ATPase, 1 
SRRM2 serine/arginine repetitive matrix 2 
172 PSMC1 proteasome (prosome, macropain) 
26S subunit, ATPase, 1 
TRAF6 TNF receptor-associated factor 6 
173 PSMC1 proteasome (prosome, macropain) 
26S subunit, ATPase, 1 
UBC ubiquitin C 
174 PSMC1 proteasome (prosome, macropain) 
26S subunit, ATPase, 1 
UCHL5 ubiquitin carboxyl-terminal hydrolase L5 
175 PSMC1 proteasome (prosome, macropain) 
26S subunit, ATPase, 1 
USP14 ubiquitin specific peptidase 14 (tRNA-
guanine transglycosylase) 
176 PSMC1 proteasome (prosome, macropain) 
26S subunit, ATPase, 1 
VCP valosin-containing protein 
177 RBCK1 RanBP-type and C3HC4-type zinc 
finger containing 1 
BACH1 BTB and CNC homology 1, basic leucine 
zipper transcription factor 1 
178 RBCK1 RanBP-type and C3HC4-type zinc 
finger containing 1 
IKBKG inhibitor of kappa light polypeptide gene 
enhancer in B-cells, kinase gamma 
179 RBCK1 RanBP-type and C3HC4-type zinc 
finger containing 1 
IREB2 iron-responsive element binding protein 
2 
180 RBCK1 RanBP-type and C3HC4-type zinc 
finger containing 1 
PRKCB protein kinase C, beta 
181 RBCK1 RanBP-type and C3HC4-type zinc 
finger containing 1 
RBCK1 RanBP-type and C3HC4-type zinc finger 
containing 1 
182 RBCK1 RanBP-type and C3HC4-type zinc 
finger containing 1 
RNF31 ring finger protein 31 
183 RBCK1 RanBP-type and C3HC4-type zinc 
finger containing 1 
TNF tumor necrosis factor (TNF superfamily, 
member 2) 
184 RBCK1 RanBP-type and C3HC4-type zinc 
finger containing 1 
UBA1 ubiquitin-like modifier activating enzyme 
1 
185 RBCK1 RanBP-type and C3HC4-type zinc 
finger containing 1 
UBC ubiquitin C 
186 RBCK1 RanBP-type and C3HC4-type zinc 
finger containing 1 
UBE2D3 ubiquitin-conjugating enzyme E2D 3 
(UBC4/5 homolog, yeast) 
187 RBCK1 RanBP-type and C3HC4-type zinc 
finger containing 1 
UBE2D4 ubiquitin-conjugating enzyme E2D 4 
(putative) 
188 RBCK1 RanBP-type and C3HC4-type zinc 
finger containing 1 
UBE2G1 ubiquitin-conjugating enzyme E2G 1 
(UBC7 homolog, yeast) 
189 RBCK1 RanBP-type and C3HC4-type zinc 
finger containing 1 
UBE2K ubiquitin-conjugating enzyme E2K 
(UBC1 homolog, yeast) 
190 RBCK1 RanBP-type and C3HC4-type zinc 
finger containing 1 
UBE2L3 ubiquitin-conjugating enzyme E2L 3 
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191 RBCK1 RanBP-type and C3HC4-type zinc 
finger containing 1 
UBE2L6 ubiquitin-conjugating enzyme E2L 6 
192 RBCK1 RanBP-type and C3HC4-type zinc 
finger containing 1 
UBE2N ubiquitin-conjugating enzyme E2N 
(UBC13 homolog, yeast) 
193 RBCK1 RanBP-type and C3HC4-type zinc 
finger containing 1 
UBE2S ubiquitin-conjugating enzyme E2S 
194 RBCK1 RanBP-type and C3HC4-type zinc 
finger containing 1 
UBE2U ubiquitin-conjugating enzyme E2U 
(putative) 
195 RHPN1 rhophilin, Rho GTPase binding 
protein 1 
CALCOCO2 calcium binding and coiled-coil domain 2
196 RHPN1 rhophilin, Rho GTPase binding 
protein 1 
EFEMP2 EGF-containing fibulin-like extracellular 
matrix protein 2 
197 RHPN1 rhophilin, Rho GTPase binding 
protein 1 
KRT15 keratin 15 
198 RHPN1 rhophilin, Rho GTPase binding 
protein 1 
TRIM37 tripartite motif-containing 37 
199 RIC8A resistance to inhibitors of 
cholinesterase 8 homolog A (C. 
elegans) 
GNA13 guanine nucleotide binding protein (G 
protein), alpha 13 
200 RIC8A resistance to inhibitors of 
cholinesterase 8 homolog A (C. 
elegans) 
GNAI1 guanine nucleotide binding protein (G 
protein), alpha inhibiting activity 
polypeptide 1 
201 RIC8A resistance to inhibitors of 
cholinesterase 8 homolog A (C. 
elegans) 
GNAI2 guanine nucleotide binding protein (G 
protein), alpha inhibiting activity 
polypeptide 2 
202 RIC8A resistance to inhibitors of 
cholinesterase 8 homolog A (C. 
elegans) 
GNAI3 guanine nucleotide binding protein (G 
protein), alpha inhibiting activity 
polypeptide 3 
203 RIC8A resistance to inhibitors of 
cholinesterase 8 homolog A (C. 
elegans) 
GNAO1 guanine nucleotide binding protein (G 
protein), alpha activating activity 
polypeptide O 
204 RIC8A resistance to inhibitors of 
cholinesterase 8 homolog A (C. 
elegans) 
GNAQ guanine nucleotide binding protein (G 
protein), q polypeptide 
205 RIC8A resistance to inhibitors of 
cholinesterase 8 homolog A (C. 
elegans) 
GNAS GNAS complex locus 
206 RIC8A resistance to inhibitors of 
cholinesterase 8 homolog A (C. 
elegans) 
MAPK8IP3 mitogen-activated protein kinase 8 
interacting protein 3 
207 RIC8A resistance to inhibitors of 
cholinesterase 8 homolog A (C. 
elegans) 
TERF1 telomeric repeat binding factor (NIMA-
interacting) 1 
208 RIC8A resistance to inhibitors of 
cholinesterase 8 homolog A (C. 
elegans) 
TUBB2A tubulin, beta 2A 
209 RIC8A resistance to inhibitors of 
cholinesterase 8 homolog A (C. 
elegans) 
UBQLN1 ubiquilin 1 
210 RIC8A resistance to inhibitors of 
cholinesterase 8 homolog A (C. 
elegans) 
ZNF585B zinc finger protein 585B 
211 SLC9A3R2 solute carrier family 9 
(sodium/hydrogen exchanger), 
member 3 regulator 2 
ACTN4 actinin, alpha 4 
212 SLC9A3R2 solute carrier family 9 
(sodium/hydrogen exchanger), 
member 3 regulator 2 
ADORA2B adenosine A2b receptor 
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213 SLC9A3R2 solute carrier family 9 
(sodium/hydrogen exchanger), 
member 3 regulator 2 
ADRB2 adrenergic, beta-2-, receptor, surface 
214 SLC9A3R2 solute carrier family 9 
(sodium/hydrogen exchanger), 
member 3 regulator 2 
CFTR cystic fibrosis transmembrane 
conductance regulator (ATP-binding 
cassette sub-family C, member 7) 
215 SLC9A3R2 solute carrier family 9 
(sodium/hydrogen exchanger), 
member 3 regulator 2 
EZR ezrin 
216 SLC9A3R2 solute carrier family 9 
(sodium/hydrogen exchanger), 
member 3 regulator 2 
KCNJ1 potassium inwardly-rectifying channel, 
subfamily J, member 1 
217 SLC9A3R2 solute carrier family 9 
(sodium/hydrogen exchanger), 
member 3 regulator 2 
LPAR2 lysophosphatidic acid receptor 2 
218 SLC9A3R2 solute carrier family 9 
(sodium/hydrogen exchanger), 
member 3 regulator 2 
OTUD7B OTU domain containing 7B 
219 SLC9A3R2 solute carrier family 9 
(sodium/hydrogen exchanger), 
member 3 regulator 2 
PDPK1 3-phosphoinositide dependent protein 
kinase-1 
220 SLC9A3R2 solute carrier family 9 
(sodium/hydrogen exchanger), 
member 3 regulator 2 
PDZK1 PDZ domain containing 1 
221 SLC9A3R2 solute carrier family 9 
(sodium/hydrogen exchanger), 
member 3 regulator 2 
PHLPP1 PH domain and leucine rich repeat 
protein phosphatase 1 
222 SLC9A3R2 solute carrier family 9 
(sodium/hydrogen exchanger), 
member 3 regulator 2 
PHLPP2 PH domain and leucine rich repeat 
protein phosphatase 2 
223 SLC9A3R2 solute carrier family 9 
(sodium/hydrogen exchanger), 
member 3 regulator 2 
PIK3CA phosphoinositide-3-kinase, catalytic, 
alpha polypeptide 
224 SLC9A3R2 solute carrier family 9 
(sodium/hydrogen exchanger), 
member 3 regulator 2 
PLCB3 phospholipase C, beta 3 
(phosphatidylinositol-specific) 
225 SLC9A3R2 solute carrier family 9 
(sodium/hydrogen exchanger), 
member 3 regulator 2 
PODXL podocalyxin-like 
226 SLC9A3R2 solute carrier family 9 
(sodium/hydrogen exchanger), 
member 3 regulator 2 
PTH1R parathyroid hormone 1 receptor 
227 SLC9A3R2 solute carrier family 9 
(sodium/hydrogen exchanger), 
member 3 regulator 2 
SGK1 serum/glucocorticoid regulated kinase 1 
228 SLC9A3R2 solute carrier family 9 
(sodium/hydrogen exchanger), 
member 3 regulator 2 
SLC26A3 solute carrier family 26, member 3 
229 SLC9A3R2 solute carrier family 9 
(sodium/hydrogen exchanger), 
member 3 regulator 2 
SLC9A3 solute carrier family 9 (sodium/hydrogen 
exchanger), member 3 
230 SLC9A3R2 solute carrier family 9 
(sodium/hydrogen exchanger), 
member 3 regulator 2 
TRIP6 thyroid hormone receptor interactor 6 
231 SLC9A3R2 solute carrier family 9 
(sodium/hydrogen exchanger), 
member 3 regulator 2 
WWTR1 WW domain containing transcription 
regulator 1 
232 SNX9 sorting nexin 9 ADAM15 ADAM metallopeptidase domain 15 
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233 SNX9 sorting nexin 9 ADAM9 ADAM metallopeptidase domain 9 
(meltrin gamma) 
234 SNX9 sorting nexin 9 CLTC clathrin, heavy chain (Hc) 
235 SNX9 sorting nexin 9 DNM2 dynamin 2 
236 SNX9 sorting nexin 9 MPP6 membrane protein, palmitoylated 6 
(MAGUK p55 subfamily member 6) 
237 STK16 serine/threonine kinase 16 ADAMTSL4 ADAMTS-like 4 
238 STK16 serine/threonine kinase 16 CNTF ciliary neurotrophic factor 
239 STK16 serine/threonine kinase 16 EBLN2 endogenous Bornavirus-like 
nucleoprotein 2 
240 STK16 serine/threonine kinase 16 ELK1 ELK1, member of ETS oncogene family 
241 STK16 serine/threonine kinase 16 EXT2 exostoses (multiple) 2 
242 STK16 serine/threonine kinase 16 HNF4A hepatocyte nuclear factor 4, alpha 
243 STK16 serine/threonine kinase 16 ICA1 islet cell autoantigen 1, 69kDa 
244 STK16 serine/threonine kinase 16 KCTD17 potassium channel tetramerisation 
domain containing 17 
245 STK16 serine/threonine kinase 16 MKKS McKusick-Kaufman syndrome 
246 STK16 serine/threonine kinase 16 NAGK N-acetylglucosamine kinase 
247 STK16 serine/threonine kinase 16 PASK PAS domain containing serine/threonine 
kinase 
248 STK16 serine/threonine kinase 16 ROCK2 Rho-associated, coiled-coil containing 
protein kinase 2 
249 STK16 serine/threonine kinase 16 RPIA ribose 5-phosphate isomerase A 
250 STK16 serine/threonine kinase 16 SNRK SNF related kinase 
251 STK16 serine/threonine kinase 16 STK16 serine/threonine kinase 16 
252 STK16 serine/threonine kinase 16 TGIF1 TGFB-induced factor homeobox 1 
253 STK16 serine/threonine kinase 16 VHL von Hippel-Lindau tumor suppressor 
254 Ufc1 ubiquitin-fold modifier conjugating 
enzyme 1 
CDK5RAP3 CDK5 regulatory subunit associated 
protein 3 
255 Ufc1 ubiquitin-fold modifier conjugating 
enzyme 1 
UBA5 ubiquitin-like modifier activating enzyme 
5 
256 Ufc1 ubiquitin-fold modifier conjugating 
enzyme 1 
Ufm1 ubiquitin-fold modifier 1 
257 ZNHIT1 zinc finger, HIT type 1 TP53 tumor protein p53 
258 ZNHIT1 zinc finger, HIT type 1 MAPK14 mitogen-activated protein kinase 14 
259 ZNHIT1 zinc finger, HIT type 1 UBC ubiquitin C 
260 ZNHIT1 zinc finger, HIT type 1 H2AFZ H2A histone family, member Z 
261 ZNHIT1 zinc finger, HIT type 1 ACTR6 ARP6 actin-related protein 6 homolog 
(yeast) 
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Supplementary table 3. Complete list of detected phage lambda/E. coli interactions.  
Bait locus 
tag 
Lambda 
bait 
E. coli 
prey 
Prey 
count 
ECK ID JW ID b ID Annotation 
lambdap01 nu1 dcrB 2 ECK3456 JW5682 b3472 protein DcrB 
lambdap01 nu1 yajI 2 ECK0406 JW5056 b0412 YajI 
lambdap01 nu1 mltB 2 ECK2696 JW2671 b2701 lytic murein 
transglycosylase B 
lambdap01 nu1 yfiO 1 ECK2593 JW2577 b2595 lipoprotein YfiO 
lambdap01 nu1 yohN 1 ECK2100 JW5346 b2107 conserved hypothetical 
protein 
lambdap01 nu1 ycfM 1 ECK1091 JW5157 b1105 lipoprotein, putative 
lambdap01 nu1 nohA 1 ECK1541 JW1541 b1548 bacteriophage DNA 
packaging protein 
lambdap01 nu1 yraP 1 ECK3138 JW3119 b3150 conserved exported 
protein 
lambdap01 nu1 ynjB 1 ECK1752 JW5284 b1754 conserved hypothetical 
protein 
lambdap02 A nohA 9 ECK1541 JW1541 b1548 bacteriophage DNA 
packaging protein 
lambdap02 A nohB 4 ECK0552 JW0549 b0560 bacteriophage DNA 
packaging protein 
lambdap02 A leuB 1 ECK0075 JW5807 b0073 3-isopropylmalate 
dehydrogenase 
lambdap03 W flxA 5 ECK1560 JW1558 b1566 protein FlxA 
lambdap03 W yfaE 1 ECK2228 JW2230 b2236 adrenodoxin family 
ferredoxin 
lambdap06 nu3 flxA 4 ECK1560 JW1558 b1566 protein FlxA 
lambdap07 D flxA 4 ECK1560 JW1558 b1566 protein FlxA 
lambdap09 Fi dicB 48 ECK1569 JW1566 b1575 conserved domain protein
lambdap09 Fi mltB 11 ECK2696 JW2671 b2701 lytic murein 
transglycosylase B 
lambdap09 Fi flxA 6 ECK1560 JW1558 b1566 protein FlxA 
lambdap09 Fi metN 6 ECK0199 JW0195 b0199 D-methionine ABC 
transporter, ATP-binding 
protein 
lambdap09 Fi phnG 6 ECK4094 JW4062 b4101 protein PhnG 
lambdap09 Fi ydgH 4 ECK1599 JW1596 b1604 protein YdgH 
lambdap09 Fi fixB 3 ECK0043 JW0041 b0042 protein FixB 
lambdap09 Fi ygiT 3 ECK3012 JW2989 b3021 transcriptional regulator, 
XRE family 
lambdap09 Fi minE 2 ECK1162 JW1163 b1174 cell division topological 
specificity factor MinE 
lambdap09 Fi smpA 2 ECK2613 JW2598 b2617 small protein A 
lambdap09 Fi proQ 1 ECK1830 JW5300 b1831 ProP effector 
lambdap09 Fi cchB 1 ECK2451 JW2440 b2456 ethanolamine utilization 
protein EutN 
lambdap09 Fi dcrB 1 ECK3456 JW5682 b3472 protein DcrB 
lambdap09 Fi yeeD 1 ECK2006 JW1994 b2012 conserved domain protein
lambdap09 Fi ycfL 1 ECK1090 JW1090 b1104 conserved hypothetical 
protein 
lambdap09 Fi ydcE 1 ECK1455 JW1456 b1461 conserved domain protein
lambdap09 Fi fixX 1 ECK0045 JW0043 b0044 conserved hypothetical 
protein 
lambdap09 Fi fimG 1 ECK4310 JW4282 b4319 protein FimG 
lambdap11 Z ynfN 1 ECK1545 JW5254 b1551 hypothetical protein 
lambdap12 U ydaW 1 ECK1359 JW5211 b1361 conserved hypothetical 
protein 
lambdap13 V ydaL 1 ECK1337 JW1334 b1340 Smr protein/MutS2 
lambdap13 V yheL 1 ECK3330 JW3305 b3343 sulfur relay protein 
TusD/DsrH 
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lambdap13 V artI 1 ECK0854 JW0847 b0863 arginine-binding 
periplasmic protein 1 
lambdap13 V panF 1 ECK3245 JW3226 b3258 sodium/pantothenate 
symporter 
lambdap13 V sfmC 1 ECK0524 JW0520 b0531 chaperone protein FimC 
lambdap13 V ydeQ 1 ECK1495 JW1496 b1502 protein FimH 
lambdap14 G dicB 84 ECK1569 JW1566 b1575 conserved domain protein
lambdap14 G ycgE 48 ECK1149 JW1149 b1162 HTH-type transcriptional 
regulator MlrA 
lambdap14 G clpP 43 ECK0431 JW0427 b0437 ATP-dependent Clp 
protease, proteolytic 
subunit ClpP 
lambdap14 G fhuF 21 ECK4357 JW4331 b4367 ferric iron reductase 
protein FhuF 
lambdap14 G flxA 18 ECK1560 JW1558 b1566 protein FlxA 
lambdap14 G fdoH 8 ECK3886 JW3864 b3893 formate dehydrogenase, 
beta subunit 
lambdap14 G yohN 5 ECK2100 JW5346 b2107 conserved hypothetical 
protein 
lambdap14 G chaC 4 ECK1212 JW1209 b1218 cation transport protein 
ChaC 
lambdap14 G ycbQ 4 ECK0929 JW5122 b0938 fimbrial subunit 
lambdap14 G metN 4 ECK0199 JW0195 b0199 D-methionine ABC 
transporter, ATP-binding 
protein 
lambdap14 G proQ 3 ECK1830 JW5300 b1831 ProP effector 
lambdap14 G yliL 3 ECK0805 JW5969 b0816 b0816 hypothetical 
protein (yliL) 
lambdap14 G yceK 2 ECK1036 JW5151 b1050 lipoprotein, putative 
lambdap14 G ykgL 2 ECK0294 JW5033 b0295 hypothetical protein 
(ykgL) 
lambdap14 G ydaL 2 ECK1337 JW1334 b1340 Smr protein/MutS2 
lambdap14 G iscR 1 ECK2528 JW2515 b2531 iron-sulfur cluster 
assembly transcription 
factor IscR 
lambdap14 G fabl 1 ECK1283 JW1281 b1288 b1288 enoyl-[acyl-carrier-
protein] reductase, 
NADH-dependent (fabI) 
lambdap14 G hypA 1 ECK2721 JW2696 b2726 hydrogenase nickel 
insertion protein HypA 
lambdap14 G yeaE 1 ECK1779 JW1770 b1781 oxidoreductase, aldo/keto 
reductase family 
lambdap14 G yliI 1 ECK0827 JW0821 b0837 hydrophobic compound 
transport factor 
lambdap14 G ynjE 1 ECK1755 JW5287 b1757 putative thiosulfate sulfur 
transferase 
lambdap14 G yqeG 1 ECK2843 JW2813 b2845 serine transporter 
lambdap16 H dicB 84 ECK1569 JW1566 b1575 conserved domain protein
lambdap16 H flxA 10 ECK1560 JW1558 b1566 protein FlxA 
lambdap16 H yliL 10 ECK0805 JW5969 b0816 b0816 hypothetical 
protein (yliL) 
lambdap16 H fixX 7 ECK0045 JW0043 b0044 conserved hypothetical 
protein 
lambdap16 H acpS 5 ECK2561 JW2547 b2563 holo-(acyl-carrier-protein) 
synthase 
lambdap16 H yeiW 4 ECK2164 JW5361 b4502 proteinase inhibitor 
lambdap16 H ymjB 4 ECK1314 JW5203 b4524 putative ATP-binding 
component of a transport 
system 
lambdap16 H ybgD 4 ECK0708 JW0709 b0719 fimbrial protein 
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lambdap16 H ycbQ 4 ECK0929 JW5122 b0938 fimbrial subunit 
lambdap16 H yfcQ 4 ECK2328 JW2331 b2334 conserved hypothetical 
protein 
lambdap16 H yohH 4 ECK2132 JW5358 b2139 YohH 
lambdap16 H phnG 4 ECK4094 JW4062 b4101 protein PhnG 
lambdap16 H dnaN 3 ECK3693 JW3678 b3701 DNA polymerase III, beta 
subunit 
lambdap16 H ECK1157 3 ECK1157 JW5901+
JW5176 
b44 putative ATP-binding 
component of a transport 
system 
lambdap16 H hyfG 3 ECK2483 JW2472 b2487 hydrogenase-4 
component G 
lambdap16 H sfmF 3 ECK0527 JW5072 b0534 major fimbrial subunit 
lambdap16 H ynfC 3 ECK1580 JW5258 b1585 lipoprotein YnfC 
lambdap16 H yehD 3 ECK2104 JW2098 b2111 fimbrial protein 
lambdap16 H yraH 3 ECK3130 JW3111 b3142 fimbrial protein 
lambdap16 H ydaW 3 ECK1359 JW5211 b1361 conserved hypothetical 
protein 
lambdap16 H metN 3 ECK0199 JW0195 b0199 D-methionine ABC 
transporter, ATP-binding 
protein 
lambdap16 H sfmA 2 ECK0523 JW0519 b0530 type-1 fimbrial protein, A 
chain 
lambdap16 H cspF 2 ECK1552 JW1550 b1558 conserved domain protein
lambdap16 H ydiT 2 ECK1698 JW1690 b1700 conserved hypothetical 
protein 
lambdap16 H ynjB 1 ECK1752 JW5284 b1754 conserved hypothetical 
protein 
lambdap16 H mltB 1 ECK2696 JW2671 b2701 lytic murein 
transglycosylase B 
lambdap16 H ECK3207 1 ECK3207 JW3187 b4549 conserved hypothetical 
protein 
lambdap16 H fimG 1 ECK4310 JW4282 b4319 protein FimG 
lambdap16 H yraK 1 ECK3133 JW3114 b3145 lipoprotein, putative 
lambdap16 H yadM 1 ECK0137 JW0134 b0138 conserved hypothetical 
protein 
lambdap16 H yodA 1 ECK1969 JW1956 b1973 zinc-binding lipoprotein 
AdcA 
lambdap16 H yeeD 1 ECK2006 JW1994 b2012 conserved domain protein
lambdap16 H ycbU 1 ECK0933 JW0925 b0942 fimbrial subunit 
lambdap16 H ygiL 1 ECK3034 JW3011 b3043 fimbrial protein 
lambdap16 H rpmA 1 ECK3174 JW3152 b3185 ribosomal protein L27 
lambdap19 K insN 2 ECK0257 JW5024 b0255 transposase InsN for 
insertion sequence 
element A 
lambdap19 K ynjB 2 ECK1752 JW5284 b1754 conserved hypothetical 
protein 
lambdap19 K fliA 2 ECK1921 JW1907 b1922 RNA polymerase sigma 
factor for flagellar operon 
lambdap19 K ydaL 1 ECK1337 JW1334 b1340 Smr protein/MutS2 
lambdap20 I torI 1 ECK2359 JW5387 b4501 conserved domain protein
lambdap20 I ydcM 1 ECK1426 JW5228 b1432 ISAfe8, transposase 
lambdap20 I yegR 1 ECK2081 JW5837 b2085  
lambdap26 lom ydaL 1 ECK1337 JW1334 b1340 Smr protein/MutS2 
lambdap27 orf-401 stfR 89 ECK1367 JW1366 b1372 putative membrane 
protein 
lambdap27 orf-401 dicB 4 ECK1569 JW1566 b1575 conserved domain protein
lambdap27 orf-401 fucU 1 ECK2799 JW2775 b2804 fucose operon FucU 
protein 
lambdap27 orf-401 yeeD 1 ECK2006 JW1994 b2012 conserved domain protein
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lambdap28 orf-314 tfaR 152 ECK1368 JW1367 b1373 tail fiber assembly protein 
lambdap28 orf-314 clpP 7 ECK0431 JW0427 b0437 ATP-dependent Clp 
protease, proteolytic 
subunit ClpP 
lambdap28 orf-314 ycgE 4 ECK1149 JW1149 b1162 HTH-type transcriptional 
regulator MlrA 
lambdap28 orf-314 tfaQ 2 ECK1539 JW1539 b1546 tail fiber assembly protein 
lambdap28 orf-314 ycfZ 1 ECK1107 JW1107 b1121 inner membrane protein 
YcfZ 
lambdap28 orf-314 yicI 1 ECK3646 JW3631 b3656 alpha-glucosidase 
lambdap33 int fliA 17 ECK1921 JW1907 b1922 RNA polymerase sigma 
factor for flagellar operon 
lambdap33 int nohB 7 ECK0552 JW0549 b0560 bacteriophage DNA 
packaging protein 
lambdap33 int nlpI 6 ECK3151 JW3132 b3163 lipoprotein NlpI 
lambdap33 int paaC 6 ECK1387 JW1385 b1390 phenylacetate-CoA 
oxygenase, PaaI subunit 
lambdap33 int ynjB 5 ECK1752 JW5284 b1754 conserved hypothetical 
protein 
lambdap33 int spr 2 ECK2169 JW2163 b2175 lipoprotein spr 
lambdap33 int tbpA 2 ECK0069 JW0067 b0068 thiamin/thiamin 
pyrophosphate ABC 
transporter, 
thiamin/thiamin 
pyrophospate-binding 
protein 
lambdap33 int mltB 2 ECK2696 JW2671 b2701 lytic murein 
transglycosylase B 
lambdap33 int ynfO 1 ECK1542 JW5251 b4533 conserved hypothetical 
protein 
lambdap33 int stfR 1 ECK1367 JW1366 b1372 putative membrane 
protein 
lambdap33 int frvR 1 ECK3890 JW3868 b3897 putative frv operon 
regulatory protein 
lambdap33 int fliM 1 ECK1943 JW1929 b1945 flagellar motor switch 
protein FliM 
lambdap33 int ansB 1 ECK2952 JW2924 b2957 L-asparaginase II 
lambdap33 int nohA 1 ECK1541 JW1541 b1548 bacteriophage DNA 
packaging protein 
lambdap36 ea8.5 dicB 45 ECK1569 JW1566 b1575 conserved domain protein
lambdap36 ea8.5 phnG 36 ECK4094 JW4062 b4101 protein PhnG 
lambdap36 ea8.5 flxA 17 ECK1560 JW1558 b1566 protein FlxA 
lambdap36 ea8.5 spr 7 ECK2169 JW2163 b2175 lipoprotein spr 
lambdap36 ea8.5 mltB 7 ECK2696 JW2671 b2701 lytic murein 
transglycosylase B 
lambdap36 ea8.5 yjhV 4 ECK4276 JW4246 b4286 conserved hypothetical 
protein 
lambdap36 ea8.5 fixX 4 ECK0045 JW0043 b0044 conserved hypothetical 
protein 
lambdap36 ea8.5 ydaW 4 ECK1359 JW5211 b1361 conserved hypothetical 
protein 
lambdap36 ea8.5 metN 4 ECK0199 JW0195 b0199 D-methionine ABC 
transporter, ATP-binding 
protein 
lambdap36 ea8.5 yjdI 3 ECK4119 JW4087 b4126 conserved hypothetical 
protein 
lambdap36 ea8.5 yohH 3 ECK2132 JW5358 b2139 YohH 
lambdap36 ea8.5 minE 2 ECK1162 JW1163 b1174 cell division topological 
specificity factor MinE 
lambdap36 ea8.5 yraP 2 ECK3138 JW3119 b3150 conserved exported 
protein 
lambdap36 ea8.5 yeiW 2 ECK2164 JW5361 b4502 proteinase inhibitor 
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lambdap36 ea8.5 ymdE 2 ECK1016 JW5145 b1028 hypothetical protein  
lambdap36 ea8.5 smpA 2 ECK2613 JW2598 b2617 small protein A 
lambdap36 ea8.5 ubiF 2 ECK0654 JW0659 b0662 2-octaprenyl-3-methyl-6-
methoxy-1,4-benzoquinol 
hydroxylase 
lambdap36 ea8.5 ynfO 2 ECK1542 JW5251 b4533 conserved hypothetical 
protein 
lambdap36 ea8.5 ydcE 2 ECK1455 JW1456 b1461 conserved domain protein
lambdap36 ea8.5 wza 2 ECK2056 JW2047 b2062 membrane protein 
lambdap36 ea8.5 yajI 1 ECK0406 JW5056 b0412 YajI 
lambdap36 ea8.5 ynjB 1 ECK1752 JW5284 b1754 conserved hypothetical 
protein 
lambdap36 ea8.5 yjgZ 1 ECK4267 JW4236 b4277   
lambdap36 ea8.5 ynfC 1 ECK1580 JW5258 b1585 lipoprotein YnfC 
lambdap36 ea8.5 sfmF 1 ECK0527 JW5072 b0534 major fimbrial subunit 
lambdap36 ea8.5 ECK2994 1 ECK2994 JW5496 b3000 carboxymethylenebutenol
idase 
lambdap36 ea8.5 mltC 1 ECK2958 JW5481 b2963 membrane-bound lytic 
murein transglycosylase 
C 
lambdap36 ea8.5 ybhC 1 ECK0761 JW0755 b0772 acyl-CoA thioester 
hydrolase YbgC 
lambdap36 ea8.5 yaiV 1 ECK0370 JW0366 b0375 conserved hypothetical 
protein 
lambdap36 ea8.5 ECK0356 1 ECK0356 JW0350 b0359 putative transferase 
lambdap36 ea8.5 csgC 1 ECK1029 JW1026 b1043 putative curli production 
protein CsgC 
lambdap36 ea8.5 fimG 1 ECK4310 JW4282 b4319 protein FimG 
lambdap37 orf61 mltB 4 ECK2696 JW2671 b2701 lytic murein 
transglycosylase B 
lambdap37 orf61 yqhC 3 ECK3002 JW5849 b3010 putative HTH-type 
transcriptional regulator 
YqhC 
lambdap37 orf61 spr 3 ECK2169 JW2163 b2175 lipoprotein spr 
lambdap37 orf61 yiaF 3 ECK3541 JW5655 b3554 lipoprotein, putative 
lambdap37 orf61 yjdI 2 ECK4119 JW4087 b4126 conserved hypothetical 
protein 
lambdap37 orf61 yheL 2 ECK3330 JW3305 b3343 sulfur relay protein 
TusD/DsrH 
lambdap37 orf61 flxA 2 ECK1560 JW1558 b1566 protein FlxA 
lambdap37 orf61 wza 2 ECK2056 JW2047 b2062 membrane protein 
lambdap37 orf61 phnG 2 ECK4094 JW4062 b4101 protein PhnG 
lambdap37 orf61 yihD 1 ECK3850 JW3830 b3858 protein YihD 
lambdap37 orf61 dicB 1 ECK1569 JW1566 b1575 conserved domain protein
lambdap37 orf61 yjhV 1 ECK4276 JW4246 b4286 conserved hypothetical 
protein 
lambdap37 orf61 ynjB 1 ECK1752 JW5284 b1754 conserved hypothetical 
protein 
lambdap37 orf61 ubiF 1 ECK0654 JW0659 b0662 2-octaprenyl-3-methyl-6-
methoxy-1,4-benzoquinol 
hydroxylase 
lambdap37 orf61 yccT 1 ECK0955 JW0947 b0964 protein YccT 
lambdap37 orf61 rseB 1 ECK2569 JW2555 b2571 sigma-E factor regulatory 
protein RseB 
lambdap37 orf61 cysH 1 ECK2757 JW2732 b2762 phosphoadenosine 
phosphosulfate reductase
lambdap37 orf61 ECK1962 1 ECK1962 JW1949 b1966 outer membrane protein 
N 
lambdap37 orf61 nfsA 1 ECK0842 JW0835 b0851 oxygen-insensitive 
NADPH nitroreductase 
lambdap37 orf61 yohN 1 ECK2100 JW5346 b2107 conserved hypothetical 
protein 
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lambdap37 orf61 yhdW 1 ECK3255 JW3236 b3268 general L-amino acid-
binding periplasmic 
protein AapJ 
lambdap37 orf61 yeiW 1 ECK2164 JW5361 b4502 proteinase inhibitor 
lambdap37 orf61 sgcE 1 ECK4290 JW4263 b4301 protein SgcE 
lambdap37 orf61 yhfG 1 ECK3350 JW3325 b3362 conserved hypothetical 
protein 
lambdap37 orf61 flgJ 1 ECK1066 JW1068 b1081 flagellar rod assembly 
protein/muramidase FlgJ 
lambdap38 orf63 yqhC 4 ECK3002 JW5849 b3010 putative HTH-type 
transcriptional regulator 
YqhC 
lambdap39 orf60a tbpA 1 ECK0069 JW0067 b0068 thiamin/thiamin 
pyrophosphate ABC 
transporter, 
thiamin/thiamin 
pyrophospate-binding 
protein 
lambdap41 exo ynjB 9 ECK1752 JW5284 b1754 conserved hypothetical 
protein 
lambdap41 exo spr 2 ECK2169 JW2163 b2175 lipoprotein spr 
lambdap41 exo tbpA 2 ECK0069 JW0067 b0068 thiamin/thiamin 
pyrophosphate ABC 
transporter, 
thiamin/thiamin 
pyrophospate-binding 
protein 
lambdap41 exo yiaF 1 ECK3541 JW5655 b3554 lipoprotein, putative 
lambdap42 Gam ynjB 9 ECK1752 JW5284 b1754 conserved hypothetical 
protein 
lambdap42 Gam spr 7 ECK2169 JW2163 b2175 lipoprotein spr 
lambdap42 Gam yiaF 5 ECK3541 JW5655 b3554 lipoprotein, putative 
lambdap42 Gam ynfO 4 ECK1542 JW5251 b4533 conserved hypothetical 
protein 
lambdap42 Gam mltB 1 ECK2696 JW2671 b2701 lytic murein 
transglycosylase B 
lambdap42 Gam yncM 1 ECK1453 JW5237 b1459 hypothetical protein 
(yncM)  
lambdap42 Gam yhfG 1 ECK3350 JW3325 b3362 conserved hypothetical 
protein 
lambdap42 Gam yqhC 1 ECK3002 JW5849 b3010 putative HTH-type 
transcriptional regulator 
YqhC 
lambdap45 ea10 yqjI 63 ECK3061 JW3042 b3071 transcriptional regulator, 
PadR family protein 
lambdap45 ea10 frvA 43 ECK3893 JW3871 b3900 phosphoenolpyruvate-
dependent sugar 
phosphotransferase 
system, eiia 2, putative 
lambdap45 ea10 ynfO 33 ECK1542 JW5251 b4533 conserved hypothetical 
protein 
lambdap45 ea10 rmf 17 ECK0944 JW0936 b0953 ribosome modulation 
factor (rmf) 
lambdap45 ea10 dicB 8 ECK1569 JW1566 b1575 conserved domain protein
lambdap45 ea10 rpmA 8 ECK3174 JW3152 b3185 ribosomal protein L27 
lambdap45 ea10 yliL 8 ECK0805 JW5969 b0816 hypothetical protein (yliL) 
lambdap45 ea10 rpsG 7 ECK3328 JW3303 b3341 ribosomal protein S7 
lambdap45 ea10 flxA 6 ECK1560 JW1558 b1566 protein FlxA 
lambdap45 ea10 cedA 5 ECK1729 JW1720 b1731 conserved hypothetical 
protein 
lambdap45 ea10 yjiR 5 ECK4331 JW4303 b4340 aminotransferase, 
classes I and II 
superfamily 
APPENDIX 
 
130
lambdap45 ea10 mltB 4 ECK2696 JW2671 b2701 lytic murein 
transglycosylase B 
lambdap45 ea10 priC 4 ECK0461 JW0456 b0467 primosomal replication 
protein N 
lambdap45 ea10 rpsS 4 ECK3303 JW3278 b3316 30S ribosomal protein 
S19 
lambdap45 ea10 ypjJ 4 ECK2641 JW5421 b4548 hypothetical protein (ypjJ)
lambdap45 ea10 cobB 3 ECK1106 JW1106 b1120 NAD-dependent 
deacetylase 
lambdap45 ea10 soxS 3 ECK4054 JW4023 b4062 regulatory protein SoxS 
lambdap45 ea10 ykiA 3 ECK0387 JW0383 b0392 conserved hypothetical 
protein 
lambdap45 ea10 yncM 3 ECK1453 JW5237 b1459 hypothetical protein 
(yncM) 
lambdap45 ea10 ycbG 3 ECK0947 JW0939 b0956 protein YcbG 
lambdap45 ea10 glcC 3 ECK2975 JW2947 b2980 Glc operon transcriptional 
activator 
lambdap45 ea10 phnG 3 ECK4094 JW4062 b4101 protein PhnG 
lambdap45 ea10 spr 3 ECK2169 JW2163 b2175 lipoprotein spr 
lambdap45 ea10 ydaL 3 ECK1337 JW1334 b1340 Smr protein/MutS2 
lambdap45 ea10 hupA 2 ECK3992 JW3964 b4000 DNA-binding protein HU-
alpha 
lambdap45 ea10 rplC 2 ECK3307 JW3282 b3320 ribosomal protein L3 
lambdap45 ea10  
ECK0356 
2 ECK0356 JW0350 b0359 b0359 predicted acyl 
transferase 
lambdap45 ea10 chaA 2 ECK1210 JW1207 b1216 calcium/proton antiporter 
lambdap45 ea10 cspH 2 ECK0979 JW5134 b0989 conserved domain protein
lambdap45 ea10 prfH 2 ECK0237 JW0226 b0236 putative peptide chain 
release factor H 
lambdap45 ea10 rrmJ 2 ECK3168 JW3146 b3179 ribosomal RNA large 
subunit methyltransferase 
J 
lambdap45 ea10 soxR 2 ECK4055 JW4024 b4063 redox-sensitive 
transcriptional activator 
SoxR 
lambdap45 ea10 yaiV 2 ECK0370 JW0366 b0375 conserved hypothetical 
protein 
lambdap45 ea10 ybjP 2 ECK0856 JW0849 b0865 YbjP 
lambdap45 ea10 ycaL 2 ECK0900 JW0892 b0909 peptidase M48, Ste24p 
lambdap45 ea10 ycdC 2 ECK1004 JW0998 b1013 HTH-type transcriptional 
regulator RutR 
lambdap45 ea10 ydcI 2 ECK1416 JW5226 b1422 putative HTH-type 
transcriptional regulator 
YdcI 
lambdap45 ea10 yeaM 2 ECK1788 JW1779 b1790 putative HTH-type 
transcriptional regulator 
YeaM 
lambdap45 ea10 ykgM 2 ECK0295 JW5034 b4506 ribosomal protein L36 
lambdap45 ea10 ykfI 2 ECK0246 JW0234 b0245 YeeV protein 
lambdap45 ea10 ymfC 2 ECK1121 JW1121 b1135 RNA pseudouridylate 
synthase family protein 
lambdap45 ea10 wza 2 ECK2056 JW2047 b2062 membrane protein 
lambdap45 ea10 yjgZ 2 ECK4267 JW4236 b4277  
lambdap45 ea10 yjhV 2 ECK4276 JW4246 b4286 conserved hypothetical 
protein 
lambdap45 ea10 metN 1 ECK0199 JW0195 b0199 D-methionine ABC 
transporter, ATP-binding 
protein 
lambdap45 ea10 ydaW 1 ECK1359 JW5211 b1361 conserved hypothetical 
protein 
lambdap45 ea10 ydcE 1 ECK1455 JW1456 b1461 conserved domain protein
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lambdap45 ea10 ygiT 1 ECK3012 JW2989 b3021 transcriptional regulator, 
XRE family 
lambdap45 ea10 yhiK 1 ECK3474 JW5674 b3489 hypothetical protein 
lambdap45 ea10 cdaR 1 ECK0161 JW5013 b0162 carbohydrate diacid 
regulator 
lambdap45 ea10 cobC 1 ECK0631 JW0633 b0638 alpha-ribazole 
phosphatase 
lambdap45 ea10 ECK3633 1 ECK3633 JW3618 b3643 defective ribonuclease 
PH 
lambdap45 ea10 ECK4273 1 ECK4273 JW5772 b4561 transposase 
lambdap45 ea10 glcD 1 ECK2974 JW2946 b2979 glycolate oxidase, subunit 
GlcD 
lambdap45 ea10 hcaB 1 ECK2538 JW2525 b2541 2,3-dihydroxy-2,3-
dihydro-phenylpropionate 
dehydrogenase 
lambdap45 ea10 melR 1 ECK4111 JW4079 b4118 melibiose operon 
regulatory protein 
lambdap45 ea10 mltC 1 ECK2958 JW5481 b2963 membrane-bound lytic 
murein transglycosylase 
C 
lambdap45 ea10 mrdA 1 ECK0628 JW0630 b0635 penicillin-binding protein 
2 
lambdap45 ea10 nuoA 1 ECK2282 JW2283 b2288 NADH-quinone 
oxidoreductase chain a 
lambdap45 ea10 wbbJ 1 ECK2027 JW2018 b2033 b2033 predicted acyl 
transferase (wbbJ) 
lambdap45 ea10 wzb 1 ECK2055 JW2046 b2061 Low molecular weight 
protein-tyrosine-
phosphatase wzb 
lambdap45 ea10 ycjD 1 ECK1284 JW1282 b1289 14kDa protein 
lambdap45 ea10 ydgH 1 ECK1599 JW1596 b1604 protein YdgH 
lambdap45 ea10 ydiB 1 ECK1690 JW1682 b1692 quinate/shikimate 
dehydrogenase 
lambdap45 ea10 yeeS 1 ECK1995 JW1984 b2002 Z1217 protein 
lambdap45 ea10 yfdY 1 ECK2373 JW2374 b2377 conserved hypothetical 
protein 
lambdap45 ea10 yfjG 1 ECK2615 JW2600 b2619 oligoketide cyclase/lipid 
transport protein 
lambdap45 ea10 ygcR 1 ECK2765 JW5441 b2770 putative transport protein 
lambdap45 ea10 ygeP 1 ECK2858 JW2831 b2862 hypothetical protein 
(ygeP) 
lambdap45 ea10 ygiU 1 ECK3013 JW2990 b3022 b3022 predicted cyanide 
hydratase (ygiU) 
lambdap45 ea10 yigI 1 ECK3814 JW5588 b3820 f161 
lambdap45 ea10 yjdI 1 ECK4119 JW4087 b4126 conserved hypothetical 
protein 
lambdap45 ea10 ymdB 1 ECK1031 JW1032 b1045 protein YmdB 
lambdap45 ea10 ymfO 1 ECK1137 JW1137 b1151 portal protein 
lambdap45 ea10 yohH 1 ECK2132 JW5358 b2139 YohH 
lambdap45 ea10 yqhC 1 ECK3002 JW5849 b3010 putative HTH-type 
transcriptional regulator 
YqhC 
lambdap48   pntA 1 ECK1598 JW1595 b1603 NAD(P) 
transhydrogenase, alpha 
subunit 
lambdap48   ydcH 1 ECK1419 JW5823 b1426 conserved domain protein
lambdap49 N mltB 7 ECK2696 JW2671 b2701 lytic murein 
transglycosylase B 
lambdap49 N ynjB 6 ECK1752 JW5284 b1754 conserved hypothetical 
protein 
lambdap49 N ynfO 5 ECK1542 JW5251 b4533 conserved hypothetical 
protein 
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lambdap49 N yihD 4 ECK3850 JW3830 b3858 protein YihD 
lambdap49 N yicI 4 ECK3646 JW3631 b3656 alpha-glucosidase 
lambdap49 N hcr 3 ECK0863 JW5117 b0872 NADH oxidoreductase 
hcr 
lambdap49 N ydcE 3 ECK1455 JW1456 b1461 conserved domain protein
lambdap49 N ygiT 3 ECK3012 JW2989 b3021 transcriptional regulator, 
XRE family 
lambdap49 N yiaF 3 ECK3541 JW5655 b3554 lipoprotein, putative 
lambdap49 N secB 3 ECK3599 JW3584 b3609 protein-export chaperone 
SecB 
lambdap49 N ego 2 ECK1506 JW1506 b1513 putative ABC transporter 
ATP-binding protein ego 
lambdap49 N ppc 2 ECK3947 JW3928 b3956 phosphoenolpyruvate 
carboxylase 
lambdap49 N nohA 2 ECK1541 JW1541 b1548 bacteriophage DNA 
packaging protein 
lambdap49 N nuoG 2 ECK2277 JW2278 b2283 NADH-quinone 
oxidoreductase, chain g 
lambdap49 N yebR 2 ECK1831 JW1821 b1832 protein YebR 
lambdap49 N yjeP 2 ECK4155 JW4120 b4159 BspA protein 
lambdap49 N fliA 1 ECK1921 JW1907 b1922 RNA polymerase sigma 
factor for flagellar operon 
lambdap49 N insN 1 ECK0257 JW5024 b0255 transposase InsN for 
insertion sequence 
element A 
lambdap49 N spr 1 ECK2169 JW2163 b2175 lipoprotein spr 
lambdap49 N tbpA 1 ECK0069 JW0067 b0068 thiamin/thiamin 
pyrophosphate ABC 
transporter, 
thiamin/thiamin 
pyrophospate-binding 
protein 
lambdap49 N ydaW 1 ECK1359 JW5211 b1361 conserved hypothetical 
protein 
lambdap49 N yjgZ 1 ECK4267 JW4236 b4277  
lambdap49 N ybeB 1 ECK0630 JW5090 b0637 iojap-like ribosome-
associated protein 
lambdap49 N nusA 1 ECK3158 JW3138 b3169 transcription elongation 
protein NusA 
lambdap49 N rpoS 1 ECK2736 JW5437 b2741 RNA polymerase sigma 
factor RpoS 
lambdap49 N yccT 1 ECK0955 JW0947 b0964 protein YccT 
lambdap49 N caiD 1 ECK0037 JW0035 b0036 carnitinyl-CoA 
dehydratase 
lambdap49 N ccmD 1 ECK2190 JW2186 b2198 conserved domain protein
lambdap49 N ccmH 1 ECK2186 JW2182 b2194 cytoChrome c-type 
biogenesis protein CcmH 
lambdap49 N cysB 1 ECK1269 JW1267 b1275 HTH-type transcriptional 
regulator CysB 
lambdap49 N envR 1 ECK3251 JW3232 b3264 probable acrEF/envCD 
operon repressor 
lambdap49 N glpK 1 ECK3918 JW3897 b3926 glycerol kinase 
lambdap49 N minC 1 ECK1164 JW1165 b1176 septum site-determining 
protein MinC 
lambdap49 N nrfB 1 ECK4064 JW4032 b4071 cytochrome c nitrite 
reductase, pentaheme 
subunit 
lambdap49 N ogrK 1 ECK2079 JW2067 b2082 Ogr 
lambdap49 N phoB 1 ECK0393 JW0389 b0399 phosphate regulon 
transcriptional regulatory 
protein PhoB 
lambdap49 N slp 1 ECK3490 JW3474 b3506 outer membrane protein 
slp 
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lambdap49 N yagT 1 ECK0285 JW0280 b0286 ferredoxin 
lambdap49 N ybjP 1 ECK0856 JW0849 b0865 YbjP 
lambdap49 N ycbG 1 ECK0947 JW0939 b0956 protein YcbG 
lambdap49 N ycgB 1 ECK1176 JW1177 b1188 unidentified protein 
lambdap49 N ycgE 1 ECK1149 JW1149 b1162 HTH-type transcriptional 
regulator MlrA 
lambdap49 N ydhL 1 ECK1644 JW5827 b1648 conserved hypothetical 
protein (ydhL) 
lambdap49 N ydiT 1 ECK1698 JW1690 b1700 conserved hypothetical 
protein 
lambdap49 N ydjA 1 ECK1763 JW1754 b1765 protein YdjA 
lambdap49 N yeeW 1 ECK1999 JW1988 b2006 YeeW protein 
lambdap49 N yfdL 1 ECK2349 JW5384 b2355 conserved hypothetical 
protein 
lambdap49 N yfdM 1 ECK2350 JW2352 b2356 DNA N-6-adenine-
methyltransferase (Dam) 
superfamily 
lambdap49 N yfhL 1 ECK2560 JW2546 b2562 iron-sulfur cluster-binding 
protein 
lambdap49 N yqhC 1 ECK3002 JW5849 b3010 putative HTH-type 
transcriptional regulator 
YqhC 
lambdap49 N yhdW 1 ECK3255 JW3236 b3268 general L-amino acid-
binding periplasmic 
protein AapJ 
lambdap49 N yibA 1 ECK3583 JW3568 b3594 protein YibA 
lambdap49 N yiiF 1 ECK3883 JW5563 b3890 conserved hypothetical 
protein 
lambdap49 N yjfN 1 ECK4184 JW5742 b4188 conserved hypothetical 
protein 
lambdap53 rexb yiaF 1 ECK3541 JW5655 b3554 lipoprotein, putative 
lambdap59 cll yiaF 1 ECK3541 JW5655 b3554 lipoprotein, putative 
lambdap59 cll yjbE 1 ECK4018 JW3986 b4026 putative outer membrane 
protein 
lambdap59 cll ylcG 1 ECK0542 JW5076 b4509 conserved hypothetical 
protein 
lambdap61 P fliA 14 ECK1921 JW1907 b1922 RNA polymerase sigma 
factor for flagellar operon 
lambdap61 P ynfO 7 ECK1542 JW5251 b4533 conserved hypothetical 
protein 
lambdap61 P ygiT 5 ECK3012 JW2989 b3021 transcriptional regulator, 
XRE family 
lambdap61 P atpC 3 ECK3724 JW3709 b3731 ATP synthase F1, epsilon 
subunit 
lambdap61 P ycbG 2 ECK0947 JW0939 b0956 protein YcbG 
lambdap61 P eutC 2 ECK2435 JW2433 b2440 ethanolamine ammonia-
lyase, light chain 
lambdap61 P ydaG 2 ECK1353 JW5210 b1355 conserved hypothetical 
protein 
lambdap61 P fliM 2 ECK1943 JW1929 b1945 flagellar motor switch 
protein FliM 
lambdap61 P yqhC 2 ECK3002 JW5849 b3010 putative HTH-type 
transcriptional regulator 
YqhC 
lambdap61 P ydcE 2 ECK1455 JW1456 b1461 conserved domain protein
lambdap61 P yjhV 2 ECK4276 JW4246 b4286 conserved hypothetical 
protein 
lambdap61 P yiaF 1 ECK3541 JW5655 b3554 lipoprotein, putative 
lambdap61 P insN 1 ECK0257 JW5024 b0255 transposase InsN for 
insertion sequence 
element A 
lambdap61 P yihD 1 ECK3850 JW3830 b3858 protein YihD 
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lambdap61 P acrE 1 ECK3252 JW3233 b3265 acriflavine resistance 
protein E 
lambdap61 P ycdC 1 ECK1004 JW0998 b1013 HTH-type transcriptional 
regulator RutR 
lambdap61 P slp 1 ECK3490 JW3474 b3506 outer membrane protein 
slp 
lambdap61 P glyQ 1 ECK3548 JW3531 b3560 glycyl-tRNA synthetase, 
alpha subunit 
lambdap61 P ycfL 1 ECK1090 JW1090 b1104 conserved hypothetical 
protein 
lambdap61 P holA 1 ECK0633 JW0635 b0640 DNA polymerase III, delta 
subunit 
lambdap61 P rpoE 1 ECK2571 JW2557 b2573 RNA polymerase sigma 
factor RpoE 
lambdap61 P ansB 1 ECK2952 JW2924 b2957 L-asparaginase II 
lambdap61 P dinJ 1 ECK0227 JW0216 b0226 DNA-damage-inducible 
protein J 
lambdap61 P paaC 1 ECK1387 JW1385 b1390 phenylacetate-CoA 
oxygenase, PaaI subunit 
lambdap61 P phoB 1 ECK0393 JW0389 b0399 phosphate regulon 
transcriptional regulatory 
protein PhoB 
lambdap62 ren ynjB 8 ECK1752 JW5284 b1754 conserved hypothetical 
protein 
lambdap62 ren yiaF 4 ECK3541 JW5655 b3554 lipoprotein, putative 
lambdap63 NinB flxA 8 ECK1560 JW1558 b1566 protein FlxA 
lambdap63 NinB yqjI 6 ECK3061 JW3042 b3071 transcriptional regulator, 
PadR family protein 
lambdap63 NinB ynjB 5 ECK1752 JW5284 b1754 conserved hypothetical 
protein 
lambdap63 NinB fliA 4 ECK1921 JW1907 b1922 RNA polymerase sigma 
factor for flagellar operon 
lambdap63 NinB dicB 3 ECK1569 JW1566 b1575 conserved domain protein
lambdap63 NinB metN 3 ECK0199 JW0195 b0199 D-methionine ABC 
transporter, ATP-binding 
protein 
lambdap63 NinB phnG 3 ECK4094 JW4062 b4101 protein PhnG 
lambdap63 NinB yiaF 3 ECK3541 JW5655 b3554 lipoprotein, putative 
lambdap63 NinB ynfO 3 ECK1542 JW5251 b4533 conserved hypothetical 
protein 
lambdap63 NinB rpsE 2 ECK3290 JW3265 b3303 ribosomal protein S5 
lambdap63 NinB yajI 2 ECK0406 JW5056 b0412 YajI 
lambdap63 NinB insN 1 ECK0257 JW5024 b0255 transposase InsN for 
insertion sequence 
element A 
lambdap63 NinB ydaW 1 ECK1359 JW5211 b1361 conserved hypothetical 
protein 
lambdap63 NinB ygiT 1 ECK3012 JW2989 b3021 transcriptional regulator, 
XRE family 
lambdap63 NinB yihD 1 ECK3850 JW3830 b3858 protein YihD 
lambdap63 NinB ydcA 1 ECK1411 JW1416 b1419 conserved hypothetical 
protein 
lambdap63 NinB yjiT 1 ECK4333 JW5787 b4342 conserved hypothetical 
protein 
lambdap64 NinC spr 5 ECK2169 JW2163 b2175 lipoprotein spr 
lambdap64 NinC yiaF 2 ECK3541 JW5655 b3554 lipoprotein, putative 
lambdap64 NinC mltB 1 ECK2696 JW2671 b2701 lytic murein 
transglycosylase B 
lambdap64 NinC fliA 1 ECK1921 JW1907 b1922 RNA polymerase sigma 
factor for flagellar operon 
lambdap64 NinC flxA 1 ECK1560 JW1558 b1566 protein FlxA 
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lambdap65 NinD dicB 15 ECK1569 JW1566 b1575 conserved domain protein
lambdap65 NinD phnG 13 ECK4094 JW4062 b4101 protein PhnG 
lambdap65 NinD yjhV 13 ECK4276 JW4246 b4286 conserved hypothetical 
protein 
lambdap65 NinD yjgZ 7 ECK4267 JW4236 b4277   
lambdap65 NinD ydiT 6 ECK1698 JW1690 b1700 conserved hypothetical 
protein 
lambdap65 NinD ydaW 5 ECK1359 JW5211 b1361 conserved hypothetical 
protein 
lambdap65 NinD pyrF 5 ECK1276 JW1273 b1281 orotidine 5'-phosphate 
decarboxylase 
lambdap65 NinD yfiM 5 ECK2584 JW2570 b2586 conserved hypothetical 
protein 
lambdap65 NinD yhdW 5 ECK3255 JW3236 b3268 general L-amino acid-
binding periplasmic 
protein AapJ 
lambdap65 NinD minE 4 ECK1162 JW1163 b1174 cell division topological 
specificity factor MinE 
lambdap65 NinD yjdI 4 ECK4119 JW4087 b4126 conserved hypothetical 
protein 
lambdap65 NinD smpA 4 ECK2613 JW2598 b2617 small protein A 
lambdap65 NinD slp 4 ECK3490 JW3474 b3506 outer membrane protein 
slp 
lambdap65 NinD yajI 3 ECK0406 JW5056 b0412 YajI 
lambdap65 NinD csrA 3 ECK2691 JW2666 b2696 carbon storage regulator 
lambdap65 NinD HycG 3 ECK2714 JW2689 b2719 hydrogenase-4 
component I 
lambdap65 NinD sdiA 3 ECK1915 JW1901 b1916 regulatory protein SdiA 
lambdap65 NinD soxS 3 ECK4054 JW4023 b4062 regulatory protein SoxS 
lambdap65 NinD yebR 3 ECK1831 JW1821 b1832 protein YebR 
lambdap65 NinD yeeW 3 ECK1999 JW1988 b2006 YeeW protein 
lambdap65 NinD yohH 3 ECK2132 JW5358 b2139 YohH 
lambdap65 NinD ECK2994 2 ECK2994 JW5496 b3000 carboxymethylenebutenol
idase 
lambdap65 NinD yeiW 2 ECK2164 JW5361 b4502 proteinase inhibitor 
lambdap65 NinD yheL 2 ECK3330 JW3305 b3343 sulfur relay protein 
TusD/DsrH 
lambdap65 NinD fhuF 2 ECK4357 JW4331 b4367 ferric iron reductase 
protein FhuF 
lambdap65 NinD mltC 2 ECK2958 JW5481 b2963 membrane-bound lytic 
murein transglycosylase 
C 
lambdap65 NinD feaB 2 ECK1382 JW1380 b1385 phenylacetaldehyde 
dehydrogenase 
lambdap65 NinD ykfI 2 ECK0246 JW0234 b0245 YeeV protein 
lambdap65 NinD ydcE 2 ECK1455 JW1456 b1461 conserved domain protein
lambdap65 NinD fixX 2 ECK0045 JW0043 b0044 conserved hypothetical 
protein 
lambdap65 NinD insN 2 ECK0257 JW5024 b0255 transposase InsN for 
insertion sequence 
element A 
lambdap65 NinD ynfO 2 ECK1542 JW5251 b4533 conserved hypothetical 
protein 
lambdap65 NinD spr 2 ECK2169 JW2163 b2175 lipoprotein spr 
lambdap65 NinD metN 1 ECK0199 JW0195 b0199 D-methionine ABC 
transporter, ATP-binding 
protein 
lambdap65 NinD flxA 1 ECK1560 JW1558 b1566 protein FlxA 
lambdap65 NinD yccT 1 ECK0955 JW0947 b0964 protein YccT 
lambdap65 NinD ygbT 1 ECK2750 JW2725 b2755 crispr-associated protein 
Cas1 
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lambdap65 NinD yfaE 1 ECK2228 JW2230 b2236 adrenodoxin family 
ferredoxin 
lambdap65 NinD hydN 1 ECK2708 JW2683 b2713 protein AegA 
lambdap65 NinD ECK2645 1 ECK2645 JW5423 b2648 putative DNA-invertase 
from prophage CP4-44 
lambdap65 NinD yajO 1 ECK0413 JW0409 b0419 aldo/keto reductase 
lambdap65 NinD ssuB 1 ECK0924 JW0916 b0933 putative aliphatic 
sulfonates transport ATP-
binding protein SsuB 
lambdap65 NinD oppF 1 ECK1241 JW1239 b1247 oligopeptide transport 
ATP-binding protein 
OppF 
lambdap65 NinD hyfH 1 ECK2484 JW2473 b2488 hydrogenase-4 
component H 
lambdap65 NinD flhC 1 ECK1892 JW1880 b1891 flagellar transcriptional 
activator FlhC 
lambdap65 NinD eutC 1 ECK2435 JW2433 b2440 ethanolamine ammonia-
lyase, light chain 
lambdap65 NinD ymjB 1 ECK1314 JW5203 b4524 putative ATP-binding 
component of a transport 
system 
lambdap65 NinD yjiT 1 ECK4333 JW5787 b4342 conserved hypothetical 
protein 
lambdap65 NinD ygcQ 1 ECK2764 JW5440 b2769 putative electron transfer 
flavoprotein subunit YgcQ
lambdap65 NinD purR 1 ECK1654 JW1650 b1658 transcriptional repressor 
for pur regulon, GlyA, 
glnB, prsA, speA 
lambdap65 NinD holD 1 ECK4363 JW4334 b4372 DNA polymerase III, psi 
subunit 
lambdap65 NinD glcD 1 ECK2974 JW2946 b2979 glycolate oxidase, subunit 
GlcD 
lambdap65 NinD hyfI 1 ECK2485 JW5805 b2489 hydrogenase-4 
component I 
lambdap65 NinD paaC 1 ECK1387 JW1385 b1390 phenylacetate-CoA 
oxygenase, PaaI subunit 
lambdap65 NinD xdhC 1 ECK2864 JW2836 b2868 [2Fe-2S] binding domain 
protein 
lambdap65 NinD ycbQ 1 ECK0929 JW5122 b0938 fimbrial subunit 
lambdap65 NinD yhjG 1 ECK3509 JW3492 b3524 b3524 predicted outer 
membrane biogenesis 
protein (yhjG) {Esc 
lambdap65 NinD yhiJ 1 ECK3473 JW3455 b3488 conserved hypothetical 
protein 
lambdap65 NinD ykgM 1 ECK0295 JW5034 b4506 ribosomal protein L36 
lambdap65 NinD yicI 1 ECK3646 JW3631 b3656 alpha-glucosidase 
lambdap65 NinD ilvM 1 ECK3761 JW3742 b3769 acetolactate synthase 
isozyme II small subunit 
lambdap65 NinD ymdE 1 ECK1016 JW5145 b1028 conserved hypothetical 
protein 
lambdap65 NinD rseB 1 ECK2569 JW2555 b2571 sigma-E factor regulatory 
protein RseB 
lambdap65 NinD rarA 1 ECK1000 JW0994 b1009 protein RutD 
lambdap65 NinD csgE 1 ECK1025 JW1022 b1039 curli production 
assembly/transport 
component CsgE 
lambdap65 NinD ykgJ 1 ECK0287 JW0282 b0288 predicted ferredoxin 
(ykgJ)  
lambdap65 NinD ygiL 1 ECK3034 JW3011 b3043 fimbrial protein 
lambdap65 NinD minC 1 ECK1164 JW1165 b1176 septum site-determining 
protein MinC 
lambdap65 NinD fixB 1 ECK0043 JW0041 b0042 protein FixB 
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lambdap65 NinD ECK0356 1 ECK0356 JW0350 b0359 putative transferase 
lambdap65 NinD flgA 1 ECK1057 JW1059 b1072 flagella basal body P-ring 
formation protein FlgA 
lambdap65 NinD yoaF 1 ECK1791 JW1782 b1793 lipoprotein, putative 
lambdap65 NinD flhE 1 ECK1879 JW1867 b1878 flagellar protein FlhE 
lambdap65 NinD ypfN 1 ECK2468 JW2457 b4547 conserved hypothetical 
protein 
lambdap66 NinE ynjB 4 ECK1752 JW5284 b1754 conserved hypothetical 
protein 
lambdap66 NinE nlpI 3 ECK3151 JW3132 b3163 lipoprotein NlpI 
lambdap66 NinE fliA 2 ECK1921 JW1907 b1922 RNA polymerase sigma 
factor for flagellar operon 
lambdap66 NinE spr 1 ECK2169 JW2163 b2175 lipoprotein spr 
lambdap66 NinE yiaF 1 ECK3541 JW5655 b3554 lipoprotein, putative 
lambdap66 NinE tbpA 1 ECK0069 JW0067 b0068 thiamin/thiamin 
pyrophosphate ABC 
transporter, 
thiamin/thiamin 
pyrophospate-binding 
protein 
lambdap66 NinE phoB 1 ECK0393 JW0389 b0399 phosphate regulon 
transcriptional regulatory 
protein PhoB 
lambdap71 Q ynfO 6 ECK1542 JW5251 b4533 conserved hypothetical 
protein 
lambdap71 Q fliA 4 ECK1921 JW1907 b1922 RNA polymerase sigma 
factor for flagellar operon 
lambdap71 Q yihD 4 ECK3850 JW3830 b3858 protein YihD 
lambdap71 Q nlpI 4 ECK3151 JW3132 b3163 lipoprotein NlpI 
lambdap71 Q ynjB 3 ECK1752 JW5284 b1754 conserved hypothetical 
protein 
lambdap71 Q yibA 2 ECK3583 JW3568 b3594 protein YibA 
lambdap71 Q glyQ 2 ECK3548 JW3531 b3560 glycyl-tRNA synthetase, 
alpha subunit 
lambdap71 Q yqhC 2 ECK3002 JW5849 b3010 putative HTH-type 
transcriptional regulator 
YqhC 
lambdap71 Q yajI 1 ECK0406 JW5056 b0412 YajI 
lambdap71 Q yiaF 1 ECK3541 JW5655 b3554 lipoprotein, putative 
lambdap71 Q ybeB 1 ECK0630 JW5090 b0637 iojap-like ribosome-
associated protein 
lambdap71 Q rfaD 1 ECK3609 JW3594 b3619 ADP-L-glycero-D-manno-
heptose-6-epimerase 
lambdap71 Q rpoE 1 ECK2571 JW2557 b2573 RNA polymerase sigma 
factor RpoE 
lambdap71 Q yjeB 1 ECK4174 JW4136 b4178 protein YjeB 
lambdap71 Q ycfM 1 ECK1091 JW5157 b1105 lipoprotein, putative 
lambdap71 Q fhuF 1 ECK4357 JW4331 b4367 ferric iron reductase 
protein FhuF 
lambdap71 Q yfcC 1 ECK2292 JW2295 b2298 short-chain fatty acids 
transporter 
lambdap71 Q yodC 1 ECK1955 JW1940 b1957 conserved hypothetical 
protein 
lambdap71 Q paaC 1 ECK1387 JW1385 b1390 phenylacetate-CoA 
oxygenase, PaaI subunit 
lambdap73 orf-64 spr 2 ECK2169 JW2163 b2175 lipoprotein spr 
lambdap73 orf-64 ynjB 1 ECK1752 JW5284 b1754 conserved hypothetical 
protein 
lambdap73 orf-64 yiaF 1 ECK3541 JW5655 b3554 lipoprotein, putative 
lambdap73 orf-64 ygiT 1 ECK3012 JW2989 b3021 transcriptional regulator, 
XRE family 
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lambdap73 orf-64 rpoE 1 ECK2571 JW2557 b2573 RNA polymerase sigma 
factor RpoE 
lambdap73 orf-64 caiD 1 ECK0037 JW0035 b0036 carnitinyl-CoA 
dehydratase 
lambdap74 S ynjB 3 ECK1752 JW5284 b1754 conserved hypothetical 
protein 
lambdap74 S yiaF 1 ECK3541 JW5655 b3554 lipoprotein, putative 
lambdap75 R dicB 10 ECK1569 JW1566 b1575 conserved domain protein
lambdap75 R fhuF 10 ECK4357 JW4331 b4367 ferric iron reductase 
protein FhuF 
lambdap75 R flxA 5 ECK1560 JW1558 b1566 protein FlxA 
lambdap75 R metN 3 ECK0199 JW0195 b0199 D-methionine ABC 
transporter, ATP-binding 
protein 
lambdap75 R caiF 3 ECK0035 JW0033 b0034 transcriptional activatory 
protein CaiF 
lambdap75 R ynjB 2 ECK1752 JW5284 b1754 conserved hypothetical 
protein 
lambdap75 R ydaW 1 ECK1359 JW5211 b1361 conserved hypothetical 
protein 
lambdap75 R yfcQ 1 ECK2328 JW2331 b2334 conserved hypothetical 
protein 
lambdap75 R ydcK 1 ECK1421 JW1424 b1428 conserved hypothetical 
protein 
lambdap75 R ynbE 1 ECK1379 JW1377 b1382 conserved domain protein
lambdap76 Rz mltB 22 ECK2696 JW2671 b2701 lytic murein 
transglycosylase B 
lambdap76 Rz ynjB 4 ECK1752 JW5284 b1754 conserved hypothetical 
protein 
lambdap76 Rz yiaF 2 ECK3541 JW5655 b3554 lipoprotein, putative 
lambdap76 Rz spr 2 ECK2169 JW2163 b2175 lipoprotein spr 
lambdap77 Bor ynjB 2 ECK1752 JW5284 b1754 conserved hypothetical 
protein 
lambdap78 orf_78 ispB 4 ECK3176 JW3154 b3187 octaprenyl-diphosphate 
synthase 
lambdap78 0 ynjB 1 ECK1752 JW5284 b1754 conserved hypothetical 
protein 
lambdap78 0 ydaW 1 ECK1359 JW5211 b1361 conserved hypothetical 
protein 
lambdap78 0 insN 1 ECK0257 JW5024 b0255 transposase InsN for 
insertion sequence 
element A 
lambdap78 lambdap78 phoB 1 ECK0393 JW0389 b0399 phosphate regulon 
transcriptional regulatory 
protein PhoB 
lambdap79 orf_79 ybcW 1 ECK0551 JW0548 b0559 conserved hypothetical 
protein 
lambdap79 orf_79 tfaR 1 ECK1368 JW1367 b1373 tail fiber assembly protein 
lambdap80 ea47 yihD 10 ECK3850 JW3830 b3858 protein YihD 
lambdap80 ea47 ynfO 10 ECK1542 JW5251 b4533 conserved hypothetical 
protein 
lambdap80 ea47 ynjB 8 ECK1752 JW5284 b1754 conserved hypothetical 
protein 
lambdap80 ea47 spr 7 ECK2169 JW2163 b2175 lipoprotein spr 
lambdap80 ea47 ubiF 5 ECK0654 JW0659 b0662 2-octaprenyl-3-methyl-6-
methoxy-1,4-benzoquinol 
hydroxylase 
lambdap80 ea47 yiaF 4 ECK3541 JW5655 b3554 lipoprotein, putative 
lambdap80 ea47 yjiT 4 ECK4333 JW5787 b4342 conserved hypothetical 
protein 
lambdap80 ea47 flxA 3 ECK1560 JW1558 b1566 protein FlxA 
lambdap80 ea47 sucC 2 ECK0716 JW0717 b0728 succinyl-CoA synthetase 
beta chain 
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lambdap80 ea47 ubiH 2 ECK2902 JW2875 b2907 2-polyprenyl-6-
methoxyphenol 4-
hydroxylase 
lambdap80 ea47 fliA 2 ECK1921 JW1907 b1922 RNA polymerase sigma 
factor for flagellar operon 
lambdap80 ea47 metN 1 ECK0199 JW0195 b0199 D-methionine ABC 
transporter, ATP-binding 
protein 
lambdap80 ea47 mltB 1 ECK2696 JW2671 b2701 lytic murein 
transglycosylase B 
lambdap80 ea47 ydaW 1 ECK1359 JW5211 b1361 conserved hypothetical 
protein 
lambdap80 ea47 ygiT 1 ECK3012 JW2989 b3021 transcriptional regulator, 
XRE family 
lambdap80 ea47 hybO 1 ECK2991 JW2965 b2997 [Ni/Fe] hydrogenase, 
small subunit 
lambdap80 ea47 modC 1 ECK0754 JW0748 b0765 molybdate ABC 
transporter, ATP-binding 
protein 
lambdap80 ea47 rng 1 ECK3235 JW3216 b3247 ribonuclease, Rne/Rng 
family 
lambdap80 ea47 thiF 1 ECK3984 JW3956 b3992 thiazole biosynthesis 
adenylyltransferase ThiF 
lambdap80 ea47 wbbK 1 ECK2026 JW2017 b2032 glycosyl transferase, 
group 1 family protein 
lambdap80 ea47 ycdC 1 ECK1004 JW0998 b1013 HTH-type transcriptional 
regulator RutR 
lambdap80 ea47 yqhC 1 ECK3002 JW5849 b3010 putative HTH-type 
transcriptional regulator 
YqhC 
lambdap80 ea47 yhiJ 1 ECK3473 JW3455 b3488 conserved hypothetical 
protein 
lambdap81 ea31 yiaF 1 ECK3541 JW5655 b3554 lipoprotein, putative 
lambdap83 ea22 dicB 42 ECK1569 JW1566 b1575 conserved domain protein
lambdap83 ea22 norR 26 ECK2704 JW5843 b2709 anaerobic nitric oxide 
reductase transcription 
regulator NorR 
lambdap83 ea22 phnG 11 ECK4094 JW4062 b4101 protein PhnG 
lambdap83 ea22 glcC 7 ECK2975 JW2947 b2980 Glc operon transcriptional 
activator 
lambdap83 ea22 mltB 5 ECK2696 JW2671 b2701 lytic murein 
transglycosylase B 
lambdap83 ea22 spr 4 ECK2169 JW2163 b2175 lipoprotein spr 
lambdap83 ea22 ydaW 4 ECK1359 JW5211 b1361 conserved hypothetical 
protein 
lambdap83 ea22 yliL 4 ECK0805 JW5969 b0816 hypothetical protein (yliL) 
lambdap83 ea22 metN 3 ECK0199 JW0195 b0199 D-methionine ABC 
transporter, ATP-binding 
protein 
lambdap83 ea22 soxS 3 ECK4054 JW4023 b4062 regulatory protein SoxS 
lambdap83 ea22 ybiS 2 ECK0809 JW0803 b0819 protein YbiS 
lambdap83 ea22 ymcD 2 ECK0978 JW5133 b0987 hypothetical protein 
lambdap83 ea22 fixX 2 ECK0045 JW0043 b0044 conserved hypothetical 
protein 
lambdap83 ea22 fliA 1 ECK1921 JW1907 b1922 RNA polymerase sigma 
factor for flagellar operon 
lambdap83 ea22 flxA 1 ECK1560 JW1558 b1566 protein FlxA 
lambdap83 ea22 tbpA 1 ECK0069 JW0067 b0068 thiamin/thiamin 
pyrophosphate ABC 
transporter, 
thiamin/thiamin 
pyrophospate-binding 
protein 
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lambdap83 ea22 wza 1 ECK2056 JW2047 b2062 membrane protein 
lambdap83 ea22 yajI 1 ECK0406 JW5056 b0412 YajI 
lambdap83 ea22 ydcE 1 ECK1455 JW1456 b1461 conserved domain protein
lambdap83 ea22 yjgZ 1 ECK4267 JW4236 b4277   
lambdap83 ea22 yjhV 1 ECK4276 JW4246 b4286 conserved hypothetical 
protein 
lambdap83 ea22 ynfO 1 ECK1542 JW5251 b4533 conserved hypothetical 
protein 
lambdap83 ea22 ynjB 1 ECK1752 JW5284 b1754 conserved hypothetical 
protein 
lambdap83 ea22 rpsJ 1 ECK3308 JW3283 b3321 ribosomal protein S10 
lambdap83 ea22 ansB 1 ECK2952 JW2924 b2957 L-asparaginase II 
lambdap83 ea22 eutC 1 ECK2435 JW2433 b2440 ethanolamine ammonia-
lyase, light chain 
lambdap83 ea22 fimG 1 ECK4310 JW4282 b4319 protein FimG 
lambdap83 ea22 minE 1 ECK1162 JW1163 b1174 cell division topological 
specificity factor MinE 
lambdap83 ea22 proQ 1 ECK1830 JW5300 b1831 ProP effector 
lambdap83 ea22 recG 1 ECK3642 JW3627 b3652 ATP-dependent DNA 
helicase RecG 
lambdap83 ea22 rseB 1 ECK2569 JW2555 b2571 sigma-E factor regulatory 
protein RseB 
lambdap83 ea22 sfmA 1 ECK0523 JW0519 b0530 type-1 fimbrial protein, A 
chain 
lambdap83 ea22 tolB 1 ECK0729 JW5100 b0740 Tol-Pal system beta 
propeller repeat protein 
TolB 
lambdap83 ea22 ybgD 1 ECK0708 JW0709 b0719 fimbrial protein 
lambdap83 ea22 ybjP 1 ECK0856 JW0849 b0865 YbjP 
lambdap83 ea22 ycfL 1 ECK1090 JW1090 b1104 conserved hypothetical 
protein 
lambdap83 ea22 yfcQ 1 ECK2328 JW2331 b2334 conserved hypothetical 
protein 
lambdap83 ea22 ygeK 1 ECK2853 JW5458 b2855 hypothetical protein 
lambdap83 ea22 ykiA 1 ECK0387 JW0383 b0392 conserved hypothetical 
protein 
lambdap83 ea22 ylcG 1 ECK0542 JW5076 b4509 conserved hypothetical 
protein 
lambdap83 ea22 ymcC 1 ECK0977 JW0969 b0986 YmcC 
lambdap83 ea22 ymfT 1 ECK1132 JW5169 b1146 conserved hypothetical 
protein 
lambdap83 ea22 yncH 1 ECK1449 JW5235 b1455 conserved hypothetical 
protein 
lambdap83 ea22 yoaH 1 ECK1809 JW1800 b1811 conserved domain protein
lambdap88 cl yiaF 3 ECK3541 JW5655 b3554 lipoprotein, putative 
lambdap88 cl pldB 3 ECK3819 JW5584 b3825 lysophospholipase L2 
lambdap88 cl eutC 2 ECK2435 JW2433 b2440 ethanolamine ammonia-
lyase, light chain 
lambdap88 cl fliM 2 ECK1943 JW1929 b1945 flagellar motor switch 
protein FliM 
lambdap88 cl mdtE 2 ECK3497 JW3481 b3513 multidrug resistance 
protein MdtE 
lambdap88 cl rseB 2 ECK2569 JW2555 b2571 sigma-E factor regulatory 
protein RseB 
lambdap88 cl smpA 2 ECK2613 JW2598 b2617 small protein A 
lambdap88 cl ydiT 2 ECK1698 JW1690 b1700 conserved hypothetical 
protein 
lambdap88 cl flxA 2 ECK1560 JW1558 b1566 protein FlxA 
lambdap88 cl phnG 2 ECK4094 JW4062 b4101 protein PhnG 
lambdap88 cl ydaW 2 ECK1359 JW5211 b1361 conserved hypothetical 
protein 
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lambdap88 cl mltB 1 ECK2696 JW2671 b2701 lytic murein 
transglycosylase B 
lambdap88 cl wza 1 ECK2056 JW2047 b2062 membrane protein 
lambdap88 cl yihD 1 ECK3850 JW3830 b3858 protein YihD 
lambdap88 cl yjgZ 1 ECK4267 JW4236 b4277   
lambdap88 cl ECK0356 1 ECK0356 JW0350 b0359 putative transferase 
lambdap88 cl ECK3769 1 ECK3769 JW3750 b3777 conserved hypothetical 
protein 
lambdap88 cl lacA 1 ECK0339 JW0333 b0342 galactoside O-
acetyltransferase 
lambdap88 cl lpxL 1 ECK1039 JW1041 b1054 lipid A biosynthesis 
lauroyl acyltransferase 
lambdap88 cl napB 1 ECK2195 JW5367 b2203 periplasmiC nitrate 
reductase, diheme 
cytochrome c subunit 
lambdap88 cl nuoC 1 ECK2280 JW5375 b2286 NADH-quinone 
oxidoreductase chain c/d 
lambdap88 cl slp 1 ECK3490 JW3474 b3506 outer membrane protein 
slp 
lambdap88 cl xdhC 1 ECK2864 JW2836 b2868 [2Fe-2S] binding domain 
protein 
lambdap88 cl ybcY 1 ECK0554 JW0551 b0562 b0562DLP12 predicted 
SAM-dependent 
methyltransferase (ybcY) 
lambdap88 cl ybgD 1 ECK0708 JW0709 b0719 fimbrial protein 
lambdap88 cl ycjR 1 ECK1309 JW5202 b1314 AP endonuclease, family 
2 
lambdap88 cl yfdX 1 ECK2371 JW2372 b2375 protein YfdX 
lambdap88 cl yhdW 1 ECK3255 JW3236 b3268 general L-amino acid-
binding periplasmic 
protein AapJ 
lambdap88 cl yjdI 1 ECK4119 JW4087 b4126 conserved hypothetical 
protein 
lambdap88 cl ykgJ 1 ECK0287 JW0282 b0288 predicted ferredoxin 
(ykgJ) 
lambdap88 cl yqhC 1 ECK3002 JW5849 b3010 putative HTH-type 
transcriptional regulator 
YqhC 
lambdap88 cl ubiF 1 ECK0654 JW0659 b0662 2-octaprenyl-3-methyl-6-
methoxy-1,4-benzoquinol 
hydroxylase 
lambdap89 O ppk 15 ECK2497 JW2486 b2501 polyphosphate kinase 
lambdap89 O yjhP 15 ECK4296 JW4268 b4306 conserved hypothetical 
protein 
lambdap89 O tfaQ 3 ECK1539 JW1539 b1546 tail fiber assembly protein 
lambdap89 O mviM 2 ECK1053 JW1055 b1068 putative Virulence factor 
MviM homolog 
lambdap89 O clpP 1 ECK0431 JW0427 b0437 ATP-dependent Clp 
protease, proteolytic 
subunit ClpP 
lambdap89 O dsdX 1 ECK2361 JW2362 b2365 DsdX permease 
lambdap89 O yaaW 1 ECK0011 JW0010 b0011 positive regulator for 
sigma H 
lambdap90 orf206b prfH 3 ECK0237 JW0226 b0236 putative peptide chain 
release factor H 
lambdap90 orf206b yjbF 2 ECK4019 JW5711 b4027 YmcC 
lambdap90 orf206b ypfJ 2 ECK2471 JW2460 b2475 neutral zinc 
metallopeptidase family 
lambdap90 orf206b yajI 1 ECK0406 JW5056 b0412 YajI 
lambdap90 orf206b clpP 1 ECK0431 JW0427 b0437 ATP-dependent Clp 
protease, proteolytic 
subunit ClpP 
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lambdap90 orf206b hokD 1 ECK1556 JW1554 b1562 b1562 small toxic 
polypeptide (hokD) 
lambdap90 orf206b yjdP 1 ECK4084 JW5890 b4487 conserved hypothetical 
protein 
 
